NIH Grants that mention Trastuzumab (marketed as Herceptin by Roche), RePORT 9 December 2010
Project Title |
Project Number |
Project Start Date |
Budget Start Date |
Budget End Date |
FY |
Contact Principal Investigator |
Organization Name |
Organization City |
Organization State |
Organization Country |
Administering IC |
Total Cost |
NIH Spending Categorization |
BREAST CANCER |
3U10CA025224-23S1 |
2002-01-01 |
1998-10-01 |
30-Sep-99 |
2002 |
PEREZ, EDITH A |
MAYO CLINIC COLL OF MEDICINE, ROCHESTER |
ROCHESTER |
MN |
UNITED STATES |
NCI |
$78,870 |
No NIH Category available. |
BREAST CANCER |
5U10CA025224-23 |
2002-01-11 |
1998-10-01 |
30-Sep-99 |
2002 |
PEREZ, EDITH A |
MAYO CLINIC COLL OF MEDICINE, ROCHESTER |
ROCHESTER |
MN |
UNITED STATES |
NCI |
$78,870 |
No NIH Category available. |
SPECIFIC IMMUNOTHERAPY WITH MONOCLONAL ANTIBODIES |
2R01CA039930-15 |
1988-09-30 |
2001-04-01 |
31-Mar-02 |
2001 |
BAST, ROBERT C |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$249,000 |
No NIH Category available. |
COEXPRESSION OF EGFRVLLL/ERBB2 IN HUMAN BREAST CANCER |
1R01CA088871-01A1 |
2001-09-01 |
2001-09-01 |
31-Aug-02 |
2001 |
TANG, CAREEN K |
GEORGETOWN UNIVERSITY |
WASHINGTON |
DC |
UNITED STATES |
NCI |
$257,632 |
No NIH Category available. |
MECHANISM BASED EVALUATIONS OF ERBB TARGETED AGENTS |
1U54CA090788-01 |
2001-09-26 |
2001-09-26 |
31-Dec-01 |
2001 |
TEMPERO, MARGARET A |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$644,670 |
No NIH Category available. |
SPECIFIC IMMUNOTHERAPY WITH MONOCLONAL ANTIBODIES |
5R01CA039930-16 |
1988-09-30 |
2002-04-01 |
31-Mar-03 |
2002 |
BAST, ROBERT C |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$249,000 |
No NIH Category available. |
MECHANISM-BASED EVALUATIONS OF ERBB-TARGETED AGENTS |
5U54CA090788-02 |
2001-09-26 |
2002-05-01 |
31-Dec-02 |
2002 |
TEMPERO, MARGARET A |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$1,180,630 |
No NIH Category available. |
FCR ENHANCED AG PRESENTATION--INDUCTION TUMOR IMMUNITY |
1R01CA094037-01 |
2002-08-01 |
2002-08-01 |
31-Jul-03 |
2002 |
CLYNES, RAPHAEL A |
COLUMBIA UNIVERSITY HEALTH SCIENCES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$327,409 |
No NIH Category available. |
COEXPRESSION OF EGFRVLLL/ERBB2 IN HUMAN BREAST CANCER |
5R01CA088871-02 |
2001-09-01 |
2002-09-01 |
31-Aug-03 |
2002 |
TANG, CAREEN K |
GEORGETOWN UNIVERSITY |
WASHINGTON |
DC |
UNITED STATES |
NCI |
$257,632 |
No NIH Category available. |
SIGNALING BY NEUREGULINS AND ERBB4 IN BREAST CANCER |
2R01CA080065-04 |
1998-12-01 |
2002-09-05 |
30-Jun-03 |
2002 |
STERN, DAVID F |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$377,963 |
No NIH Category available. |
ERBB1 AND ERBB2 BLOCKADE IN ADVANCED BREAST CANCER |
1R21CA099250-01 |
2002-09-23 |
2002-09-23 |
31-Aug-03 |
2002 |
DE BONO, JOHANN S |
CANCER THERAPY AND RESEARCH CENTER |
SAN ANTONIO |
TX |
UNITED STATES |
NCI |
$278,458 |
No NIH Category available. |
MECHANISM-BASED EVALUATIONS OF ERBB-TARGETED AGENTS |
5U54CA090788-03 |
2001-09-26 |
2003-01-01 |
31-Dec-03 |
2003 |
TEMPERO, MARGARET A |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$1,213,114 |
No NIH Category available. |
PHASE II DOXORUBICIN/VINORELBINE IN WTP53 BREAST CANCER |
1R01CA095275-01A1 |
2003-02-05 |
2003-02-05 |
31-Jan-04 |
2003 |
TOPPMEYER, DEBORAH L |
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH |
PISCATAWAY |
NJ |
UNITED STATES |
NCI |
$255,060 |
No NIH Category available. |
SPECIFIC IMMUNOTHERAPY WITH MONOCLONAL ANTIBODIES |
5R01CA039930-17 |
1988-09-30 |
2003-04-01 |
31-Mar-04 |
2003 |
BAST, ROBERT C |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$249,000 |
No NIH Category available. |
FCR ENHANCED AG PRESENTATION--INDUCTION TUMOR IMMUNITY |
5R01CA094037-02 |
2002-08-01 |
2003-08-01 |
31-Jul-04 |
2003 |
CLYNES, RAPHAEL A |
COLUMBIA UNIVERSITY HEALTH SCIENCES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$327,409 |
No NIH Category available. |
SIGNALING BY NEUREGULINS AND ERBB4 IN BREAST CANCER |
5R01CA080065-05 |
1998-12-01 |
2003-08-13 |
30-Jun-04 |
2003 |
STERN, DAVID F |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$376,919 |
No NIH Category available. |
COEXPRESSION OF EGFRVLLL/ERBB2 IN HUMAN BREAST CANCER |
5R01CA088871-03 |
2001-09-01 |
2003-09-01 |
31-Aug-04 |
2003 |
TANG, CAREEN K |
GEORGETOWN UNIVERSITY |
WASHINGTON |
DC |
UNITED STATES |
NCI |
$257,632 |
No NIH Category available. |
ERBB1 AND ERBB2 BLOCKADE IN ADVANCED BREAST CANCER |
5R21CA099250-02 |
2002-09-23 |
2003-09-25 |
30-Sep-03 |
2003 |
ROWINSKY, ERIC K |
CANCER THERAPY AND RESEARCH CENTER |
SAN ANTONIO |
TX |
UNITED STATES |
NCI |
$3,269 |
No NIH Category available. |
ERBB1 AND ERBB2 BLOCKADE IN ADVANCED BREAST CANCER |
6R21CA099250-03 |
2002-09-23 |
2003-10-01 |
31-Aug-06 |
2003 |
TAKIMOTO, CHRIS H |
CANCER THERAPY AND RESEARCH CENTER |
SAN ANTONIO |
TX |
UNITED STATES |
NCI |
$264,086 |
No NIH Category available. |
TAILORED DOSE DOCETAXEL + TRASTUZUMAB IN BREAST CANCER |
5M01RR000042-44 |
2004-03-01 |
2004-03-01 |
28-Feb-05 |
2004 |
SCHOTT, ANNE F |
UNIVERSITY OF MICHIGAN AT ANN ARBOR |
ANN ARBOR |
MI |
UNITED STATES |
NCRR |
$6,607 |
No NIH Category available. |
PHASE II DOXORUBICIN/VINORELBINE IN WTP53 BREAST CANCER |
5R01CA095275-02 |
2003-02-05 |
2004-03-10 |
31-Jan-05 |
2004 |
TOPPMEYER, DEBORAH L |
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH |
PISCATAWAY |
NJ |
UNITED STATES |
NCI |
$268,397 |
No NIH Category available. |
MECHANISM-BASED EVALUATIONS OF ERBB-TARGETED AGENTS |
5U54CA090788-04 |
2001-09-26 |
2004-03-30 |
31-Dec-04 |
2004 |
TEMPERO, MARGARET A |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$1,077,842 |
No NIH Category available. |
SPECIFIC IMMUNOTHERAPY WITH MONOCLONAL ANTIBODIES |
5R01CA039930-18 |
1988-09-30 |
2004-04-01 |
31-Mar-07 |
2004 |
BAST, ROBERT C |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$249,000 |
No NIH Category available. |
N9831: DOXORUBICIN/CYCLOPHOSPHAMIDE/TAXOL +OR -TRASTUZUMAB FOR BREAST CANCER |
2M01RR000096-43 |
2004-04-20 |
2004-04-20 |
31-Mar-05 |
2004 |
HOCHSTER, HOWARD S |
NEW YORK UNIVERSITY SCHOOL OF MEDICINE |
NEW YORK |
NY |
UNITED STATES |
NCRR |
$2,033 |
No NIH Category available. |
SIGNALING BY NEUREGULINS AND ERBB4 IN BREAST CANCER |
5R01CA080065-06 |
1998-12-01 |
2004-07-06 |
30-Jun-05 |
2004 |
STERN, DAVID F |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$376,700 |
No NIH Category available. |
FCR ENHANCED AG PRESENTATION--INDUCTION TUMOR IMMUNITY |
5R01CA094037-03 |
2002-08-01 |
2004-08-20 |
31-Jul-05 |
2004 |
CLYNES, RAPHAEL A |
COLUMBIA UNIVERSITY HEALTH SCIENCES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$327,409 |
No NIH Category available. |
COEXPRESSION OF EGFRVLLL/ERBB2 IN HUMAN BREAST CANCER |
5R01CA088871-04 |
2001-09-01 |
2004-09-01 |
31-Aug-05 |
2004 |
TANG, CAREEN K |
GEORGETOWN UNIVERSITY |
WASHINGTON |
DC |
UNITED STATES |
NCI |
$257,632 |
No NIH Category available. |
LCCC 0310 DENDRITIC CELL VACCINE GIVEN WITH TRASTUZUMAB AND VINORELBINE |
5M01RR000046-45 |
2004-12-01 |
2004-12-01 |
30-Nov-05 |
2005 |
SERODY, JONATHAN STUART |
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL |
CHAPEL HILL |
NC |
UNITED STATES |
NCRR |
$5,655 |
No NIH Category available. |
SIGNALING BY NEUREGULINS AND ERBB4 IN BREAST CANCER |
3R01CA080065-06S1 |
1998-12-01 |
2005-02-01 |
30-Jun-05 |
2005 |
STERN, DAVID F |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$21,902 |
No NIH Category available. |
PHASE II DOXORUBICIN/VINORELBINE IN WTP53 BREAST CANCER |
5R01CA095275-03 |
2003-02-05 |
2005-02-01 |
31-Jan-09 |
2005 |
TOPPMEYER, DEBORAH L |
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH |
PISCATAWAY |
NJ |
UNITED STATES |
NCI |
$268,397 |
No NIH Category available. |
N9831: DOXORUBICIN/CYCLOPHOSPHAMIDE/TAXOL +OR -TRASTUZUMAB FOR BREAST CANCER |
5M01RR000096-44 |
2005-04-01 |
2005-04-01 |
31-Mar-06 |
2005 |
HOCHSTER, HOWARD S |
NEW YORK UNIVERSITY SCHOOL OF MEDICINE |
NEW YORK |
NY |
UNITED STATES |
NCRR |
$26,259 |
No NIH Category available. |
PH I STUDY OF EGFR AND HER2 BLOCKADE W OSI-774, TRASTUZUMAB AND PACLITAXEL |
5M01RR001346-24 |
2005-04-01 |
2005-04-01 |
31-Mar-06 |
2005 |
TOLCHER, ANTHONY W |
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT |
SAN ANTONIO |
TX |
UNITED STATES |
NCRR |
$45,529 |
No NIH Category available. |
MODULATION BY BOTANICALS OF ANTIBODY BASED CANCER IMMUNO |
1P50AT002779-01 |
2005-04-01 |
2005-04-01 |
31-Mar-06 |
2005 |
CHEUNG, NAI-KONG V |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCCAM |
$280,773 |
No NIH Category available. |
MULTIMODALITY THERAPY FOR METASTATIC BREAST CANCER |
1R21CA105837-01A2 |
2005-04-15 |
2005-04-15 |
31-Mar-06 |
2005 |
SERODY, JONATHAN STUART |
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL |
CHAPEL HILL |
NC |
UNITED STATES |
NCI |
$288,350 |
No NIH Category available. |
BREAST CANCER RESPONSE MARKERS TO A DUAL HER1/2 BLOCKER |
1R01CA112305-01A1 |
2005-06-16 |
2005-06-16 |
31-May-06 |
2005 |
CHANG, JENNY C-N |
BAYLOR COLLEGE OF MEDICINE |
HOUSTON |
TX |
UNITED STATES |
NCI |
$266,021 |
No NIH Category available. |
SIGNALING BY NEUREGULINS AND ERBB4 IN BREAST CANCER |
5R01CA080065-07 |
1998-12-01 |
2005-07-01 |
30-Jun-06 |
2005 |
STERN, DAVID F |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$376,474 |
No NIH Category available. |
SIGNALING BY NEUREGULINS AND ERBB4 IN BREAST CANCER |
3R01CA080065-07S1 |
2005-02-01 |
2005-07-01 |
30-Jun-06 |
2005 |
STERN, DAVID F |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$30,663 |
No NIH Category available. |
FCR ENHANCED AG PRESENTATION--INDUCTION TUMOR IMMUNITY |
5R01CA094037-04 |
2002-08-01 |
2005-08-01 |
31-Jul-06 |
2005 |
CLYNES, RAPHAEL A |
COLUMBIA UNIVERSITY HEALTH SCIENCES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$327,409 |
No NIH Category available. |
COEXPRESSION OF EGFRVLLL/ERBB2 IN HUMAN BREAST CANCER |
5R01CA088871-05 |
2001-09-01 |
2005-09-01 |
31-Aug-06 |
2005 |
TANG, CAREEN K |
GEORGETOWN UNIVERSITY |
WASHINGTON |
DC |
UNITED STATES |
NCI |
$257,632 |
No NIH Category available. |
BLOOD TEST DETECTS CHANGE FROM HER2- TO+IN BREAST CANCER |
1R01CA101790-01A3 |
2005-09-01 |
2005-09-01 |
31-Aug-06 |
2005 |
UHR, JONATHAN W |
UNIVERSITY OF TEXAS SW MED CTR/DALLAS |
DALLAS |
TX |
UNITED STATES |
NCI |
$266,900 |
No NIH Category available. |
MECHANISM-BASED EVALUATIONS OF ERBB-TARGETED AGENTS |
5U54CA090788-05 |
2001-09-26 |
2005-09-15 |
31-Dec-05 |
2005 |
TEMPERO, MARGARET A |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$987,374 |
No NIH Category available. |
FATTY ACID SYNTHASE /MOLECULAR TARGET /BREAST CANCER THE |
1R01CA116623-01 |
2005-09-16 |
2005-09-16 |
30-Jun-06 |
2005 |
LUPU, RUTH |
NORTHSHORE UNIV HEALTHSYSTEM RES INST |
EVANSTON |
IL |
UNITED STATES |
NCI |
$416,745 |
No NIH Category available. |
DANA-FARBER/HARVARD SPORE IN BREAST CANCER |
3P50CA089393-06S1 |
2000-09-30 |
2005-09-21 |
31-Aug-06 |
2005 |
IGLEHART, JAMES DIRK |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$50,000 |
No NIH Category available. |
DANA-FARBER/HARVARD SPORE IN BREAST CANCER |
3P50CA089393-06S2 |
2000-09-30 |
2005-09-21 |
31-Aug-06 |
2005 |
IGLEHART, JAMES DIRK |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$74,999 |
No NIH Category available. |
DANA-FARBER/HARVARD SPORE IN BREAST CANCER |
3P50CA089393-06S3 |
2000-09-30 |
2005-09-21 |
31-Aug-06 |
2005 |
IGLEHART, JAMES DIRK |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$224,999 |
No NIH Category available. |
DANA-FARBER/HARVARD SPORE IN BREAST CANCER |
2P50CA089393-06 |
2000-09-30 |
2005-09-21 |
31-Aug-06 |
2005 |
IGLEHART, JAMES DIRK |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$2,299,999 |
No NIH Category available. |
UTMDACC SPORE IN BREAST CANCER |
1P50CA116199-01 |
2005-09-23 |
2005-09-23 |
31-Aug-06 |
2005 |
HORTOBAGYI, GABRIEL N |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$2,300,000 |
No NIH Category available. |
LCCC 0310 DENDRITIC CELL VACCINE GIVEN WITH TRASTUZUMAB AND VINORELBINE |
5M01RR000046-46 |
2005-12-01 |
2005-12-01 |
30-Nov-06 |
2006 |
SERODY, JONATHAN STUART |
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL |
CHAPEL HILL |
NC |
UNITED STATES |
NCRR |
$8,673 |
No NIH Category available. |
ROLE OF NEUREGULIN/ERBB SIGNALING IN THE ADULT HEART |
2R01HL068144-05A1 |
2001-09-30 |
2006-04-01 |
30-Jun-06 |
2006 |
SAWYER, DOUGLAS B |
BOSTON MEDICAL CENTER |
BOSTON |
MA |
UNITED STATES |
NHLBI |
$124,579 |
No NIH Category available. |
P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACLITAXEL W/WO TRAS |
5M01RR010732-12 |
2006-04-01 |
2006-04-01 |
31-Mar-07 |
2006 |
RYBKA, WITOLD B. |
PENNSYLVANIA STATE UNIV HERSHEY MED CTR |
HERSHEY |
PA |
UNITED STATES |
NCRR |
$18,927 |
No NIH Category available. |
INDIVIDUALIZED TX OF BREAST CANCER BASED ON TUMOR MOLECULAR CHARACTERISTICS |
5M01RR000096-45 |
2006-04-01 |
2006-04-01 |
31-Mar-07 |
2006 |
FORMENTI, SILVIA C |
NEW YORK UNIVERSITY SCHOOL OF MEDICINE |
NEW YORK |
NY |
UNITED STATES |
NCRR |
$20,576 |
No NIH Category available. |
PH I STUDY OF EGFR AND HER2 BLOCKADE W/ OSI-774, TRASTUZUMAB AND PACLITAXEL |
5M01RR001346-25 |
2006-04-01 |
2006-04-01 |
31-Mar-07 |
2006 |
TOLCHER, ANTHONY W |
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT |
SAN ANTONIO |
TX |
UNITED STATES |
NCRR |
$23,191 |
No NIH Category available. |
P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACLITAXEL W/WO TRAS |
5M01RR010732-12 |
2006-04-01 |
2006-04-01 |
31-Mar-07 |
2006 |
RYBKA, WITOLD B. |
PENNSYLVANIA STATE UNIV HERSHEY MED CTR |
HERSHEY |
PA |
UNITED STATES |
NCRR |
$39,144 |
No NIH Category available. |
PHASE I-II STUDY OF COMBINATION IMMUNOTHERAPY FOR HER-2/NEU CYTOTOXIC T CELLS |
5M01RR000037-46 |
2006-04-01 |
2006-04-01 |
31-Mar-07 |
2006 |
DISIS, MARY L. |
UNIVERSITY OF WASHINGTON |
SEATTLE |
WA |
UNITED STATES |
NCRR |
$40,522 |
No NIH Category available. |
MODULATION BY BOTANICALS OF ANTIBODY BASED CANCER IMMUNO |
5P50AT002779-02 |
|
2006-04-01 |
31-Mar-07 |
2006 |
CHEUNG, NAI-KONG V |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCCAM |
$279,042 |
No NIH Category available. |
MULTIMODALITY THERAPY FOR METASTATIC BREAST CANCER |
5R21CA105837-02 |
2005-04-15 |
2006-05-31 |
31-Mar-08 |
2006 |
SERODY, JONATHAN STUART |
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL |
CHAPEL HILL |
NC |
UNITED STATES |
NCI |
$281,574 |
No NIH Category available. |
BREAST CANCER RESPONSE MARKERS TO A DUAL HER1/2 BLOCKER |
5R01CA112305-02 |
2005-06-16 |
2006-06-01 |
30-Apr-07 |
2006 |
CHANG, JENNY C-N |
BAYLOR COLLEGE OF MEDICINE |
HOUSTON |
TX |
UNITED STATES |
NCI |
$259,769 |
No NIH Category available. |
SIGNALING BY NEUREGULINS AND ERBB4 IN BREAST CANCER |
5R01CA080065-08 |
1998-12-01 |
2006-07-01 |
30-Nov-08 |
2006 |
STERN, DAVID F |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$367,399 |
No NIH Category available. |
ANALYSIS OF CIRCULATING TUMOR CELLS IN A PHASE I/II STUDY FOR BREAST CANCER |
1R21CA121541-01 |
2006-07-07 |
2006-07-07 |
30-Jun-07 |
2006 |
SWABY, RAMONA F |
FOX CHASE CANCER CENTER |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$273,173 |
No NIH Category available. |
FCR ENHANCED AG PRESENTATION--INDUCTION TUMOR IMMUNITY |
5R01CA094037-05 |
2002-08-01 |
2006-08-01 |
31-Jul-07 |
2006 |
CLYNES, RAPHAEL A |
COLUMBIA UNIVERSITY HEALTH SCIENCES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$319,714 |
No NIH Category available. |
MECHANISM-BASED EVALUATIONS OF ERBB-TARGETED AGENTS |
5U54CA090788-06 |
2001-09-26 |
2006-08-22 |
31-Dec-08 |
2006 |
TEMPERO, MARGARET A |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$467,532 |
No NIH Category available. |
FATTY ACID SYNTHASE: CHARACTERIZATION AS A NOVEL MOLECULAR TARGET FOR BREAST CAN* |
5R01CA116623-02 |
2005-09-16 |
2006-08-25 |
31-May-07 |
2006 |
LUPU, RUTH |
NORTHSHORE UNIV HEALTHSYSTEM RES INST |
EVANSTON |
IL |
UNITED STATES |
NCI |
$418,986 |
No NIH Category available. |
ROLE OF NEUREGULIN/ERBB SIGNALING IN THE ADULT HEART |
7R01HL068144-06 |
2001-09-30 |
2006-09-01 |
31-Mar-07 |
2006 |
SAWYER, DOUGLAS B |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NHLBI |
$237,671 |
No NIH Category available. |
BLOOD TEST DETECTS CHANGE FROM HER2- TO+IN BREAST CANCER |
5R01CA101790-02 |
2005-09-01 |
2006-09-01 |
31-Aug-07 |
2006 |
UHR, JONATHAN W |
UNIVERSITY OF TEXAS SW MED CTR/DALLAS |
DALLAS |
TX |
UNITED STATES |
NCI |
$260,628 |
No NIH Category available. |
DANA-FARBER/HARVARD SPORE IN BREAST CANCER |
3P50CA089393-07S1 |
2000-09-30 |
2006-09-26 |
31-Aug-07 |
2006 |
IGLEHART, JAMES DIRK |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$703,004 |
No NIH Category available. |
DANA-FARBER/HARVARD SPORE IN BREAST CANCER |
5P50CA089393-07 |
2000-09-30 |
2006-09-27 |
31-Aug-07 |
2006 |
IGLEHART, JAMES DIRK |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$2,245,949 |
No NIH Category available. |
UTMDACC SPORE IN BREAST CANCER |
3P50CA116199-02S1 |
2005-09-23 |
2006-09-28 |
31-Aug-07 |
2006 |
HORTOBAGYI, GABRIEL N |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$419,559 |
No NIH Category available. |
UTMDACC SPORE IN BREAST CANCER |
5P50CA116199-02 |
2005-09-23 |
2006-09-28 |
31-Aug-07 |
2006 |
HORTOBAGYI, GABRIEL N |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$2,245,950 |
No NIH Category available. |
CANCER CENTER CORE SUPPORT GRANT |
3P30CA016042-33S4 |
1977-12-01 |
2006-12-01 |
1-Apr-09 |
2007 |
GASSON, JUDITH CHERYL |
UNIVERSITY OF CALIFORNIA LOS ANGELES |
LOS ANGELES |
CA |
UNITED STATES |
NCI |
$76,807 |
No NIH Category available. |
CANCER CENTER CORE SUPPORT GRANT |
3P30CA016042-33S2 |
1977-12-01 |
2006-12-01 |
1-Apr-09 |
2007 |
GASSON, JUDITH CHERYL |
UNIVERSITY OF CALIFORNIA LOS ANGELES |
LOS ANGELES |
CA |
UNITED STATES |
NCI |
$108,416 |
No NIH Category available. |
CANCER CENTER CORE SUPPORT GRANT |
3P30CA016042-33S3 |
1977-12-01 |
2006-12-01 |
1-Apr-09 |
2007 |
GASSON, JUDITH CHERYL |
UNIVERSITY OF CALIFORNIA LOS ANGELES |
LOS ANGELES |
CA |
UNITED STATES |
NCI |
$113,053 |
No NIH Category available. |
CANCER CENTER CORE SUPPORT GRANT |
3P30CA016042-33S6 |
1977-12-01 |
2006-12-01 |
1-Apr-09 |
2008 |
GASSON, JUDITH CHERYL |
UNIVERSITY OF CALIFORNIA LOS ANGELES |
LOS ANGELES |
CA |
UNITED STATES |
NCI |
$113,837 |
Biotechnology;Cancer;Clinical Research;Clinical Trials;Urologic Diseases |
CANCER CENTER CORE SUPPORT GRANT |
5P30CA016042-33 |
1977-12-01 |
2006-12-01 |
1-Apr-09 |
2007 |
GASSON, JUDITH CHERYL |
UNIVERSITY OF CALIFORNIA LOS ANGELES |
LOS ANGELES |
CA |
UNITED STATES |
NCI |
$4,541,766 |
No NIH Category available. |
TARGETED ALPHA-PARTICLE EMITTER THERAPY OF METASTASES |
5R01CA113797-02 |
2005-12-09 |
2006-12-01 |
30-Nov-07 |
2007 |
SGOUROS, GEORGE |
JOHNS HOPKINS UNIVERSITY |
BALTIMORE |
MD |
UNITED STATES |
NCI |
$278,181 |
No NIH Category available. |
LCCC 0310 DENDRITIC CELL VACCINE GIVEN WITH TRASTUZUMAB AND VINORELBINE |
5M01RR000046-47 |
2006-12-01 |
2006-12-01 |
30-Nov-07 |
2007 |
SERODY, JONATHAN STUART |
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL |
CHAPEL HILL |
NC |
UNITED STATES |
NCRR |
$5,252 |
No NIH Category available. |
IMMUNOTHERAPY FOR GLIOMAS WITH MONOCLONAL ANTIBODIES TARGETING MCSP |
5R21NS054167-02 |
2006-01-01 |
2006-12-31 |
30-Dec-08 |
2007 |
FENSTERMAKER, ROBERT A |
ROSWELL PARK CANCER INSTITUTE CORP |
BUFFALO |
NY |
UNITED STATES |
NINDS |
$230,024 |
No NIH Category available. |
NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT |
5U10CA012027-37 |
1976-12-01 |
2007-02-01 |
31-Jan-08 |
2007 |
WOLMARK, NORMAN |
NSABP FOUNDATION, INC. |
PITTSBURGH |
PA |
UNITED STATES |
NCI |
$8,403,989 |
No NIH Category available. |
ERBB2 TARGETED ANTITUMOR STRATEGIES IN BREAST CANCER |
5R01CA080195-09 |
1999-01-01 |
2007-02-01 |
31-Jan-09 |
2007 |
ARTEAGA, CARLOS L |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$302,816 |
No NIH Category available. |
ERBB RECEPTOR HOMO-AND HETERO-DIMERIZATION |
5R01CA079992-09 |
1999-02-01 |
2007-02-01 |
31-Jan-08 |
2007 |
LEMMON, MARK A. |
UNIVERSITY OF PENNSYLVANIA |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$242,246 |
No NIH Category available. |
PHARMACODYNAMIC ASSESSMENT OF RTK INHIBITORS IN CANCER |
5R01CA112385-03 |
2005-02-23 |
2007-02-01 |
31-Jan-08 |
2007 |
HALLAHAN, DENNIS E |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$258,357 |
No NIH Category available. |
NSABP PARTICIPATING SITES |
5U10CA118735-02 |
2006-04-10 |
2007-02-01 |
31-Jan-08 |
2007 |
CHANG, JENNY C-N |
BAYLOR COLLEGE OF MEDICINE |
HOUSTON |
TX |
UNITED STATES |
NCI |
$66,456 |
No NIH Category available. |
MODELING CELL RECEPTOR SIGNALING PATHWAYS |
5R01GM072821-03 |
2005-03-01 |
2007-03-01 |
31-Jul-08 |
2007 |
RESAT, HALUK |
BATTELLE PACIFIC NORTHWEST LABORATORIES |
RICHLAND |
WA |
UNITED STATES |
NIGMS |
$275,798 |
No NIH Category available. |
BRAIN TUMORS - IMMUNOLOGICAL AND BIOLOGICAL STUDIES |
5R37CA011898-37 |
1976-12-01 |
2007-04-01 |
31-Mar-08 |
2007 |
BIGNER, DARELL D |
DUKE UNIVERSITY |
DURHAM |
NC |
UNITED STATES |
NCI |
$642,571 |
No NIH Category available. |
SPECTROSCOPIC LOCALIZATION OF BREAST CANCER |
5R44CA083597-05 |
1999-08-13 |
2007-04-01 |
31-Mar-08 |
2007 |
BENARON, DAVID A. |
SPECTROS CORPORATION |
Portola Valley |
CA |
UNITED STATES |
NCI |
$995,474 |
No NIH Category available. |
REGULATION OF ERBB2/NEU-INDUCED MAMMARY GLAND CANCER |
2R01CA090398-06A1 |
2001-03-05 |
2007-04-01 |
31-Jan-08 |
2007 |
KERI, RUTH A |
CASE WESTERN RESERVE UNIVERSITY |
CLEVELAND |
OH |
UNITED STATES |
NCI |
$216,920 |
No NIH Category available. |
ROLE OF NEUREGULIN/ERBB SIGNALING IN THE ADULT HEART |
5R01HL068144-07 |
2001-09-30 |
2007-04-01 |
31-Mar-08 |
2007 |
SAWYER, DOUGLAS B |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NHLBI |
$327,212 |
No NIH Category available. |
PHASE II STUDY OF A HER-2/NEU INTRACELLULAR DOMAIN (ICD) PEPTIDE-BASED VACCINE |
5M01RR000037-47 |
2007-04-01 |
2007-04-01 |
16-Sep-07 |
2007 |
DISIS, MARY L. |
UNIVERSITY OF WASHINGTON |
SEATTLE |
WA |
UNITED STATES |
NCRR |
$609 |
No NIH Category available. |
NSABP B-31 |
5M01RR006192-14 |
2007-04-01 |
2007-04-01 |
31-Mar-08 |
2007 |
KURTZMAN, SCOTT |
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT |
FARMINGTON |
CT |
UNITED STATES |
NCRR |
$784 |
No NIH Category available. |
PHASE I-II STUDY OF COMBINATION IMMUNOTHERAPY FOR HER-2/NEU CYTOTOXIC T CELLS |
5M01RR000037-47 |
2007-04-01 |
2007-04-01 |
16-Sep-07 |
2007 |
DISIS, MARY L. |
UNIVERSITY OF WASHINGTON |
SEATTLE |
WA |
UNITED STATES |
NCRR |
$2,053 |
No NIH Category available. |
P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACLITAXEL W/WO TRAS |
5M01RR010732-13 |
2007-04-01 |
2007-04-01 |
31-Mar-08 |
2007 |
RYBKA, WITOLD B. |
PENNSYLVANIA STATE UNIV HERSHEY MED CTR |
HERSHEY |
PA |
UNITED STATES |
NCRR |
$3,267 |
No NIH Category available. |
P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACLITAXEL W/WO TRAS |
5M01RR010732-13 |
2007-04-01 |
2007-04-01 |
31-Mar-08 |
2007 |
RYBKA, WITOLD B. |
PENNSYLVANIA STATE UNIV HERSHEY MED CTR |
HERSHEY |
PA |
UNITED STATES |
NCRR |
$5,083 |
No NIH Category available. |
BI-WEEKLY TAXOL & RT IN ANDROGEN ABLATED ADVANCED PROSTATE CANCER |
5M01RR000096-46 |
2007-04-01 |
2007-04-01 |
31-Mar-08 |
2007 |
FORMENTI, SILVIA C |
NEW YORK UNIVERSITY SCHOOL OF MEDICINE |
NEW YORK |
NY |
UNITED STATES |
NCRR |
$10,258 |
No NIH Category available. |
INDIVIDUALIZED TX OF BREAST CANCER BASED ON TUMOR MOLECULAR CHARACTERISTICS |
5M01RR000096-46 |
2007-04-01 |
2007-04-01 |
31-Mar-08 |
2007 |
FORMENTI, SILVIA C |
NEW YORK UNIVERSITY SCHOOL OF MEDICINE |
NEW YORK |
NY |
UNITED STATES |
NCRR |
$61,938 |
No NIH Category available. |
MODULATION BY BOTANICALS OF ANTIBODY BASED CANCER IMMUNOTHERAPY |
5P50AT002779-03 |
|
2007-04-01 |
31-Mar-08 |
2007 |
CHEUNG, NAI-KONG V |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCCAM |
$283,563 |
No NIH Category available. |
NEXT GENERATION STRATEGIES TO INTERCEPT ERBB SIGNALING |
5R37CA072981-11 |
1997-04-25 |
2007-04-04 |
31-Mar-08 |
2007 |
YARDEN, YOSEF NONE |
WEIZMANN INSTITUTE OF SCIENCE |
REHOVOT |
|
ISRAEL |
NCI |
$230,408 |
No NIH Category available. |
NORTH CENTRAL CANCER TREATMENT GROUP |
3U10CA025224-28S1 |
1982-01-01 |
2007-04-20 |
31-Dec-07 |
2007 |
BUCKNER, JAN C |
MAYO CLINIC |
ROCHESTER |
MN |
UNITED STATES |
NCI |
$222,000 |
No NIH Category available. |
NORTH CENTRAL CANCER TREATMENT GROUP |
3U10CA025224-28S2 |
1982-01-01 |
2007-04-20 |
31-Dec-07 |
2007 |
BUCKNER, JAN C |
MAYO CLINIC |
ROCHESTER |
MN |
UNITED STATES |
NCI |
$300,000 |
No NIH Category available. |
NORTH CENTRAL CANCER TREATMENT GROUP |
3U10CA025224-28S3 |
1982-01-01 |
2007-04-20 |
31-Dec-07 |
2007 |
BUCKNER, JAN C |
MAYO CLINIC |
ROCHESTER |
MN |
UNITED STATES |
NCI |
$2,543,699 |
No NIH Category available. |
GROWTH FACTOR RECEPTOR SIGNALING IN BREAST CANCER |
5P01CA099031-05 |
2003-04-01 |
2007-04-20 |
31-Mar-10 |
2007 |
HUNG, MIEN-CHIE |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$1,131,894 |
No NIH Category available. |
TARGETING JAB1 ONCOGENIC FUNCTION IN BREAST CANCER |
2R01CA090853-06 |
2001-04-01 |
2007-04-25 |
31-Jan-08 |
2007 |
CLARET, FRANCOIS X |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$255,009 |
No NIH Category available. |
EASTERN COOPERATIVE ONCOLOGY GROUP |
5U10CA016116-34 |
1978-06-01 |
2007-05-01 |
30-Apr-08 |
2007 |
FORASTIERE, ARLENE ANN |
JOHNS HOPKINS UNIVERSITY |
BALTIMORE |
MD |
UNITED STATES |
NCI |
$279,594 |
No NIH Category available. |
HER2 PATHWAY IN BREAST CANCER PROGRESSION AND TREATMENT |
5R01CA065746-13 |
1995-02-01 |
2007-05-01 |
30-Apr-08 |
2007 |
KUMAR, RAKESH |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$250,558 |
No NIH Category available. |
MOLECULAR STUDIES OF ESOPHAGEAL ADENOCARCINOMA |
5R01CA071606-11 |
1997-06-05 |
2007-05-01 |
30-Apr-08 |
2007 |
BEER, DAVID GEORGE |
UNIVERSITY OF MICHIGAN AT ANN ARBOR |
ANN ARBOR |
MI |
UNITED STATES |
NCI |
$305,949 |
No NIH Category available. |
BREAST CANCER RESPONSE MARKERS TO A DUAL HER1/2 BLOCKER |
5R01CA112305-03 |
2005-06-16 |
2007-05-01 |
30-Apr-08 |
2007 |
CHANG, JENNY C-N |
BAYLOR COLLEGE OF MEDICINE |
HOUSTON |
TX |
UNITED STATES |
NCI |
$252,236 |
No NIH Category available. |
FUNCTIONS IN TUMORS OF RECURRENTLY AMPLIFIED PREFOLDIN-4 |
5R01CA112608-03 |
2005-07-25 |
2007-05-01 |
30-Apr-08 |
2007 |
HANAHAN, DOUGLAS |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$283,709 |
No NIH Category available. |
METABOLIC PHENOTYPING WITH PET TO MONITOR AND PREDICT RESPONSE TO KINASE |
5P50CA086306-08 |
|
2007-05-01 |
30-Apr-08 |
2007 |
CZERNIN, JOHANNES |
UNIVERSITY OF CALIFORNIA LOS ANGELES |
LOS ANGELES |
CA |
UNITED STATES |
NCI |
$258,182 |
No NIH Category available. |
IMPROVING INTERSTITIAL TRANSPORT IN TUMORS |
5P01CA080124-07 |
|
2007-05-01 |
30-Apr-08 |
2007 |
JAIN, RAKESH K. |
MASSACHUSETTS GENERAL HOSPITAL |
BOSTON |
MA |
UNITED STATES |
NCI |
$309,412 |
No NIH Category available. |
FUNCTION OF MUC4 IN MAMMARY EPITHELIA AND TUMORS |
5R01CA052498-15 |
1991-09-30 |
2007-06-01 |
31-May-08 |
2007 |
CARRAWAY, KERMIT L. |
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE |
MIAMI |
FL |
UNITED STATES |
NCI |
$262,065 |
No NIH Category available. |
DEVELOPMENT OF ERBB2 BASED BREAST CANCER VACCINES |
5R01CA076340-10 |
1997-12-04 |
2007-06-01 |
31-May-10 |
2007 |
WEI, WEI-ZEN |
WAYNE STATE UNIVERSITY |
DETROIT |
MI |
UNITED STATES |
NCI |
$269,170 |
No NIH Category available. |
TARGETED INTERVENTION OF BREAST ONCOGENIC PATHWAYS |
3R01CA098473-05S1 |
2003-06-13 |
2007-06-01 |
31-May-08 |
2007 |
SEBTI, SAID M |
H. LEE MOFFITT CANCER CTR & RES INST |
TAMPA |
FL |
UNITED STATES |
NCI |
$121,464 |
No NIH Category available. |
PROFILING EGFR AND HER2 IN BREAST CANCER USING MULTIPLEX TISSUE IMMUNOSTAINING |
1R43CA123994-01A2 |
2007-06-15 |
2007-06-15 |
30-Nov-07 |
2007 |
JAMES, WILLIAM M |
20/20 GENESYSTEMS, INC. |
ROCKVILLE |
MD |
UNITED STATES |
NCI |
$117,930 |
No NIH Category available. |
PAUL CALABRESI PROGRAM IN CLINICAL-TRANSLATIONAL RESEARCH AT MAYO CLINIC |
5K12CA090628-07 |
2001-09-25 |
2007-07-01 |
30-Jun-08 |
2007 |
HARTMANN, LYNN C. |
MAYO CLINIC |
ROCHESTER |
MN |
UNITED STATES |
NCI |
$665,657 |
No NIH Category available. |
ANTIBODY MICROARRAYS FOR CANCER DIAGNOSTICS |
5R44CA105540-03 |
2004-03-01 |
2007-07-01 |
31-Dec-08 |
2007 |
NIELSEN, ULRIK B. |
MERRIMACK PHARMACEUTICALS, INC. |
CAMBRIDGE |
MA |
UNITED STATES |
NCI |
$386,520 |
No NIH Category available. |
GROWTH FACTOR AS ANTI-ANGIOGENESIS AGENTS |
5R01CA106829-04 |
2004-09-30 |
2007-07-01 |
30-Jun-08 |
2007 |
SEBTI, SAID M |
H. LEE MOFFITT CANCER CTR & RES INST |
TAMPA |
FL |
UNITED STATES |
NCI |
$321,936 |
No NIH Category available. |
IN VIVO THERMOACOUSTIC IMAGING OF HER2 STATUS |
5R44CA114839-03 |
2005-04-07 |
2007-07-01 |
30-Jun-08 |
2007 |
KRUGER, ROBERT A |
OPTOSONICS, INC. |
ORIENTAL |
NC |
UNITED STATES |
NCI |
$815,842 |
No NIH Category available. |
IDENTIFICATION AND CHARACTERIZATION OF ACTIVATED TYROSINE KINASES IN GLIOBLASTOMA |
1F32CA121769-01A1 |
2007-07-01 |
2007-07-01 |
30-Jun-08 |
2007 |
STOMMEL, JAYNE |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$52,898 |
No NIH Category available. |
MECHANISMS OF INVERTEBRATE EGF RECEPTOR INHIBITION |
1R01CA125432-01A1 |
2007-07-01 |
2007-07-01 |
31-May-08 |
2007 |
LEMMON, MARK A. |
UNIVERSITY OF PENNSYLVANIA |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$236,888 |
No NIH Category available. |
CLINICAL PRODUCTION |
2P01CA043904-16A1 |
2007-07-01 |
2007-07-01 |
30-Jun-08 |
2007 |
YAZAKI, PAUL |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$296,825 |
No NIH Category available. |
MOLECULAR TARGETS FOR PROGNOSIS AND THERAPY |
5P50CA083636-09 |
|
2007-07-01 |
30-Jun-08 |
2007 |
HOOD, LEROY E |
FRED HUTCHINSON CANCER RESEARCH CENTER |
SEATTLE |
WA |
UNITED STATES |
NCI |
$548,026 |
No NIH Category available. |
ANALYSIS OF CIRCULATING TUMOR CELLS IN A PHASE I/II STUDY FOR BREAST CANCER |
5R21CA121541-02 |
2006-07-07 |
2007-07-05 |
30-Jun-10 |
2007 |
SWABY, RAMONA F |
FOX CHASE CANCER CENTER |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$307,278 |
No NIH Category available. |
FATTY ACID SYNTHASE:MOLECULAR TARGET FOR BREAST CANCER THERAPY & CHEMOPREVENTION |
5R01CA116623-03 |
2005-09-16 |
2007-07-24 |
31-May-08 |
2007 |
LUPU, RUTH |
NORTHSHORE UNIV HEALTHSYSTEM RES INST |
EVANSTON |
IL |
UNITED STATES |
NCI |
$418,872 |
No NIH Category available. |
CROSSTALK TGFBETA AND HER2 (ERBB2) SIGNALING IN MAMMARY TUMORIGENESIS |
1K99CA125892-01 |
2007-07-25 |
2007-07-25 |
30-Jun-08 |
2007 |
WANG, SHIZHEN EMILY |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$117,905 |
No NIH Category available. |
THE AGING GUT: REGULATION OF CELL PROLIFERATION |
2R01AG014343-10A1 |
1997-09-01 |
2007-08-01 |
31-Jul-08 |
2007 |
MAJUMDAR, ADHIP N. |
WAYNE STATE UNIVERSITY |
DETROIT |
MI |
UNITED STATES |
NIA |
$232,470 |
No NIH Category available. |
STRUCTURAL STUDIES OF GROWTH FACTOR RECEPTOR FUNCTION |
5R01CA090466-06 |
2001-04-01 |
2007-08-01 |
31-Jul-08 |
2007 |
LEAHY, DANIEL J |
JOHNS HOPKINS UNIVERSITY |
BALTIMORE |
MD |
UNITED STATES |
NCI |
$222,384 |
No NIH Category available. |
MICELLE SURFACE ENGINEERING FOR ACTIVE TARGETING BY ACIDIC TUMOR EXTRACELLULAR PH |
5R01CA122356-02 |
2006-08-22 |
2007-08-01 |
31-Jul-08 |
2007 |
BAE, YOU HAN |
UNIVERSITY OF UTAH |
SALT LAKE CITY |
UT |
UNITED STATES |
NCI |
$257,668 |
No NIH Category available. |
NEW BIFUNCTIONAL LIGANDS FOR RADIOIMMUNOTHERAPY |
5R01CA112503-02 |
2006-09-01 |
2007-08-01 |
31-Jul-08 |
2007 |
CHONG, HYUN-SOON |
ILLINOIS INSTITUTE OF TECHNOLOGY |
CHICAGO |
IL |
UNITED STATES |
NCI |
$138,368 |
No NIH Category available. |
OPENING THE BLOOD BRAIN BARRIER FOR MOLECULAR IMAGING |
5U41RR019703-03 |
2007-08-01 |
2007-08-01 |
31-Jul-08 |
2007 |
HYNYNEN, KULLERVO |
BRIGHAM AND WOMEN'S HOSPITAL |
BOSTON |
MA |
UNITED STATES |
NCRR |
$12,196 |
No NIH Category available. |
ERBB2 DOWNREGULATION THROUGH HSP90 INHIBITION |
1R01CA116552-01A2 |
2007-08-01 |
2007-08-01 |
31-Oct-07 |
2007 |
BAND, HAMID |
NORTHSHORE UNIV HEALTHSYSTEM RES INST |
EVANSTON |
IL |
UNITED STATES |
NCI |
$49,190 |
No NIH Category available. |
DEVELOPMENT OF AN EFC ASSAY TO MEASURE GROWTH FACTOR RECEPTOR DIMER FORMATION FOR |
1R43CA130236-01 |
2007-08-01 |
2007-08-01 |
30-Apr-08 |
2007 |
OLSON, KEITH |
DISCOVERX CORPORATION |
FREMONT |
CA |
UNITED STATES |
NCI |
$113,104 |
No NIH Category available. |
BREAST CANCER VACCINE STRATEGIES FOR HER2-OVEREXPRESSING AND LUM. B TUMORS |
5P50CA058223-15 |
|
2007-08-01 |
31-Jul-08 |
2007 |
SERODY, JONATHAN STUART |
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL |
CHAPEL HILL |
NC |
UNITED STATES |
NCI |
$218,703 |
No NIH Category available. |
WUMC-CANCER AND LEUKEMIA GROUP B |
5U10CA077440-10 |
1998-05-08 |
2007-08-03 |
31-Mar-08 |
2007 |
BARTLETT, NANCY L |
WASHINGTON UNIVERSITY |
SAINT LOUIS |
MO |
UNITED STATES |
NCI |
$334,381 |
No NIH Category available. |
RESEARCH PROGRAMS-SIGNAL TRANSDUCTION |
2P30CA016359-29 |
2007-08-09 |
2007-08-09 |
31-Jul-08 |
2007 |
SCHLESSINGER, JOSEPH |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$19,358 |
No NIH Category available. |
RADIOIMMUNOTHERAPY: CLINICAL STUDIES |
2P01CA043904-16A1 |
2007-07-01 |
2007-08-13 |
30-Jun-08 |
2007 |
WONG, JEFFREY Y |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$230,528 |
No NIH Category available. |
RADIOPHARMACY AND ASSAYS |
2P01CA043904-16A1 |
2007-07-01 |
2007-08-13 |
30-Jun-08 |
2007 |
COLCHER, DAVID MORRIS |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$472,615 |
No NIH Category available. |
NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT |
3U10CA012027-37S1 |
1976-12-01 |
2007-08-20 |
31-Jan-08 |
2007 |
WOLMARK, NORMAN |
NSABP FOUNDATION, INC. |
PITTSBURGH |
PA |
UNITED STATES |
NCI |
$450,000 |
No NIH Category available. |
DANA-FARBER/HARVARD SPORE IN BREAST CANCER |
3P50CA089393-08S1 |
2000-09-30 |
2007-09-01 |
31-Aug-08 |
2007 |
IGLEHART, JAMES DIRK |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$412,443 |
No NIH Category available. |
DANA-FARBER/HARVARD SPORE IN BREAST CANCER |
5P50CA089393-08 |
2000-09-30 |
2007-09-01 |
31-Aug-08 |
2007 |
IGLEHART, JAMES DIRK |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$2,180,817 |
No NIH Category available. |
MODIFIED HER-2 TUMOR ANTIGENS FOR VACCINATION IN CANCER |
5R42CA106107-03 |
2004-03-01 |
2007-09-01 |
31-Aug-10 |
2007 |
MAMULA, MARK J. |
L2 DIAGNOSTICS, LLC |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$574,787 |
No NIH Category available. |
DISCOVERY AND CHARACTERIZATION OF BREAST CANCER GENES |
5K01CA101777-04 |
2004-09-07 |
2007-09-01 |
31-Aug-08 |
2007 |
HODGSON, JOHN G |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$148,770 |
No NIH Category available. |
BLOOD TEST DETECTS CHANGE FROM HER2- TO + IN BREAST CANCER |
5R01CA101790-03 |
2005-09-01 |
2007-09-01 |
31-Aug-08 |
2007 |
UHR, JONATHAN W |
UNIVERSITY OF TEXAS SW MED CTR/DALLAS |
DALLAS |
TX |
UNITED STATES |
NCI |
$253,070 |
No NIH Category available. |
UTMDACC SPORE IN BREAST CANCER |
5P50CA116199-03 |
2005-09-23 |
2007-09-01 |
31-Aug-08 |
2007 |
HORTOBAGYI, GABRIEL N |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$2,180,817 |
No NIH Category available. |
LIPOSOMAL DELIVERY OF HIGH LET EMITTERS TO CELL NUCLEI |
5F32CA123651-02 |
2006-09-01 |
2007-09-01 |
31-Aug-08 |
2007 |
HAR-EL, YAH-EL |
JOHNS HOPKINS UNIVERSITY |
BALTIMORE |
MD |
UNITED STATES |
NCI |
$48,796 |
No NIH Category available. |
CHARACTERIZATION OF METHODS FOR PRESERVATION OF PHOSPHOPROTEINS IN FIXED TISSUES |
5R21CA123006-02 |
2006-09-01 |
2007-09-01 |
31-Aug-08 |
2007 |
HSI, ERIC |
CLEVELAND CLINIC LERNER COL/MED-CWRU |
CLEVELAND |
OH |
UNITED STATES |
NCI |
$168,773 |
No NIH Category available. |
VALIDATION AND QUANTIFICATION OF FFPE ANTIGEN RETRIEVAL BY PROTEOME ANALYSIS |
5R41CA122715-02 |
2006-09-01 |
2007-09-01 |
31-Aug-08 |
2007 |
SAXENA, SATYA PRAKASH |
CALIBRANT BIOSYSTEMS, INC. |
Gaithersburg |
MD |
UNITED STATES |
NCI |
$219,582 |
No NIH Category available. |
MOUSE MODELING AND ANIMAL DEVELOPMENT |
2P01CA095426-06 |
2007-09-01 |
2007-09-01 |
31-Aug-08 |
2007 |
MUTHUSAMY, NATARAJAN |
OHIO STATE UNIVERSITY |
COLUMBUS |
OH |
UNITED STATES |
NCI |
$223,606 |
No NIH Category available. |
P-2: TARGET COMBINATIONS FOR HER2 - POSITIVE BREAST CANCER |
5P50CA089393-08 |
|
2007-09-01 |
31-Aug-08 |
2007 |
HARRIS, LYNDSAY N |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$133,233 |
No NIH Category available. |
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C |
5P50CA092629-07 |
|
2007-09-01 |
31-Aug-08 |
2007 |
ROSEN, NEAL |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$413,330 |
No NIH Category available. |
COMBINATORIAL LIBRARY SCREENING CORE |
5U54CA119343-03 |
|
2007-09-01 |
31-Aug-08 |
2007 |
LIU, RIHE |
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL |
CHAPEL HILL |
NC |
UNITED STATES |
NCI |
$425,854 |
No NIH Category available. |
IMPROVING THE PHARMACOKINETICS OF A NEW PROTEIN-BASED PAN-HER ANTAGONIST. |
1R43CA130378-01 |
2007-09-10 |
2007-09-10 |
9-Mar-08 |
2007 |
MONTICELLO, DANIEL J |
MOLECULAR LOGIX, INC. |
THE WOODLANDS |
TX |
UNITED STATES |
NCI |
$136,332 |
No NIH Category available. |
NOVEL TARGETED THERAPY FOR BREAST CANCER |
1R43CA124179-01A1 |
2007-09-11 |
2007-09-11 |
29-Feb-08 |
2007 |
SERRERO, GINETTE |
A AND G PHARMACEUTICAL, INC. |
COLUMBIA |
MD |
UNITED STATES |
NCI |
$120,600 |
No NIH Category available. |
ESTROGEN RECEPTOR PHOSPHORYLATION AND PROMOTER RECRUITMENT IN BREAST CANCER. |
5F31CA126489-02 |
2006-09-14 |
2007-09-14 |
13-Sep-08 |
2007 |
DUPLESSIS, TAMIKA T |
TULANE UNIVERSITY OF LOUISIANA |
NEW ORLEANS |
LA |
UNITED STATES |
NCI |
$28,120 |
No NIH Category available. |
REGULATION OF HER2/NEU BY ACTIVATION LOOP PHOSPHORYLATION AND ALG-2 |
1K22CA128951-01 |
2007-09-18 |
2007-09-18 |
31-Aug-08 |
2007 |
BOSE, RON |
WASHINGTON UNIVERSITY |
SAINT LOUIS |
MO |
UNITED STATES |
NCI |
$143,183 |
No NIH Category available. |
MECHANISM OF ACTION OF DIFFERENTIATION AGENTS |
7R37CA038173-22 |
1986-07-01 |
2007-09-20 |
30-Jun-08 |
2007 |
BRATTAIN, MICHAEL G. |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
OMAHA |
NE |
UNITED STATES |
NCI |
$321,158 |
No NIH Category available. |
NOVEL PLATFORM TECHNOLOGY FOR DEVELOPING THERAPEUTIC HUMAN MABS |
1R43CA126070-01A1 |
2007-09-21 |
2007-09-21 |
30-Nov-08 |
2007 |
KRAVITZ, RACHEL HANNAH |
NEOCLONE BIOTECHNOLOGY INTERNATIONAL |
MADISON |
WI |
UNITED STATES |
NCI |
$140,000 |
No NIH Category available. |
EVALUATION OF NOVEL CYTOTOXIC COMPOUNDS FOR IMMUNOCONJUGATES |
1R43CA128322-01 |
2007-09-21 |
2007-09-21 |
31-Aug-08 |
2007 |
BELL, STANLEY C |
ONCONOVA THERAPEUTICS, INC. |
NEWTOWN |
PA |
UNITED STATES |
NCI |
$155,103 |
No NIH Category available. |
INNATE IMMUNITY: ELUCIDATION AND MODULATION FOR CANCER THERAPY |
2P01CA095426-06 |
2002-02-01 |
2007-09-24 |
31-Aug-08 |
2007 |
CALIGIURI, MICHAEL A |
OHIO STATE UNIVERSITY |
COLUMBUS |
OH |
UNITED STATES |
NCI |
$1,987,279 |
No NIH Category available. |
ANTIBODY THERAPY FOR BREAST CANCER: INVESTIGATION OF IMMUNE MODULATION WITH IL-21 |
2P01CA095426-06 |
2007-09-01 |
2007-09-24 |
31-Aug-08 |
2007 |
CARSON, WILLIAM E. |
OHIO STATE UNIVERSITY |
COLUMBUS |
OH |
UNITED STATES |
NCI |
$392,148 |
No NIH Category available. |
REWIRING ERBB SIGNALING IN CANCER CELLS |
2R01CA098881-05A1 |
2003-07-01 |
2007-09-25 |
31-Jul-08 |
2007 |
LANDGRAF, RALF |
UNIVERSITY OF CALIFORNIA LOS ANGELES |
LOS ANGELES |
CA |
UNITED STATES |
NCI |
$273,042 |
No NIH Category available. |
UTMDACC SPORE IN BREAST CANCER |
3P50CA116199-03S1 |
2005-09-23 |
2007-09-25 |
31-Aug-08 |
2007 |
HORTOBAGYI, GABRIEL N |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$398,581 |
No NIH Category available. |
EARLY SCREENING OF BREAST LESION TRIAL (PHASE III PIVOTAL) |
1R44CA126441-01 |
2007-09-27 |
2007-09-27 |
28-Feb-08 |
2007 |
BENARON, DAVID A. |
SPECTROS CORPORATION |
Portola Valley |
CA |
UNITED STATES |
NCI |
$222,084 |
No NIH Category available. |
PROCESSING AC-227 SOURCES FOR LEAD-212 AND RADIUM-223 REQUIRED BY CANCER RESEARCH |
1R41CA124302-01A1 |
2007-09-28 |
2007-09-28 |
31-Aug-09 |
2007 |
SODERQUIST, CHUCK Z |
ALPHAMED, INC |
Wrentham |
MA |
UNITED STATES |
NCI |
$111,300 |
No NIH Category available. |
CELLULARLY RESOLVED MOLECULAR PATHWAY ASSESSMENT IN BIOPSIES VIA SPECTRAL IMAGING |
1R44CA130026-01 |
2007-09-28 |
2007-09-28 |
31-Jan-09 |
2007 |
LEVENSON, RICHARD M. |
CAMBRIDGE RESEARCH AND INSTRUMENTATION |
WOBURN |
MA |
UNITED STATES |
NCI |
$227,868 |
No NIH Category available. |
A NOVEL TRANSGENIC SILKWORM SYSTEM FOR RECOMBINANT GLYCOPROTEIN PRODUCTION |
1R01GM080672-01A1 |
2007-09-29 |
2007-09-29 |
31-Jul-08 |
2007 |
JARVIS, DONALD L. |
UNIVERSITY OF WYOMING |
LARAMIE |
WY |
UNITED STATES |
NIGMS |
$299,250 |
No NIH Category available. |
TARGETED ALPHA-PARTICLE EMITTER THERAPY OF METASTASES |
5R01CA113797-03 |
2005-12-09 |
2007-12-01 |
30-Nov-08 |
2008 |
SGOUROS, GEORGE |
JOHNS HOPKINS UNIVERSITY |
BALTIMORE |
MD |
UNITED STATES |
NCI |
$278,677 |
Breast Cancer;Cancer;Digestive Diseases;Liver Disease |
TARGETING THE HER2 PATHWAY: MECHANISMS OF RESISTANCE & STRATEGIES TO OVERCOME |
2P50CA058183-14 |
2007-12-01 |
2007-12-01 |
30-Nov-08 |
2008 |
OSBORNE, C KENT |
BAYLOR COLLEGE OF MEDICINE |
HOUSTON |
TX |
UNITED STATES |
NCI |
$161,961 |
Breast Cancer;Cancer;Infectious Diseases |
NOVEL TREATMENT OF NF-1 ASSOCIATED MALIGNANT PERIPHERAL NERVE SHEATH TUMORS |
1R01CA122804-01A2 |
2007-12-07 |
2007-12-07 |
30-Nov-08 |
2008 |
CARROLL, STEVEN L |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
BIRMINGHAM |
AL |
UNITED STATES |
NCI |
$300,875 |
Biotechnology;Cancer;Neurofibromatosis;Neurosciences |
MODIFIERS OF TUMOR SUSCEPTIBILITY IN MURINE NEUROBLASTOMA |
3R01NS055750-01A2S1 |
2007-12-15 |
2007-12-15 |
30-Nov-08 |
2008 |
WEISS, WILLIAM A |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NINDS |
$35,000 |
Biotechnology;Cancer;Genetics;Human Genome;Neurosciences;Pediatric |
MODIFIERS OF TUMOR SUSCEPTIBILITY IN MURINE NEUROBLASTOMA |
1R01NS055750-01A2 |
2007-12-15 |
2007-12-15 |
30-Nov-08 |
2008 |
WEISS, WILLIAM A |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NINDS |
$337,331 |
Biotechnology;Cancer;Genetics;Human Genome;Neurosciences;Pediatric |
TRANSLATIONAL RESEARCH IN BREAST CANCER |
2P50CA058183-14 |
1992-09-30 |
2007-12-28 |
30-Nov-08 |
2008 |
OSBORNE, C KENT |
BAYLOR COLLEGE OF MEDICINE |
HOUSTON |
TX |
UNITED STATES |
NCI |
$2,300,000 |
No NIH Category available. |
NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT |
3U10CA012027-38S1 |
1976-12-01 |
2008-02-01 |
31-Jan-09 |
2008 |
WOLMARK, NORMAN |
NSABP FOUNDATION, INC. |
PITTSBURGH |
PA |
UNITED STATES |
NCI |
$236,163 |
No NIH Category available. |
NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT |
5U10CA012027-38 |
1976-12-01 |
2008-02-01 |
31-Jan-09 |
2008 |
WOLMARK, NORMAN |
NSABP FOUNDATION, INC. |
PITTSBURGH |
PA |
UNITED STATES |
NCI |
$7,116,748 |
No NIH Category available. |
NSABP PARTICIPATING SITES |
5U10CA118735-03 |
2006-04-10 |
2008-02-01 |
31-Jan-09 |
2008 |
CHANG, JENNY C-N |
BAYLOR COLLEGE OF MEDICINE |
HOUSTON |
TX |
UNITED STATES |
NCI |
$66,231 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials |
REGULATION OF STAT3 SIGNALING |
5R01CA122910-02 |
2007-04-01 |
2008-02-01 |
31-Jan-09 |
2008 |
REICH, NANCY C. |
STATE UNIVERSITY NEW YORK STONY BROOK |
STONY BROOK |
NY |
UNITED STATES |
NCI |
$294,500 |
Cancer;Genetics;Hematology |
TARGETING JAB1 ONCOGENIC FUNCTION IN BREAST CANCER |
5R01CA090853-07 |
2001-04-01 |
2008-02-21 |
31-Jan-09 |
2008 |
CLARET, FRANCOIS X |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$255,009 |
Biotechnology;Breast Cancer;Cancer;Genetics |
REGULATION OF ERBB2/NEU-INDUCED MAMMARY GLAND CANCER |
5R01CA090398-07 |
2001-03-05 |
2008-02-25 |
31-Jan-09 |
2008 |
KERI, RUTH A |
CASE WESTERN RESERVE UNIVERSITY |
CLEVELAND |
OH |
UNITED STATES |
NCI |
$212,114 |
Breast Cancer;Cancer;Genetics |
ERBB2 DOWNREGULATION THROUGH HSP90 INHIBITION |
7R01CA116552-02 |
2007-08-01 |
2008-02-26 |
31-May-08 |
2007 |
BAND, HAMID |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
OMAHA |
NE |
UNITED STATES |
NCI |
$239,610 |
No NIH Category available. |
REGULATION OF ERBB2/NEU-INDUCED MAMMARY GLAND CANCER |
3R01CA090398-07S1 |
2001-03-05 |
2008-03-01 |
31-Jan-09 |
2008 |
KERI, RUTH A |
CASE WESTERN RESERVE UNIVERSITY |
CLEVELAND |
OH |
UNITED STATES |
NCI |
$77,462 |
Breast Cancer;Cancer;Genetics |
GENERATION OF A THERAPEUTIC ANTIBODY DIRECTED AGAINST CCR4 FOR PATIENTS WITH |
2P50CA093683-06A2 |
2008-03-01 |
2008-03-01 |
31-Jul-09 |
2008 |
MARASCO, WAYNE A. |
BRIGHAM AND WOMEN'S HOSPITAL |
BOSTON |
MA |
UNITED STATES |
NCI |
$216,958 |
Biotechnology;Cancer;Immunization;Lymphoma;Prevention;Vaccine Related |
NEXT GENERATION STRATEGIES TO INTERCEPT ERBB SIGNALING |
5R37CA072981-12 |
1997-04-25 |
2008-04-01 |
31-Mar-09 |
2008 |
YARDEN, YOSEF NONE |
WEIZMANN INSTITUTE OF SCIENCE |
REHOVOT |
|
ISRAEL |
NCI |
$230,408 |
Biotechnology;Cancer;Prevention |
WUMC-CANCER AND LEUKEMIA GROUP B |
5U10CA077440-11 |
1998-05-08 |
2008-04-01 |
31-Mar-09 |
2008 |
BARTLETT, NANCY L |
WASHINGTON UNIVERSITY |
SAINT LOUIS |
MO |
UNITED STATES |
NCI |
$334,932 |
Breast Cancer;Cancer;Clinical Research;Clinical Trials;Colo-Rectal Cancer;Diagnostic Radiology;Digestive Diseases;Genetics;Hematology;Lung;Lung Cancer;Lymphoma;Orphan Drug;Prostate Cancer;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Transplantation;Urologic Diseases |
THE ROLE OF SYNDECAN-1 IN MOUSE MAMMARY NEOPLASIA |
2R01CA090877-06A2 |
2001-04-01 |
2008-04-01 |
31-Jan-09 |
2008 |
ALEXANDER, CAROLINE MARGARET |
UNIVERSITY OF WISCONSIN MADISON |
MADISON |
WI |
UNITED STATES |
NCI |
$295,173 |
Breast Cancer;Cancer;Stem Cell Research;Stem Cell Research - Nonembryonic - Non-Human |
ROLE OF NEUREGULIN/ERBB SIGNALING IN THE ADULT HEART |
5R01HL068144-08 |
2001-09-30 |
2008-04-01 |
31-Mar-09 |
2008 |
SAWYER, DOUGLAS B |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NHLBI |
$327,478 |
Cardiovascular;Heart Disease |
CLINICAL TRIAL: P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACL |
5M01RR010732-14 |
2008-04-01 |
2008-04-01 |
31-Mar-09 |
2008 |
RYBKA, WITOLD B. |
PENNSYLVANIA STATE UNIV HERSHEY MED CTR |
HERSHEY |
PA |
UNITED STATES |
NCRR |
$1,217 |
Breast Cancer;Cancer;Clinical Research;Clinical Trials |
CLINICAL TRIAL: INDIVIDUALIZED TX OF BREAST CANCER BASED ON TUMOR MOLECULAR CHAR |
5M01RR000096-47 |
2008-04-01 |
2008-04-01 |
31-Mar-09 |
2008 |
FORMENTI, SILVIA C |
NEW YORK UNIVERSITY SCHOOL OF MEDICINE |
NEW YORK |
NY |
UNITED STATES |
NCRR |
$2,166 |
Breast Cancer;Cancer;Clinical Research;Clinical Trials;Orphan Drug |
CLINICAL TRIAL: P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACL |
5M01RR010732-14 |
2008-04-01 |
2008-04-01 |
31-Mar-09 |
2008 |
RYBKA, WITOLD B. |
PENNSYLVANIA STATE UNIV HERSHEY MED CTR |
HERSHEY |
PA |
UNITED STATES |
NCRR |
$6,491 |
Breast Cancer;Cancer;Clinical Research;Clinical Trials |
STRUCTURE-BASED PREDICTION OF THE INTERACTOME |
1R01GM081871-01A1 |
2008-04-01 |
2008-04-01 |
31-Mar-09 |
2008 |
BERGER, BONNIE |
MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
CAMBRIDGE |
MA |
UNITED STATES |
NIGMS |
$280,891 |
Bioengineering;Biotechnology;Genetics;Human Genome;Networking and Information Technology R&D |
ROLES OF NF-KB/REL IN THE PATHOGENESIS OF BREAST CANCER |
1R01CA129129-01A1 |
2008-04-01 |
2008-04-01 |
31-Jan-09 |
2008 |
SONENSHEIN, GAIL E |
BOSTON UNIVERSITY MEDICAL CAMPUS |
BOSTON |
MA |
UNITED STATES |
NCI |
$337,188 |
Breast Cancer;Cancer;Complementary and Alternative Medicine;Genetics;Nutrition |
DEVELOPMENT OF MECHANISM-BASED STRATEGIES FOR THE TREATMENT OF ADVANCED BREAST CA |
2P01CA094060-06A1 |
2008-04-01 |
2008-04-01 |
30-Apr-09 |
2008 |
ROSEN, NEAL |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$435,045 |
Breast Cancer;Cancer;Clinical Research |
PREDICTION OF NEOADJUVANT CHEMO PATHOLOGICAL RESPONSE USING MRI MARKERS |
1R01CA127927-01A1 |
2008-04-01 |
2008-04-01 |
31-Jan-09 |
2008 |
SU, MIN-YING L |
UNIVERSITY OF CALIFORNIA IRVINE |
IRVINE |
CA |
UNITED STATES |
NCI |
$488,611 |
Breast Cancer;Cancer;Clinical Research;Diagnostic Radiology;Orphan Drug |
MODULATION BY BOTANICALS OF ANTIBODY BASED CANCER IMMUNOTHERAPY |
5P50AT002779-04 |
|
2008-04-01 |
31-Mar-09 |
2008 |
CHEUNG, NAI-KONG V |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCCAM |
$145,273 |
Biotechnology;Cancer;Complementary and Alternative Medicine;Immunization;Prevention;Vaccine Related |
MECHANISMS OF TUMOR RESISTANCE TO ANTI-HER/ERBB THERAPEUTICS |
1R01CA129036-01A1 |
2008-04-02 |
2008-04-02 |
31-Jan-09 |
2008 |
FAN, ZHEN |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$319,550 |
Biotechnology;Breast Cancer;Cancer;Hematology |
TARGETING THE IGF SYSTEM IN BREAST CANCER |
2R01CA074285-11A1 |
1998-01-01 |
2008-04-10 |
31-Mar-09 |
2008 |
YEE, DOUGLAS |
UNIVERSITY OF MINNESOTA TWIN CITIES |
MINNEAPOLIS |
MN |
UNITED STATES |
NCI |
$354,219 |
Breast Cancer;Cancer |
EASTERN COOPERATIVE ONCOLOGY GROUP |
5U10CA016116-35 |
1978-06-01 |
2008-05-01 |
30-Apr-09 |
2008 |
FORASTIERE, ARLENE ANN |
JOHNS HOPKINS UNIVERSITY |
BALTIMORE |
MD |
UNITED STATES |
NCI |
$279,595 |
Biotechnology;Brain Cancer;Brain Disorders;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Dental/Oral and Craniofacial Disease;Digestive Diseases;Genetics;Hematology;Immunization;Lung;Lung Cancer;Lymphoma;Neurosciences;Orphan Drug;Prevention;Prostate Cancer;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Transplantation;Urologic Diseases;Vaccine Related |
MOLECULAR STUDIES OF ESOPHAGEAL ADENOCARCINOMA |
5R01CA071606-12 |
1997-06-05 |
2008-05-01 |
30-Apr-09 |
2008 |
BEER, DAVID GEORGE |
UNIVERSITY OF MICHIGAN AT ANN ARBOR |
ANN ARBOR |
MI |
UNITED STATES |
NCI |
$305,939 |
Biotechnology;Cancer;Clinical Research;Digestive Diseases;Genetics |
BREAST CANCER RESPONSE MARKERS TO A DUAL HER1/2 BLOCKER |
5R01CA112305-04 |
2005-06-16 |
2008-05-01 |
30-Apr-09 |
2008 |
CHANG, JENNY C-N |
BAYLOR COLLEGE OF MEDICINE |
HOUSTON |
TX |
UNITED STATES |
NCI |
$252,236 |
Breast Cancer;Cancer;Clinical Research;Genetics |
FUNCTIONS IN TUMORS OF RECURRENTLY AMPLIFIED PREFOLDIN-4 |
5R01CA112608-04 |
2005-07-25 |
2008-05-01 |
30-Apr-09 |
2008 |
HANAHAN, DOUGLAS |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$283,709 |
Biotechnology;Breast Cancer;Cancer;Genetics |
TARGETING HER-2 PROTEIN FOR BREAST CANCER USING COMPUTATIONAL APPROACH |
5P20RR016456-07 |
2008-05-01 |
2008-05-01 |
30-Apr-09 |
2008 |
SATYANARAYANAJOIS, SEETHARAMA D |
LOUISIANA STATE UNIV A&M COL BATON ROUGE |
BATON ROUGE |
LA |
UNITED STATES |
NCRR |
$62,058 |
Breast Cancer;Cancer;Lung;Lung Cancer |
METABOLIC PHENOTYPING WITH PET TO MONITOR AND PREDICT RESPONSE TO KINASE |
5P50CA086306-09 |
|
2008-05-01 |
30-Apr-09 |
2008 |
CZERNIN, JOHANNES |
UNIVERSITY OF CALIFORNIA LOS ANGELES |
LOS ANGELES |
CA |
UNITED STATES |
NCI |
$258,131 |
Bioengineering;Brain Cancer;Brain Disorders;Cancer;Clinical Research;Diagnostic Radiology;Genetics;Lung;Lung Cancer |
IMPROVING INTERSTITIAL TRANSPORT IN TUMORS |
5P01CA080124-08 |
|
2008-05-01 |
30-Apr-09 |
2008 |
JAIN, RAKESH K. |
MASSACHUSETTS GENERAL HOSPITAL |
BOSTON |
MA |
UNITED STATES |
NCI |
$318,317 |
Biotechnology;Breast Cancer;Cancer;Gene Therapy;Genetics |
CANCER CENTER SUPPORT GRANT |
3P30CA006516-44S1 |
1977-12-01 |
2008-05-07 |
30-Nov-08 |
2008 |
BENZ, EDWARD J |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$124,531 |
No NIH Category available. |
SPECTROSCOPIC LOCALIZATION OF BREAST CANCER |
5R44CA083597-06 |
1999-08-13 |
2008-05-08 |
31-Mar-09 |
2008 |
BENARON, DAVID A. |
SPECTROS CORPORATION |
Portola Valley |
CA |
UNITED STATES |
NCI |
$999,999 |
Bioengineering;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Prevention |
PREDICTIVE BIOMARKERS OF ADJUVANT TRASTUZUMAB IN THE HER2+N9831 INTERGROUP TRIAL |
1R01CA129949-01A1 |
2008-05-20 |
2008-05-20 |
30-Apr-09 |
2008 |
PEREZ, EDITH ADALJISA |
MAYO CLINIC JACKSONVILLE |
JACKSONVILLE |
FL |
UNITED STATES |
NCI |
$386,094 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Genetics |
FUNCTION OF MUC4 IN MAMMARY EPITHELIA AND TUMORS |
5R01CA052498-16 |
1991-09-30 |
2008-06-01 |
31-May-09 |
2008 |
CARRAWAY, KERMIT L. |
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE |
MIAMI |
FL |
UNITED STATES |
NCI |
$294,823 |
Breast Cancer;Cancer;Genetics |
MECHANISMS OF INVERTEBRATE EGF RECEPTOR INHIBITION |
5R01CA125432-02 |
2007-07-01 |
2008-06-01 |
31-May-09 |
2008 |
LEMMON, MARK A. |
UNIVERSITY OF PENNSYLVANIA |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$236,813 |
Cancer |
ERBB2 DOWNREGULATION THROUGH HSP90 INHIBITION |
5R01CA116552-03 |
2007-08-01 |
2008-06-03 |
31-May-09 |
2008 |
BAND, HAMID |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
OMAHA |
NE |
UNITED STATES |
NCI |
$279,300 |
Biotechnology;Breast Cancer;Cancer |
ULTRASOUND-MEDIATED BLOOD-BRAIN BARRIER PERMEABILIZATION IN PRIMATES |
2R44NS054410-02 |
2008-06-15 |
2008-06-15 |
31-May-09 |
2008 |
LAWRENCE, MATTHEW SWAN |
RXGEN, INC. |
HAMDEN |
CT |
UNITED STATES |
NINDS |
$694,061 |
Bioengineering;Diagnostic Radiology;Neurosciences |
PAUL CALABRESI PROGRAM IN CLINICAL-TRANSLATIONAL RESEARCH AT MAYO CLINIC |
5K12CA090628-08 |
2001-09-25 |
2008-07-01 |
30-Jun-09 |
2008 |
HARTMANN, LYNN C. |
MAYO CLINIC |
ROCHESTER |
MN |
UNITED STATES |
NCI |
$1,065,864 |
Breast Cancer;Cancer;Clinical Research;Hematology;Orphan Drug |
GROWTH FACTOR AS ANTI-ANGIOGENESIS AGENTS |
5R01CA106829-05 |
2004-09-30 |
2008-07-01 |
30-Jun-09 |
2008 |
SEBTI, SAID M |
H. LEE MOFFITT CANCER CTR & RES INST |
TAMPA |
FL |
UNITED STATES |
NCI |
$326,968 |
Cancer |
IN VIVO THERMOACOUSTIC IMAGING OF HER2 STATUS |
5R44CA114839-04 |
2005-04-07 |
2008-07-01 |
30-Jun-10 |
2008 |
KRUGER, ROBERT A |
OPTOSONICS, INC. |
ORIENTAL |
NC |
UNITED STATES |
NCI |
$660,216 |
Bioengineering;Breast Cancer;Cancer;Diagnostic Radiology |
IDENTIFICATION AND CHARACTERIZATION OF ACTIVATED TYROSINE KINASES IN GLIOBLASTOMA |
5F32CA121769-02 |
2007-07-01 |
2008-07-01 |
31-Aug-08 |
2008 |
STOMMEL, JAYNE |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$11,757 |
Biotechnology;Brain Cancer;Brain Disorders;Cancer;Genetics;Neurosciences;Orphan Drug |
CROSSTALK TGFBETA AND HER2 (ERBB2) SIGNALING IN MAMMARY TUMORIGENESIS |
5K99CA125892-02 |
2007-07-25 |
2008-07-01 |
14-Sep-08 |
2008 |
WANG, SHIZHEN EMILY |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$6,941 |
Breast Cancer;Cancer |
MOLECULAR BASIS OF SLITS AS TUMOR SUPPRESSORS CONTROLLING CXCR4/SDF1 IN BREAST |
1R01CA128902-01A1 |
2008-07-01 |
2008-07-01 |
30-Apr-09 |
2008 |
HINCK, LINDSAY E |
UNIVERSITY OF CALIFORNIA SANTA CRUZ |
SANTA CRUZ |
CA |
UNITED STATES |
NCI |
$309,792 |
Breast Cancer;Cancer;Genetics |
INTEGRATED BIOCHIP SENSORS FOR DETECTION OF CANCER |
1R01CA120003-01A2 |
2008-07-01 |
2008-07-01 |
31-May-09 |
2008 |
BASHIR, RASHID |
UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN |
CHAMPAIGN |
IL |
UNITED STATES |
NCI |
$512,381 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Clinical Research;Nanotechnology |
RADIOIMMUNOTHERAPY: CLINICAL STUDIES |
5P01CA043904-17 |
|
2008-07-01 |
30-Jun-09 |
2008 |
WONG, JEFFREY Y |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$233,953 |
Breast Cancer;Cancer;Clinical Research;Clinical Trials;Colo-Rectal Cancer;Digestive Diseases |
CLINICAL PRODUCTION |
5P01CA043904-17 |
|
2008-07-01 |
30-Jun-09 |
2008 |
YAZAKI, PAUL |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$301,229 |
Biotechnology;Cancer;Clinical Research;Clinical Trials;Genetics |
RADIOPHARMACY AND ASSAYS |
5P01CA043904-17 |
|
2008-07-01 |
30-Jun-09 |
2008 |
COLCHER, DAVID MORRIS |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$479,620 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Clinical Research;Immunization |
SUBPROJECT 1 |
5U54GM074946-04 |
|
2008-07-01 |
30-Jun-09 |
2007 |
EISENBERG, DAVID |
LOS ALAMOS NAT SECTY-LOS ALAMOS NAT LAB |
LOS ALAMOS |
NM |
UNITED STATES |
NIGMS |
$542,189 |
No NIH Category available. |
MOLECULAR TARGETS FOR PROGNOSIS AND THERAPY |
5P50CA083636-10 |
|
2008-07-01 |
30-Jun-09 |
2008 |
HOOD, LEROY E |
FRED HUTCHINSON CANCER RESEARCH CENTER |
SEATTLE |
WA |
UNITED STATES |
NCI |
$567,737 |
Cancer;Clinical Research;Clinical Trials;Orphan Drug;Ovarian Cancer |
MECHANISM OF ACTION OF DIFFERENTIATION AGENTS |
5R37CA038173-23 |
1986-07-01 |
2008-07-08 |
30-Jun-10 |
2008 |
BRATTAIN, MICHAEL G. |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
OMAHA |
NE |
UNITED STATES |
NCI |
$321,158 |
Biotechnology;Breast Cancer;Cancer;Colo-Rectal Cancer;Digestive Diseases;Genetics |
PROGRAM 3 (IMMUNOLOGY AND CANCER) |
2P30CA014599-33 |
2008-07-22 |
2008-07-22 |
31-Mar-09 |
2008 |
GAJEWSKI, THOMAS F |
UNIVERSITY OF CHICAGO |
CHICAGO |
IL |
UNITED STATES |
NCI |
$15,563 |
Biotechnology;Cancer;Immunization;Vaccine Related |
HUMAN IMMUNOLOGIC MONITORING |
2P30CA014599-33 |
2008-07-22 |
2008-07-22 |
31-Mar-09 |
2008 |
GAJEWSKI, THOMAS F |
UNIVERSITY OF CHICAGO |
CHICAGO |
IL |
UNITED STATES |
NCI |
$80,536 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Immunization;Kidney Disease;Lymphoma;Orphan Drug;Transplantation;Vaccine Related |
FATTY ACID SYNTHASE:MOLECULAR TARGET FOR BREAST CANCER THERAPY & CHEMOPREVENTION |
5R01CA116623-04 |
2005-09-16 |
2008-07-30 |
31-Jul-08 |
2008 |
LUPU, RUTH |
NORTHSHORE UNIV HEALTHSYSTEM RES INST |
EVANSTON |
IL |
UNITED STATES |
NCI |
$70,483 |
Breast Cancer;Cancer;Genetics;Prevention |
THE AGING GUT: REGULATION OF CELL PROLIFERATION |
5R01AG014343-11 |
1997-09-01 |
2008-08-01 |
31-Jul-09 |
2008 |
MAJUMDAR, ADHIP N. |
WAYNE STATE UNIVERSITY |
DETROIT |
MI |
UNITED STATES |
NIA |
$227,821 |
Aging;Cancer;Digestive Diseases |
STRUCTURAL STUDIES OF GROWTH FACTOR RECEPTOR FUNCTION |
5R01CA090466-07 |
2001-04-01 |
2008-08-01 |
31-Jul-09 |
2008 |
LEAHY, DANIEL J |
JOHNS HOPKINS UNIVERSITY |
BALTIMORE |
MD |
UNITED STATES |
NCI |
$222,384 |
Breast Cancer;Cancer |
REWIRING ERBB SIGNALING IN CANCER CELLS |
7R01CA098881-06 |
2003-07-01 |
2008-08-01 |
31-Jul-09 |
2008 |
LANDGRAF, RALF |
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE |
MIAMI |
FL |
UNITED STATES |
NCI |
$273,042 |
Breast Cancer;Cancer |
FATTY ACID SYNTHASE:MOLECULAR TARGET FOR BREAST CANCER THERAPY & CHEMOPREVENTION |
7R01CA116623-05 |
2005-09-16 |
2008-08-01 |
31-May-09 |
2008 |
LUPU, RUTH |
MAYO CLINIC |
ROCHESTER |
MN |
UNITED STATES |
NCI |
$352,699 |
Breast Cancer;Cancer;Genetics;Prevention |
HER-2/IGF-IR CROSS-TALK AND HERCEPTIN RESISTANCE |
5K01CA118174-04 |
2006-08-01 |
2008-08-01 |
31-Jul-09 |
2008 |
NAHTA, RITA |
EMORY UNIVERSITY |
ATLANTA |
GA |
UNITED STATES |
NCI |
$143,856 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Nanotechnology |
PROFILING ER, PR, EGFR AND HER2 IN BREAST CANCER USING MULTIPLEX TISSUE IMMUSTA |
2R44CA123994-02 |
2006-08-01 |
2008-08-01 |
31-Jul-09 |
2008 |
JAMES, WILLIAM M |
20/20 GENESYSTEMS, INC. |
ROCKVILLE |
MD |
UNITED STATES |
NCI |
$332,174 |
Bioengineering;Biotechnology;Breast Cancer;Cancer |
MICELLE SURFACE ENGINEERING FOR ACTIVE TARGETING BY ACIDIC TUMOR EXTRACELLULAR PH |
5R01CA122356-03 |
2006-08-22 |
2008-08-01 |
31-Jul-09 |
2008 |
BAE, YOU HAN |
UNIVERSITY OF UTAH |
SALT LAKE CITY |
UT |
UNITED STATES |
NCI |
$257,668 |
Bioengineering;Cancer |
NEW BIFUNCTIONAL LIGANDS FOR RADIOIMMUNOTHERAPY |
5R01CA112503-03 |
2006-09-01 |
2008-08-01 |
31-Jul-11 |
2008 |
CHONG, HYUN-SOON |
ILLINOIS INSTITUTE OF TECHNOLOGY |
CHICAGO |
IL |
UNITED STATES |
NCI |
$138,368 |
Cancer |
MOLECULAR MAMMOGRAPHY OF HER-2 CANCERS USING GOLD NANOPARTICLES |
4R44CA124190-02 |
2006-09-26 |
2008-08-01 |
31-Jul-09 |
2008 |
HAINFELD, JAMES F. |
NANOPROBES, INC. |
YAPHANK |
NY |
UNITED STATES |
NCI |
$474,069 |
Bioengineering;Breast Cancer;Cancer;Diagnostic Radiology;Nanotechnology |
EARLY SCREENING OF BREAST LESION TRIAL (PHASE III PIVOTAL) |
4R44CA126441-02 |
2007-09-27 |
2008-08-01 |
28-Feb-09 |
2008 |
BENARON, DAVID A. |
SPECTROS CORPORATION |
Portola Valley |
CA |
UNITED STATES |
NCI |
$866,065 |
Bioengineering;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Diagnostic Radiology;Prevention |
A NOVEL TRANSGENIC SILKWORM SYSTEM FOR RECOMBINANT GLYCOPROTEIN PRODUCTION |
5R01GM080672-02 |
2007-09-29 |
2008-08-01 |
31-Jul-09 |
2008 |
JARVIS, DONALD L. |
UNIVERSITY OF WYOMING |
LARAMIE |
WY |
UNITED STATES |
NIGMS |
$280,108 |
Bioengineering;Biotechnology |
OPENING THE BLOOD BRAIN BARRIER FOR MOLECULAR IMAGING |
5U41RR019703-04 |
2008-08-01 |
2008-08-01 |
31-Jul-09 |
2008 |
HYNYNEN, KULLERVO |
BRIGHAM AND WOMEN'S HOSPITAL |
BOSTON |
MA |
UNITED STATES |
NCRR |
$28,171 |
Bioengineering;Biotechnology;Brain Cancer;Brain Disorders;Breast Cancer;Cancer;Diagnostic Radiology;Nanotechnology;Neurosciences |
MULTIVALENT ANTI-CANCER ANTIBODIES USING UNNATURAL AMINO ACID CHEMISTRY |
1F32CA134123-01 |
2008-08-01 |
2008-08-01 |
31-Jul-09 |
2008 |
HUTCHINS, BENJAMIN MITCHELL |
SCRIPPS RESEARCH INSTITUTE |
LA JOLLA |
CA |
UNITED STATES |
NCI |
$46,826 |
Cancer |
DEVELOPMENTAL RESEARCH PROGRAM |
5P50CA086438-08 |
2008-08-01 |
2008-08-01 |
30-Jun-09 |
2008 |
JURCIC, JOSEPH G |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$87,119 |
Bioengineering;Biotechnology;Cancer;Diagnostic Radiology;Genetics;Hematology;Lymphoma;Orphan Drug;Regenerative Medicine;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Transplantation |
MOLECULAR IMAGING OF CASTRATE- RESISTANCE METASTATIC PROSTATE CANCER |
5P50CA086438-08 |
2008-08-01 |
2008-08-01 |
30-Jun-09 |
2008 |
LARSON, STEVEN MARK |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$111,715 |
Bioengineering;Cancer;Diagnostic Radiology;Nanotechnology;Prostate Cancer;Urologic Diseases |
DEVELOPMENT OF METHODOLOGIES FOR THE IN VIVO IMAGING OG THE EFFECTS OF NOVEL INHI |
5P50CA086438-08 |
2008-08-01 |
2008-08-01 |
30-Jun-09 |
2008 |
ROSEN, NEAL |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$122,547 |
Biotechnology;Breast Cancer;Cancer;Diagnostic Radiology |
SIGNAL TRANSDUCTION IN THE HEART AFTER CANCER THERAPY |
1R01HL088649-01A2 |
2008-08-01 |
2008-08-01 |
30-May-09 |
2008 |
GABRIELSON, KATHLEEN LOUISE |
JOHNS HOPKINS UNIVERSITY |
BALTIMORE |
MD |
UNITED STATES |
NHLBI |
$410,000 |
Biotechnology;Cancer;Cardiovascular;Heart Disease |
RESEARCH PROGRAMS-SIGNAL TRANSDUCTION |
5P30CA016359-30 |
|
2008-08-01 |
31-Jul-09 |
2008 |
SCHLESSINGER, JOSEPH |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$27,148 |
Breast Cancer;Cancer;Orphan Drug |
BREAST CANCER VACCINE STRATEGIES FOR HER2-OVEREXPRESSING AND LUM. B TUMORS |
5P50CA058223-16 |
|
2008-08-01 |
31-Jul-09 |
2008 |
SERODY, JONATHAN STUART |
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL |
CHAPEL HILL |
NC |
UNITED STATES |
NCI |
$224,073 |
Biotechnology;Breast Cancer;Cancer;Immunization;Infectious Diseases;Orphan Drug;Prevention;Vaccine Related;Vector-Borne Diseases |
n/a |
3 |
2010-08-31 |
2008-08-31 |
397 |
2E+04 |
Not Applicable |
BOSTON |
MA |
2115 |
NCI |
|
NCI |
DANA-FARBER/HARVARD SPORE IN BREAST CANCER |
3P50CA089393-09S4 |
2000-09-30 |
2008-09-01 |
31-Aug-09 |
2009 |
IGLEHART, JAMES DIRK |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$241,960 |
No NIH Category available. |
DANA-FARBER/HARVARD SPORE IN BREAST CANCER |
5P50CA089393-09 |
2000-09-30 |
2008-09-01 |
31-Aug-09 |
2008 |
IGLEHART, JAMES DIRK |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$2,180,817 |
No NIH Category available. |
INNATE IMMUNITY: ELUCIDATION AND MODULATION FOR CANCER THERAPY |
5P01CA095426-07 |
2002-02-01 |
2008-09-01 |
31-Aug-09 |
2008 |
CALIGIURI, MICHAEL A |
OHIO STATE UNIVERSITY |
COLUMBUS |
OH |
UNITED STATES |
NCI |
$2,003,446 |
No NIH Category available. |
DISCOVERY AND CHARACTERIZATION OF BREAST CANCER GENES |
5K01CA101777-05 |
2004-09-07 |
2008-09-01 |
31-Aug-09 |
2008 |
HODGSON, JOHN G |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$148,770 |
Biotechnology;Breast Cancer;Cancer;Genetics |
EX VIVO EXPANSION OF HER-2/NEU SPECIFIC T HELPER CELLS |
5K01CA100764-06 |
2004-09-20 |
2008-09-01 |
28-Feb-10 |
2008 |
KNUTSON, KEITH L |
MAYO CLINIC |
ROCHESTER |
MN |
UNITED STATES |
NCI |
$152,658 |
Biotechnology;Breast Cancer;Cancer;Immunization;Prevention;Vaccine Related |
UTMDACC SPORE IN BREAST CANCER |
5P50CA116199-04 |
2005-09-23 |
2008-09-01 |
31-Aug-09 |
2008 |
HORTOBAGYI, GABRIEL N |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$2,180,817 |
No NIH Category available. |
LIPOSOMAL DELIVERY OF HIGH LET EMITTERS TO CELL NUCLEI |
5F32CA123651-03 |
2006-09-01 |
2008-09-01 |
31-Aug-09 |
2008 |
HAR-EL, YAH-EL |
JOHNS HOPKINS UNIVERSITY |
BALTIMORE |
MD |
UNITED STATES |
NCI |
$50,428 |
Bioengineering;Cancer;Ovarian Cancer |
REGULATION OF HER2/NEU BY ACTIVATION LOOP PHOSPHORYLATION AND ALG-2 |
5K22CA128951-02 |
2007-09-18 |
2008-09-01 |
31-Aug-09 |
2008 |
BOSE, RON |
WASHINGTON UNIVERSITY |
SAINT LOUIS |
MO |
UNITED STATES |
NCI |
$143,412 |
Biotechnology;Breast Cancer;Cancer;Genetics |
TARGETED COMBINATIONS FOR HER2- POSITIVE BREAST CANCER BIOLOGY |
5P50CA089393-09 |
2008-09-01 |
2008-09-01 |
31-Aug-09 |
2008 |
HARRIS, LYNDSAY N |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$80,804 |
Breast Cancer;Cancer |
KINASE IMAGING |
5P50CA086355-09 |
2008-09-01 |
2008-09-01 |
31-Aug-09 |
2008 |
JOSEPHSON, LEE |
MASSACHUSETTS GENERAL HOSPITAL |
BOSTON |
MA |
UNITED STATES |
NCI |
$150,344 |
Biotechnology;Cancer;Orphan Drug |
RESEARCH PROJECT 3: ROLE OF THE NF-KB/REL IN MAMMARY CARCINOGENESIS |
2P01ES011624-06A1 |
2008-09-01 |
2008-09-01 |
30-Jun-09 |
2008 |
SONENSHEIN, GAIL E |
BOSTON UNIVERSITY MEDICAL CAMPUS |
BOSTON |
MA |
UNITED STATES |
NIEHS |
$158,026 |
Breast Cancer;Cancer;Complementary and Alternative Medicine;Genetics;Nutrition |
PROTOCOL SPECIFIC RESEARCH |
2P30CA033572-25 |
2008-09-01 |
2008-09-01 |
30-Nov-08 |
2008 |
KRONTIRIS, THEODORE G |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$162,234 |
Brain Cancer;Brain Disorders;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Hematology;Orphan Drug |
PTEN DEFICIENCY AND TRASTUZUMAB RESISTANCE |
5P50CA116199-04 |
2008-09-01 |
2008-09-01 |
31-Aug-09 |
2008 |
YU, DIHUA |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$181,323 |
Cancer |
BETA-CATENIN/TCF SIGNALING IN BREAST CANCER |
1R01CA131219-01A1 |
2008-09-01 |
2008-09-01 |
31-Jul-09 |
2008 |
HOWE, LOUISE R |
WEILL MEDICAL COLLEGE OF CORNELL UNIV |
NEW YORK |
NY |
UNITED STATES |
NCI |
$345,155 |
Breast Cancer;Cancer;Colo-Rectal Cancer;Digestive Diseases;Prevention |
MOUSE MODELING AND ANIMAL DEVELOPMENT |
5P01CA095426-07 |
|
2008-09-01 |
31-Aug-09 |
2008 |
MUTHUSAMY, NATARAJAN |
OHIO STATE UNIVERSITY |
COLUMBUS |
OH |
UNITED STATES |
NCI |
$239,562 |
Biotechnology;Cancer;Genetics;Lymphoma;Orphan Drug |
ANTIBODY THERAPY FOR BREAST CANCER: INVESTIGATION OF IMMUNE MODULATION WITH IL-21 |
5P01CA095426-07 |
|
2008-09-01 |
31-Aug-09 |
2008 |
CARSON, WILLIAM E. |
OHIO STATE UNIVERSITY |
COLUMBUS |
OH |
UNITED STATES |
NCI |
$417,272 |
Breast Cancer;Cancer;Immunization |
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C |
5P50CA092629-08 |
|
2008-09-01 |
31-Aug-09 |
2008 |
ROSEN, NEAL |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$418,592 |
Aging;Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Orphan Drug;Prostate Cancer;Urologic Diseases |
COMBINATORIAL LIBRARY SCREENING CORE |
5U54CA119343-04 |
|
2008-09-01 |
31-Aug-09 |
2008 |
LIU, RIHE |
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL |
CHAPEL HILL |
NC |
UNITED STATES |
NCI |
$433,439 |
Bioengineering;Biotechnology;Cancer;Clinical Research;Clinical Trials;Nanotechnology |
TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY |
9R01CA137488-14A1 |
1995-08-15 |
2008-09-05 |
31-Aug-09 |
2008 |
NEUWELT, EDWARD A |
OREGON HEALTH AND SCIENCE UNIVERSITY |
PORTLAND |
OR |
UNITED STATES |
NCI |
$494,277 |
Brain Cancer;Brain Disorders;Breast Cancer;Cancer;Clinical Research;Lymphoma;Neurodegenerative;Neurosciences |
IDENTIFICATION AND CHARACTERIZATION OF DRIVER GENE(S) IN RECURRENT LUNG CANCER AM |
1R01CA127547-01A1 |
2008-09-08 |
2008-09-08 |
31-Jul-09 |
2008 |
MU, DAVID |
PENNSYLVANIA STATE UNIV HERSHEY MED CTR |
HERSHEY |
PA |
UNITED STATES |
NCI |
$287,938 |
Biotechnology;Cancer;Genetics;Lung;Lung Cancer |
HUMAN MUC1 MUC1 ONCOPROTEIN: DEVELOPMENT OF MUC1-DECOY SOLUBLE RECEPTORS AS ANTI- |
1R43CA135758-01 |
2008-09-09 |
2008-09-09 |
28-Feb-10 |
2008 |
RAINA, DEEPAK |
GENUS ONCOLOGY, LLC |
CHICAGO |
IL |
UNITED STATES |
NCI |
$100,000 |
Cancer;Hematology;Orphan Drug |
DETERMINANTS AND RISKS OF USE AND OVERUSE OF EXPENSIVE ONCOLOGY DRUGS |
1R01CA134964-01 |
2008-09-12 |
2008-09-12 |
31-Jul-09 |
2008 |
HERSHMAN, DAWN |
COLUMBIA UNIVERSITY HEALTH SCIENCES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$259,686 |
Aging;Breast Cancer;Cancer;Clinical Research;Health Services;Hematology;Prostate Cancer;Urologic Diseases |
NOVEL TACE INHIBITORS FOR BREAST CANCER THERAPY |
1R43CA128183-01A1 |
2008-09-15 |
2008-09-15 |
31-Aug-10 |
2008 |
MENDELSOHN, ANDREW R |
PANORAMA RESEARCH, INC. |
SUNNYVALE |
CA |
UNITED STATES |
NCI |
$192,060 |
Biotechnology;Breast Cancer;Cancer |
MEASUREMENT IN DIVERSE POPULATIONS |
1P01CA130818-01A1 |
2008-07-01 |
2008-09-16 |
31-Aug-09 |
2008 |
PONCE, NINEZ ALAFRIZ |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$76,088 |
Bioengineering;Cancer |
ECONOMICS OF PERSONALIZED MEDICINE USING GENOMICS |
1P01CA130818-01A1 |
2008-07-01 |
2008-09-16 |
31-Aug-09 |
2008 |
LADABAUM, URI |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$190,625 |
Bioengineering;Cancer;Clinical Research;Cost Effectiveness Research;Health Services;Prevention |
UTILIZATION OF PERSONALIZED MEDICINE USING GENOMICS |
1P01CA130818-01A1 |
2008-07-01 |
2008-09-16 |
31-Aug-09 |
2008 |
HAAS, JENNIFER S |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$514,902 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Clinical Research;Genetics;Health Services |
PERSONALIZED MEDICINE FOR COLORECTAL AND BREAST CANCER |
1P01CA130818-01A1 |
2008-09-16 |
2008-09-16 |
31-Aug-09 |
2008 |
PHILLIPS, KATHRYN A |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$1,767,837 |
No NIH Category available. |
ANTI-CANCER DRIG SENSITIZERS |
1R43CA132207-01 |
2008-09-19 |
2008-09-19 |
31-Mar-09 |
2008 |
ROYER, ROBERT E. |
QUATROS RESEARCH AND DEVELOPMENT, LLC |
ALBUQUERQUE |
NM |
UNITED STATES |
NCI |
$135,800 |
Breast Cancer;Cancer;Orphan Drug |
DANA-FARBER/HARVARD SPORE IN BREAST CANCER |
3P50CA089393-09S2 |
2000-09-30 |
2008-09-22 |
31-Aug-09 |
2008 |
IGLEHART, JAMES DIRK |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$237,500 |
No NIH Category available. |
NONINVASIVE ASSESSMENT OF CANCER RESPONSIVENESS TO THERAPY BY USE OF ..... |
1P50CA128323-01A1 |
2008-09-22 |
2008-09-22 |
31-Aug-09 |
2008 |
HALLAHAN, DENNIS E |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$104,362 |
Cancer;Diagnostic Radiology;Orphan Drug |
IMMUNOBIOLOGY OF P185 RECEPTOR |
2R01CA055306-14A1 |
1992-05-01 |
2008-09-24 |
31-Jul-09 |
2008 |
GREENE, MARK I |
UNIVERSITY OF PENNSYLVANIA |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$269,183 |
Biotechnology;Cancer;Immunization;Prevention |
DISSECTING MECHANISMS OF METASTASIS THROUGH COMPARATIVE SYSTEMS GENETICS |
1R01CA138265-01 |
2008-09-25 |
2008-09-25 |
31-Jul-09 |
2008 |
KIRSCH, DAVID G |
DUKE UNIVERSITY |
DURHAM |
NC |
UNITED STATES |
NCI |
$463,000 |
Biotechnology;Breast Cancer;Cancer;Genetics |
TARGETED ALPHA-PARTICLE EMITTER THERAPY OF METASTASES |
5R01CA113797-04 |
2005-12-09 |
2008-12-01 |
30-Nov-09 |
2009 |
SGOUROS, GEORGE |
JOHNS HOPKINS UNIVERSITY |
BALTIMORE |
MD |
UNITED STATES |
NCI |
$278,677 |
Breast Cancer;Cancer;Digestive Diseases;Liver Disease |
BRK SIGNALS TO ERK5 IN BREAST CANCER |
5R01CA107547-03 |
2006-12-15 |
2008-12-01 |
30-Nov-09 |
2009 |
LANGE, CAROL ANN |
UNIVERSITY OF MINNESOTA TWIN CITIES |
MINNEAPOLIS |
MN |
UNITED STATES |
NCI |
$249,308 |
Breast Cancer;Cancer |
DETERMINATION OF DISTINCT TYPES OF IMMUNE RESPONSES TO HER-2/NEU ASSOCIATED W |
5M01RR000065-47 |
2008-12-01 |
2008-12-01 |
30-Nov-09 |
2009 |
MANJILI, MASOUD H |
VIRGINIA COMMONWEALTH UNIVERSITY |
RICHMOND |
VA |
UNITED STATES |
NCRR |
$3,733 |
Breast Cancer;Cancer;Clinical Research |
TARGETING THE HER2 PATHWAY: MECHANISMS OF RESISTANCE & STRATEGIES TO OVERCOME |
5P50CA058183-15 |
|
2008-12-01 |
30-Nov-09 |
2009 |
OSBORNE, C KENT |
BAYLOR COLLEGE OF MEDICINE |
HOUSTON |
TX |
UNITED STATES |
NCI |
$163,036 |
No NIH Category available. |
NOVEL TREATMENT OF NF-1 ASSOCIATED MALIGNANT PERIPHERAL NERVE SHEATH TUMORS |
5R01CA122804-02 |
2007-12-07 |
2008-12-17 |
30-Nov-09 |
2009 |
CARROLL, STEVEN L |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
BIRMINGHAM |
AL |
UNITED STATES |
NCI |
$300,875 |
Biotechnology;Breast Cancer;Cancer;Neurofibromatosis;Neurosciences |
TSG101 - A MODULATOR OF ERBB2 SIGNALING IN BREAST CANCER |
2R01CA093797-06A2 |
2002-01-01 |
2009-01-01 |
31-Dec-09 |
2009 |
WAGNER, KAY-UWE |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
OMAHA |
NE |
UNITED STATES |
NCI |
$265,863 |
Breast Cancer;Cancer |
PROSPECTIVE VALIDATION OF GENOMIC SIGNATURES OF CHEMOSENSITIVITY IN NSCLC |
1R01CA131049-01A1 |
2009-01-01 |
2009-01-01 |
30-Nov-09 |
2009 |
POTTI, ANIL |
DUKE UNIVERSITY |
DURHAM |
NC |
UNITED STATES |
NCI |
$340,464 |
Biotechnology;Cancer;Clinical Research;Genetics;Lung;Lung Cancer |
ERBB RECEPTOR HOMO- AND HETERO-DIMERIZATION |
2R01CA079992-11 |
1999-02-01 |
2009-02-01 |
31-Dec-09 |
2009 |
LEMMON, MARK A. |
UNIVERSITY OF PENNSYLVANIA |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$255,723 |
Breast Cancer;Cancer |
SIGNALING BY NEUREGULINS AND ERBB4 IN BREAST CANCER |
2R01CA080065-09A2 |
1999-07-01 |
2009-02-01 |
30-Nov-09 |
2009 |
STERN, DAVID F |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$391,179 |
Breast Cancer;Cancer;Lung;Lung Cancer |
DANA-FARBER/HARVARD SPORE IN BREAST CANCER |
3P50CA089393-09S3 |
2000-09-30 |
2009-02-01 |
31-Aug-09 |
2009 |
IGLEHART, JAMES DIRK |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$24,615 |
Breast Cancer;Cancer |
REGULATION OF ERBB2/NEU-INDUCED MAMMARY GLAND CANCER |
3R01CA090398-08S1 |
2001-03-05 |
2009-02-01 |
31-Jan-10 |
2009 |
KERI, RUTH A |
CASE WESTERN RESERVE UNIVERSITY |
CLEVELAND |
OH |
UNITED STATES |
NCI |
$86,339 |
Breast Cancer;Cancer;Genetics |
REGULATION OF ERBB2/NEU-INDUCED MAMMARY GLAND CANCER |
5R01CA090398-08 |
2001-03-05 |
2009-02-01 |
31-Jan-10 |
2009 |
KERI, RUTH A |
CASE WESTERN RESERVE UNIVERSITY |
CLEVELAND |
OH |
UNITED STATES |
NCI |
$213,979 |
Breast Cancer;Cancer;Genetics |
TARGETING JAB1 ONCOGENIC FUNCTION IN BREAST CANCER |
5R01CA090853-08 |
2001-04-01 |
2009-02-01 |
31-Jan-10 |
2009 |
CLARET, FRANCOIS X |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$255,009 |
Biotechnology;Breast Cancer;Cancer;Genetics |
THE ROLE OF SYNDECAN-1 IN MOUSE MAMMARY NEOPLASIA |
5R01CA090877-07 |
2001-04-01 |
2009-02-01 |
31-Jan-10 |
2009 |
ALEXANDER, CAROLINE MARGARET |
UNIVERSITY OF WISCONSIN MADISON |
MADISON |
WI |
UNITED STATES |
NCI |
$295,173 |
Breast Cancer;Cancer;Stem Cell Research;Stem Cell Research - Nonembryonic - Non-Human |
PHARMACODYNAMIC ASSESSMENT OF RTK INHIBITORS IN CANCER |
5R01CA112385-05 |
2005-02-23 |
2009-02-01 |
31-Aug-09 |
2009 |
HALLAHAN, DENNIS E |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$71,937 |
Cancer;Diagnostic Radiology;Lung;Lung Cancer;Orphan Drug |
SYNDECAN-1 IN STROMAL FIBROBLASTS OF BREAST CARCINOMAS |
5R01CA107012-05 |
2005-03-01 |
2009-02-01 |
31-Jan-10 |
2009 |
FRIEDL, ANDREAS |
UNIVERSITY OF WISCONSIN MADISON |
MADISON |
WI |
UNITED STATES |
NCI |
$269,030 |
Breast Cancer;Cancer;Clinical Research |
NSABP PARTICIPATING SITES |
5U10CA118735-04 |
2006-04-10 |
2009-02-01 |
31-Jan-10 |
2009 |
CHANG, JENNY C-N |
BAYLOR COLLEGE OF MEDICINE |
HOUSTON |
TX |
UNITED STATES |
NCI |
$67,765 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Health Disparities;Minority Health |
REGULATION OF STAT3 SIGNALING |
5R01CA122910-03 |
2007-04-01 |
2009-02-01 |
31-Jan-10 |
2009 |
REICH, NANCY C. |
STATE UNIVERSITY NEW YORK STONY BROOK |
STONY BROOK |
NY |
UNITED STATES |
NCI |
$294,500 |
Cancer;Genetics;Hematology |
CELLULARLY RESOLVED MOLECULAR PATHWAY ASSESSMENT IN BIOPSIES VIA SPECTRAL IMAGING |
4R44CA130026-02 |
2007-09-28 |
2009-02-01 |
31-Jan-10 |
2009 |
LEVENSON, RICHARD M. |
CAMBRIDGE RESEARCH AND INSTRUMENTATION |
WOBURN |
MA |
UNITED STATES |
NCI |
$900,963 |
Bioengineering;Biotechnology;Breast Cancer;Cancer |
ROLES OF NF-KB/REL IN THE PATHOGENESIS OF BREAST CANCER |
5R01CA129129-02 |
2008-04-01 |
2009-02-01 |
31-Dec-09 |
2009 |
SONENSHEIN, GAIL E |
BOSTON UNIVERSITY MEDICAL CAMPUS |
BOSTON |
MA |
UNITED STATES |
NCI |
$337,188 |
Breast Cancer;Cancer;Complementary and Alternative Medicine;Genetics;Nutrition |
PREDICTION OF NEOADJUVANT CHEMO PATHOLOGICAL RESPONSE USING MRI MARKERS |
5R01CA127927-02 |
2008-04-01 |
2009-02-01 |
31-Jan-10 |
2009 |
SU, MIN-YING L |
UNIVERSITY OF CALIFORNIA IRVINE |
IRVINE |
CA |
UNITED STATES |
NCI |
$503,017 |
Breast Cancer;Cancer;Clinical Research;Diagnostic Radiology |
MECHANISMS OF TUMOR RESISTANCE TO ANTI-HER/ERBB THERAPEUTICS |
5R01CA129036-02 |
2008-04-02 |
2009-02-01 |
31-Jan-10 |
2009 |
FAN, ZHEN |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$319,550 |
Biotechnology;Breast Cancer;Cancer;Hematology |
DETERMINANTS OF TUMOR SENSITIVITY TO EGFR-TARGETED ANTIBODIES |
2R01CA050633-19A1 |
1989-06-01 |
2009-02-02 |
31-Dec-09 |
2009 |
WEINER, LOUIS M |
GEORGETOWN UNIVERSITY |
WASHINGTON |
DC |
UNITED STATES |
NCI |
$352,183 |
Biotechnology;Cancer;Genetics;Immunization |
TRANSLATIONAL RESEARCH IN BREAST CANCER |
5P50CA058183-15 |
1992-09-30 |
2009-02-17 |
30-Nov-09 |
2009 |
OSBORNE, C KENT |
BAYLOR COLLEGE OF MEDICINE |
HOUSTON |
TX |
UNITED STATES |
NCI |
$2,300,000 |
Aging;Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Estrogen;Prevention;Stem Cell Research;Stem Cell Research - Nonembryonic - Human |
CROSSTALK TGFBETA AND HER2 (ERBB2) SIGNALING IN MAMMARY TUMORIGENESIS |
7K99CA125892-03 |
2007-07-25 |
2009-02-23 |
30-Jun-09 |
2008 |
WANG, SHIZHEN EMILY |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$113,529 |
No NIH Category available. |
PREDICTION OF CHEMOTHERAPY INDUCED CARDIOMYOPATHY WITH MRI DETECT I |
5M01RR007122-18 |
2009-03-01 |
2009-03-01 |
28-Feb-10 |
2009 |
HUNDLEY, WILLIAM GREGORY |
WAKE FOREST UNIVERSITY HEALTH SCIENCES |
WINSTON-SALEM |
NC |
UNITED STATES |
NCRR |
$81,758 |
Cancer;Cardiovascular;Clinical Research;Diagnostic Radiology;Heart Disease;Heart Disease - Coronary Heart Disease |
CELL HETEROGENEITY AND EMERGENT TRASTUZUMAB RESISTANCE IN BREAST CANCER: CONCEPT |
1R15CA132124-01A2 |
2009-03-01 |
2009-03-01 |
28-Feb-11 |
2009 |
KLINKE, DAVID JOHN |
WEST VIRGINIA UNIVERSITY |
MORGANTOWN |
WV |
UNITED STATES |
NCI |
$219,750 |
Bioengineering;Breast Cancer;Cancer |
TAKE HEART: EXERCISE & DIET INTERVENTION FOR HEART FAILURE IN CANCER SURVIVORS |
1R21CA135016-01A1 |
2009-03-13 |
2009-03-13 |
28-Feb-10 |
2009 |
BASEN-ENGQUIST, KAREN M |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$169,400 |
Behavioral and Social Science;Cancer;Cardiovascular;Clinical Research;Heart Disease;Mind and Body;Nutrition;Prevention;Rehabilitation |
BRAIN TUMORS - IMMUNOLOGICAL AND BIOLOGICAL STUDIES |
5R37CA011898-39 |
1976-12-01 |
2009-04-01 |
31-Mar-10 |
2009 |
BIGNER, DARELL D |
DUKE UNIVERSITY |
DURHAM |
NC |
UNITED STATES |
NCI |
$690,468 |
Brain Cancer;Brain Disorders;Cancer;Clinical Research;Clinical Trials;Neurosciences;Orphan Drug |
NEXT GENERATION STRATEGIES TO INTERCEPT ERBB SIGNALING |
5R37CA072981-13 |
1997-04-25 |
2009-04-01 |
31-Mar-10 |
2009 |
YARDEN, YOSEF NONE |
WEIZMANN INSTITUTE OF SCIENCE |
REHOVOT |
|
ISRAEL |
NCI |
$230,408 |
Biotechnology;Cancer;Prevention |
TARGETING THE IGF SYSTEM IN BREAST CANCER |
5R01CA074285-12 |
1998-01-01 |
2009-04-01 |
28-Feb-10 |
2009 |
YEE, DOUGLAS |
UNIVERSITY OF MINNESOTA TWIN CITIES |
MINNEAPOLIS |
MN |
UNITED STATES |
NCI |
$354,167 |
Breast Cancer;Cancer |
SPECTROSCOPIC LOCALIZATION OF BREAST CANCER |
5R44CA083597-07 |
1999-08-13 |
2009-04-01 |
31-Mar-11 |
2009 |
BENARON, DAVID A. |
SPECTROS CORPORATION |
Portola Valley |
CA |
UNITED STATES |
NCI |
$982,695 |
Aging;Bioengineering;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Health Disparities;Minority Health |
STRUCTURE-BASED PREDICTION OF THE INTERACTOME |
5R01GM081871-02 |
2008-04-01 |
2009-04-01 |
31-Mar-10 |
2009 |
BERGER, BONNIE |
MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
CAMBRIDGE |
MA |
UNITED STATES |
NIGMS |
$293,189 |
Bioengineering;Biotechnology;Genetics;Human Genome;Networking and Information Technology R&D |
CLINICAL TRIAL: P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACL |
5M01RR010732-15 |
2009-04-01 |
2009-04-01 |
31-Mar-10 |
2009 |
RYBKA, WITOLD B. |
PENNSYLVANIA STATE UNIV HERSHEY MED CTR |
HERSHEY |
PA |
UNITED STATES |
NCRR |
$7,395 |
Breast Cancer;Cancer;Clinical Research;Clinical Trials |
PROGRAM 3 (IMMUNOLOGY AND CANCER) |
5P30CA014599-34 |
|
2009-04-01 |
31-Mar-10 |
2009 |
GAJEWSKI, THOMAS F |
UNIVERSITY OF CHICAGO |
CHICAGO |
IL |
UNITED STATES |
NCI |
$24,656 |
Biotechnology;Cancer;Immunization;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Transplantation;Vaccine Related |
HUMAN IMMUNOLOGIC MONITORING |
5P30CA014599-34 |
|
2009-04-01 |
31-Mar-10 |
2009 |
GAJEWSKI, THOMAS F |
UNIVERSITY OF CHICAGO |
CHICAGO |
IL |
UNITED STATES |
NCI |
$127,583 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Immunization;Orphan Drug;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Transplantation;Vaccine Related |
MODULATION BY BOTANICALS OF ANTIBODY BASED CANCER IMMUNOTHERAPY |
5P50AT002779-05 |
|
2009-04-01 |
31-Mar-10 |
2009 |
CHEUNG, NAI-KONG V |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCCAM |
$269,759 |
Biotechnology;Cancer;Complementary and Alternative Medicine;Immunization;Prevention;Vaccine Related |
ROLE OF NEUREGULIN/ERBB SIGNALING IN THE ADULT HEART |
5R01HL068144-09 |
2001-09-30 |
2009-04-02 |
31-Mar-11 |
2009 |
SAWYER, DOUGLAS B |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NHLBI |
$327,478 |
Cardiovascular;Heart Disease |
WOMEN'S CANCERS |
2P30CA016042-34 |
2009-04-02 |
2009-04-02 |
30-Nov-09 |
2009 |
GLASPY, JOHN A |
UNIVERSITY OF CALIFORNIA LOS ANGELES |
LOS ANGELES |
CA |
UNITED STATES |
NCI |
$66,090 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Genetics;Nutrition;Prevention |
SENIOR LEADERS |
2P30CA016042-34 |
2009-04-02 |
2009-04-02 |
30-Nov-09 |
2009 |
GASSON, JUDITH CHERYL |
UNIVERSITY OF CALIFORNIA LOS ANGELES |
LOS ANGELES |
CA |
UNITED STATES |
NCI |
$737,786 |
Breast Cancer;Cancer;Genetics |
SOLUBLE TCR-IL15 FUSIONS AS TARGETED THERAPEUTICS FOR CANCER |
1R43CA139810-01 |
2009-04-03 |
2009-04-03 |
2-Apr-10 |
2009 |
RHODE, PETER R |
ALTOR BIOSCIENCE CORPORATION |
MIRAMAR |
FL |
UNITED STATES |
NCI |
$202,736 |
Biotechnology;Cancer |
THE AGING GUT: REGULATION OF CELL PROLIFERATION |
3R01AG014343-11S1 |
1997-09-01 |
2009-04-15 |
31-Jul-09 |
2009 |
MAJUMDAR, ADHIP N. |
WAYNE STATE UNIVERSITY |
DETROIT |
MI |
UNITED STATES |
NIA |
$21,484 |
Aging;Cancer;Digestive Diseases |
MOLECULAR STUDIES OF ESOPHAGEAL ADENOCARCINOMA |
5R01CA071606-13 |
1997-06-05 |
2009-05-01 |
30-Apr-10 |
2009 |
BEER, DAVID GEORGE |
UNIVERSITY OF MICHIGAN AT ANN ARBOR |
ANN ARBOR |
MI |
UNITED STATES |
NCI |
$305,930 |
Biotechnology;Cancer;Clinical Research;Digestive Diseases;Genetics |
BREAST CANCER RESPONSE MARKERS TO A DUAL HER1/2 BLOCKER |
5R01CA112305-05 |
2005-06-16 |
2009-05-01 |
30-Apr-10 |
2009 |
CHANG, JENNY C-N |
BAYLOR COLLEGE OF MEDICINE |
HOUSTON |
TX |
UNITED STATES |
NCI |
$252,236 |
Breast Cancer;Cancer;Clinical Research;Genetics |
FUNCTIONS IN TUMORS OF RECURRENTLY AMPLIFIED PREFOLDIN-4 |
5R01CA112608-05 |
2005-07-25 |
2009-05-01 |
30-Apr-10 |
2009 |
HANAHAN, DOUGLAS |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$283,709 |
Biotechnology;Breast Cancer;Cancer;Genetics |
PREDICTIVE BIOMARKERS OF ADJUVANT TRASTUZUMAB IN THE HER2+N9831 INTERGROUP TRIAL |
5R01CA129949-02 |
2008-05-20 |
2009-05-01 |
30-Apr-10 |
2009 |
PEREZ, EDITH ADALJISA |
MAYO CLINIC JACKSONVILLE |
JACKSONVILLE |
FL |
UNITED STATES |
NCI |
$483,070 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Genetics |
MOLECULAR BASIS OF SLITS AS TUMOR SUPPRESSORS CONTROLLING CXCR4/SDF1 IN BREAST |
3R01CA128902-02S1 |
2008-07-01 |
2009-05-01 |
30-Apr-10 |
2009 |
HINCK, LINDSAY E |
UNIVERSITY OF CALIFORNIA SANTA CRUZ |
SANTA CRUZ |
CA |
UNITED STATES |
NCI |
$71,614 |
Breast Cancer;Cancer;Genetics |
MOLECULAR BASIS OF SLITS AS TUMOR SUPPRESSORS CONTROLLING CXCR4/SDF1 IN BREAST |
5R01CA128902-02 |
2008-07-01 |
2009-05-01 |
30-Apr-10 |
2009 |
HINCK, LINDSAY E |
UNIVERSITY OF CALIFORNIA SANTA CRUZ |
SANTA CRUZ |
CA |
UNITED STATES |
NCI |
$309,335 |
Breast Cancer;Cancer;Genetics |
TARGETING HER-2 PROTEIN FOR BREAST CANCER USING COMPUTATIONAL APPROACH |
5P20RR016456-08 |
2009-05-01 |
2009-05-01 |
30-Apr-10 |
2009 |
SATYANARAYANAJOIS, SEETHARAMA D |
LOUISIANA STATE UNIV A&M COL BATON ROUGE |
BATON ROUGE |
LA |
UNITED STATES |
NCRR |
$42,225 |
Biotechnology;Breast Cancer;Cancer |
CELL HETEROGENEITY AND EMERGENT TRASTUZUMAB RESISTANCE IN BREAST CANCER: CONCEPT |
3R15CA132124-01A2S3 |
2009-05-01 |
2009-05-01 |
28-Feb-11 |
2009 |
KLINKE, DAVID JOHN |
WEST VIRGINIA UNIVERSITY |
MORGANTOWN |
WV |
UNITED STATES |
NCI |
$51,890 |
Bioengineering;Breast Cancer;Cancer |
METABOLIC PHENOTYPING WITH PET TO MONITOR AND PREDICT RESPONSE TO KINASE |
5P50CA086306-10 |
|
2009-05-01 |
30-Apr-10 |
2009 |
CZERNIN, JOHANNES |
UNIVERSITY OF CALIFORNIA LOS ANGELES |
LOS ANGELES |
CA |
UNITED STATES |
NCI |
$257,338 |
Bioengineering;Biotechnology;Brain Cancer;Brain Disorders;Cancer;Clinical Research;Diagnostic Radiology;Genetics;Lung;Lung Cancer |
IMPROVING INTERSTITIAL TRANSPORT IN TUMORS |
5P01CA080124-09 |
|
2009-05-01 |
30-Apr-10 |
2009 |
JAIN, RAKESH K. |
MASSACHUSETTS GENERAL HOSPITAL |
BOSTON |
MA |
UNITED STATES |
NCI |
$304,190 |
Biotechnology;Breast Cancer;Cancer;Gene Therapy;Genetics |
DEVELOPMENT OF MECHANISM-BASED STRATEGIES FOR THE TREATMENT OF ADVANCED BREAST CA |
5P01CA094060-07 |
|
2009-05-01 |
30-Apr-10 |
2009 |
ROSEN, NEAL |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$447,626 |
Breast Cancer;Cancer;Clinical Research |
SMALL MOLECULE INHIBITORS OF THE TRANSCRIPTIONAL ACTIVATORS ESX AND NF-KB |
1R01CA140667-01 |
2009-05-20 |
2009-05-20 |
28-Feb-10 |
2009 |
MAPP, ANNA K. |
UNIVERSITY OF MICHIGAN AT ANN ARBOR |
ANN ARBOR |
MI |
UNITED STATES |
NCI |
$319,862 |
Breast Cancer;Cancer;Genetics |
FUNCTION OF MUC4 IN MAMMARY EPITHELIA AND TUMORS |
5R01CA052498-17 |
1991-09-30 |
2009-06-01 |
31-May-10 |
2009 |
CARRAWAY, KERMIT L. |
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE |
MIAMI |
FL |
UNITED STATES |
NCI |
$294,823 |
Biotechnology;Breast Cancer;Cancer;Genetics |
MECHANISMS OF INVERTEBRATE EGF RECEPTOR INHIBITION |
5R01CA125432-03 |
2007-07-01 |
2009-06-01 |
31-May-10 |
2009 |
LEMMON, MARK A. |
UNIVERSITY OF PENNSYLVANIA |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$236,735 |
Breast Cancer;Cancer |
ERBB2 DOWNREGULATION THROUGH HSP90 INHIBITION |
5R01CA116552-04 |
2007-08-01 |
2009-06-01 |
31-May-10 |
2009 |
BAND, HAMID |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
OMAHA |
NE |
UNITED STATES |
NCI |
$279,300 |
Biotechnology;Breast Cancer;Cancer |
ULTRASOUND-MEDIATED BLOOD-BRAIN BARRIER PERMEABILIZATION IN PRIMATES |
5R44NS054410-03 |
2008-06-15 |
2009-06-01 |
31-May-10 |
2009 |
LAWRENCE, MATTHEW SWAN |
RXGEN, INC. |
HAMDEN |
CT |
UNITED STATES |
NINDS |
$668,381 |
Bioengineering;Diagnostic Radiology;Neurosciences |
INTEGRATED BIOCHIP SENSORS FOR DETECTION OF CANCER |
5R01CA120003-02 |
2008-07-01 |
2009-06-01 |
31-May-10 |
2009 |
BASHIR, RASHID |
UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN |
CHAMPAIGN |
IL |
UNITED STATES |
NCI |
$522,787 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Clinical Research;Nanotechnology |
SIGNAL TRANSDUCTION IN THE HEART AFTER CANCER THERAPY |
5R01HL088649-02 |
2008-08-01 |
2009-06-01 |
31-May-10 |
2009 |
GABRIELSON, KATHLEEN LOUISE |
JOHNS HOPKINS UNIVERSITY |
BALTIMORE |
MD |
UNITED STATES |
NHLBI |
$410,000 |
Biotechnology;Breast Cancer;Cancer;Cardiovascular;Heart Disease |
IDENTIFICATION AND CHARACTERIZATION OF DRIVER GENE(S) IN RECURRENT LUNG CANCER AM |
3R01CA127547-01A1S1 |
2009-06-01 |
2009-06-01 |
30-Sep-10 |
2009 |
MU, DAVID |
PENNSYLVANIA STATE UNIV HERSHEY MED CTR |
HERSHEY |
PA |
UNITED STATES |
NCI |
$38,411 |
Biotechnology;Cancer;Genetics;Lung;Lung Cancer |
CELL HETEROGENEITY AND EMERGENT TRASTUZUMAB RESISTANCE IN BREAST CANCER: CONCEPT |
3R15CA132124-01A2S2 |
2009-06-01 |
2009-06-01 |
30-Sep-10 |
2009 |
KLINKE, DAVID JOHN |
WEST VIRGINIA UNIVERSITY |
MORGANTOWN |
WV |
UNITED STATES |
NCI |
$39,496 |
Bioengineering;Breast Cancer;Cancer |
CANCER AND LEUKEMIA GROUP B |
3U10CA031946-28S1 |
2009-06-01 |
2009-06-01 |
31-Mar-10 |
2009 |
SCHILSKY, RICHARD L |
UNIVERSITY OF CHICAGO |
CHICAGO |
IL |
UNITED STATES |
NCI |
$201,363 |
Cancer |
DEVELOPMENT OF PROBODIES: A NOVEL CLASS OF THERAPEUTIC ANTIBODIES COMBINING TARGE |
1R43CA139790-01 |
2009-06-01 |
2009-06-01 |
31-May-11 |
2009 |
WEST, JAMES W |
CYTOMX THERAPEUTICS, LLC |
SANTA BARBARA |
CA |
UNITED STATES |
NCI |
$260,910 |
Arthritis;Biotechnology;Cancer;Immunization;Lung;Lung Cancer |
NR1D1 PATHWAY IN BREAST CANCER |
1R01CA136658-01A1 |
2009-06-01 |
2009-06-01 |
30-Apr-10 |
2009 |
CONKLIN, DOUGLAS S |
STATE UNIVERSITY OF NEW YORK AT ALBANY |
ALBANY |
NY |
UNITED STATES |
NCI |
$314,363 |
Biotechnology;Breast Cancer;Cancer;Genetics;Nutrition |
THE ROLE OF AURORA KINASE A IN UPPER GASTROINTESTINAL ADENOCARCINOMAS |
1R01CA131225-01A2 |
2009-06-01 |
2009-06-01 |
30-Apr-10 |
2009 |
EL-RIFAI, WAEL |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$314,534 |
Cancer;Digestive Diseases;Genetics |
EARLY SCREENING OF BREAST LESION TRIAL (PHASE III PIVOTAL) |
5R44CA126441-03 |
2007-09-27 |
2009-06-26 |
28-Feb-10 |
2009 |
BENARON, DAVID A. |
SPECTROS CORPORATION |
Portola Valley |
CA |
UNITED STATES |
NCI |
$701,169 |
Bioengineering;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Diagnostic Radiology;Prevention;Prostate Cancer;Urologic Diseases |
PAUL CALABRESI PROGRAM IN CLINICAL-TRANSLATIONAL RESEARCH AT MAYO CLINIC |
5K12CA090628-09 |
2001-09-25 |
2009-07-01 |
30-Jun-10 |
2009 |
HARTMANN, LYNN C. |
MAYO CLINIC |
ROCHESTER |
MN |
UNITED STATES |
NCI |
$1,070,823 |
Breast Cancer;Cancer;Clinical Research;Hematology;Orphan Drug |
DEVELOPMENTAL RESEARCH PROGRAM |
5P50CA086438-09 |
|
2009-07-01 |
30-Jun-10 |
2009 |
JURCIC, JOSEPH G |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$159,080 |
Bioengineering;Biotechnology;Cancer;Diagnostic Radiology;Genetics;Hematology;Lymphoma;Nanotechnology;Orphan Drug;Regenerative Medicine;Transplantation |
RESEARCH PROJECT 3: ROLE OF THE NF-KB/REL IN MAMMARY CARCINOGENESIS |
5P01ES011624-07 |
|
2009-07-01 |
30-Jun-10 |
2009 |
SONENSHEIN, GAIL E |
BOSTON UNIVERSITY MEDICAL CAMPUS |
BOSTON |
MA |
UNITED STATES |
NIEHS |
$162,768 |
Breast Cancer;Cancer;Complementary and Alternative Medicine;Genetics;Nutrition |
MOLECULAR IMAGING OF CASTRATE- RESISTANCE METASTATIC PROSTATE CANCER |
5P50CA086438-09 |
|
2009-07-01 |
30-Jun-10 |
2009 |
LARSON, STEVEN MARK |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$203,991 |
Bioengineering;Cancer;Diagnostic Radiology;Nanotechnology;Prostate Cancer;Urologic Diseases |
DEVELOPMENT OF METHODOLOGIES FOR THE IN VIVO IMAGING OG THE EFFECTS OF NOVEL INHI |
5P50CA086438-09 |
|
2009-07-01 |
30-Jun-10 |
2009 |
ROSEN, NEAL |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$223,770 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Diagnostic Radiology;Nanotechnology |
RADIOIMMUNOTHERAPY: CLINICAL STUDIES |
5P01CA043904-18 |
|
2009-07-01 |
30-Jun-10 |
2009 |
WONG, JEFFREY Y |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$241,076 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Colo-Rectal Cancer;Digestive Diseases;Immunization;Vaccine Related |
CLINICAL PRODUCTION |
5P01CA043904-18 |
|
2009-07-01 |
30-Jun-10 |
2009 |
YAZAKI, PAUL |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$310,412 |
Biotechnology;Cancer;Clinical Research;Clinical Trials;Genetics |
RADIOPHARMACY AND ASSAYS |
5P01CA043904-18 |
|
2009-07-01 |
30-Jun-10 |
2009 |
COLCHER, DAVID MORRIS |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$494,263 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Clinical Research;Colo-Rectal Cancer;Digestive Diseases;Immunization;Vaccine Related |
SUBPROJECT 1 |
5U54GM074946-05 |
|
2009-07-01 |
30-Jun-10 |
2008 |
EISENBERG, DAVID |
LOS ALAMOS NAT SECTY-LOS ALAMOS NAT LAB |
LOS ALAMOS |
NM |
UNITED STATES |
NIGMS |
$542,456 |
Bioengineering;Biotechnology;Genetics |
THE IMPLEMENTATION OF A PHARMACOGENOMICS-BASED ALGORITHM FOR WARFARIN DOSING |
1K23HL089808-01A2 |
2009-07-15 |
2009-07-15 |
30-Apr-10 |
2009 |
PERERA, MINOLI |
UNIVERSITY OF CHICAGO |
CHICAGO |
IL |
UNITED STATES |
NHLBI |
$119,233 |
Clinical Research;Clinical Trials;Genetic Testing;Genetics;Health Disparities;Human Genome;Minority Health |
SIGNAL TRANSDUCTION IN THE HEART AFTER CANCER THERAPY |
3R01HL088649-01A2S1 |
2009-07-15 |
2009-07-15 |
30-Jun-11 |
2009 |
GABRIELSON, KATHLEEN LOUISE |
JOHNS HOPKINS UNIVERSITY |
BALTIMORE |
MD |
UNITED STATES |
NHLBI |
$269,045 |
Biotechnology;Breast Cancer;Cancer;Cardiovascular;Heart Disease |
MONITORING BREAST CANCER CHEMOTHERAPEUTIC RESPONSE USING DOSI, MRI AND BIOMARKERS |
1U54CA136400-01 |
2009-07-17 |
2009-07-17 |
30-Jun-10 |
2009 |
TROMBERG, BRUCE J |
UNIVERSITY OF CALIFORNIA IRVINE |
IRVINE |
CA |
UNITED STATES |
NCI |
$452,201 |
Bioengineering;Breast Cancer;Cancer;Clinical Research;Diagnostic Radiology |
FATTY ACID SYNTHASE:MOLECULAR TARGET FOR BREAST CANCER THERAPY & CHEMOPREVENTION |
5R01CA116623-06 |
2005-09-16 |
2009-07-31 |
28-Feb-11 |
2009 |
LUPU, RUTH |
MAYO CLINIC |
ROCHESTER |
MN |
UNITED STATES |
NCI |
$444,316 |
Breast Cancer;Cancer;Genetics;Prevention |
IMMUNOBIOLOGY OF P185 RECEPTOR |
5R01CA055306-15 |
1992-05-01 |
2009-08-01 |
31-Jul-10 |
2009 |
GREENE, MARK I |
UNIVERSITY OF PENNSYLVANIA |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$269,183 |
Biotechnology;Cancer;Immunization;Prevention |
THE AGING GUT: REGULATION OF CELL PROLIFERATION |
5R01AG014343-12 |
1997-09-01 |
2009-08-01 |
31-Jul-10 |
2009 |
MAJUMDAR, ADHIP N. |
WAYNE STATE UNIVERSITY |
DETROIT |
MI |
UNITED STATES |
NIA |
$294,023 |
Aging;Cancer;Digestive Diseases |
STRUCTURAL STUDIES OF GROWTH FACTOR RECEPTOR FUNCTION |
5R01CA090466-08 |
2001-04-01 |
2009-08-01 |
31-Jul-10 |
2009 |
LEAHY, DANIEL J |
JOHNS HOPKINS UNIVERSITY |
BALTIMORE |
MD |
UNITED STATES |
NCI |
$222,384 |
Breast Cancer;Cancer |
BREAST CANCER TREATMENT WITH ANTIBODY TARGETED T CELLS |
2R01CA092344-07A2 |
2001-07-01 |
2009-08-01 |
31-Jul-10 |
2009 |
LUM, LAWRENCE G |
WAYNE STATE UNIVERSITY |
DETROIT |
MI |
UNITED STATES |
NCI |
$501,226 |
Breast Cancer;Cancer;Clinical Research;Clinical Trials;Immunization;Vaccine Related |
STRUCTURE/FUNCTION STUDIES OF NUCLEOSIDE ANALOG ACTIVATING ENZYMES |
2R56CA095687-05A1 |
2002-08-22 |
2009-08-01 |
31-Jul-11 |
2009 |
LAVIE, ARNON |
UNIVERSITY OF ILLINOIS AT CHICAGO |
CHICAGO |
IL |
UNITED STATES |
NCI |
$266,973 |
Cancer |
THE MOLECULAR ACTIONS OF IMATINIB MESYLATE IN GISTS |
2R01CA106588-06 |
2004-05-01 |
2009-08-01 |
31-May-10 |
2009 |
GODWIN, ANDREW K |
FOX CHASE CANCER CENTER |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$423,095 |
Biotechnology;Cancer;Clinical Research;Clinical Trials;Colo-Rectal Cancer;Digestive Diseases;Genetics;Orphan Drug;Prevention |
HER-2/IGF-IR CROSS-TALK AND HERCEPTIN RESISTANCE |
5K01CA118174-05 |
2006-08-01 |
2009-08-01 |
31-Jul-10 |
2009 |
NAHTA, RITA |
EMORY UNIVERSITY |
ATLANTA |
GA |
UNITED STATES |
NCI |
$143,856 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Nanotechnology |
MICELLE SURFACE ENGINEERING FOR ACTIVE TARGETING BY ACIDIC TUMOR EXTRACELLULAR PH |
5R01CA122356-04 |
2006-08-22 |
2009-08-01 |
31-Jul-10 |
2009 |
BAE, YOU HAN |
UNIVERSITY OF UTAH |
SALT LAKE CITY |
UT |
UNITED STATES |
NCI |
$257,668 |
Bioengineering;Cancer |
MOLECULAR MAMMOGRAPHY OF HER-2 CANCERS USING GOLD NANOPARTICLES |
5R44CA124190-03 |
2006-09-26 |
2009-08-01 |
31-Jul-11 |
2009 |
HAINFELD, JAMES F. |
NANOPROBES, INC. |
YAPHANK |
NY |
UNITED STATES |
NCI |
$483,193 |
Bioengineering;Breast Cancer;Cancer;Diagnostic Radiology;Nanotechnology |
A NOVEL TRANSGENIC SILKWORM SYSTEM FOR RECOMBINANT GLYCOPROTEIN PRODUCTION |
5R01GM080672-03 |
2007-09-29 |
2009-08-01 |
31-Jul-10 |
2009 |
JARVIS, DONALD L. |
UNIVERSITY OF WYOMING |
LARAMIE |
WY |
UNITED STATES |
NIGMS |
$280,108 |
Bioengineering;Biotechnology |
BETA-CATENIN/TCF SIGNALING IN BREAST CANCER |
5R01CA131219-02 |
2008-09-01 |
2009-08-01 |
31-Jul-10 |
2009 |
HOWE, LOUISE R |
WEILL MEDICAL COLLEGE OF CORNELL UNIV |
NEW YORK |
NY |
UNITED STATES |
NCI |
$350,675 |
Aging;Breast Cancer;Cancer;Prevention |
IDENTIFICATION AND CHARACTERIZATION OF DRIVER GENE(S) IN RECURRENT LUNG CANCER AM |
5R01CA127547-02 |
2008-09-08 |
2009-08-01 |
31-Jul-10 |
2009 |
MU, DAVID |
PENNSYLVANIA STATE UNIV HERSHEY MED CTR |
HERSHEY |
PA |
UNITED STATES |
NCI |
$289,649 |
Biotechnology;Cancer;Genetics;Lung;Lung Cancer |
DETERMINANTS AND RISKS OF USE AND OVERUSE OF EXPENSIVE ONCOLOGY DRUGS |
5R01CA134964-02 |
2008-09-12 |
2009-08-01 |
31-Jul-10 |
2009 |
HERSHMAN, DAWN |
COLUMBIA UNIVERSITY HEALTH SCIENCES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$259,686 |
Aging;Breast Cancer;Cancer;Clinical Research;Health Disparities;Health Services;Hematology;Minority Health;Orphan Drug;Prostate Cancer;Urologic Diseases |
DISSECTING MECHANISMS OF METASTASIS THROUGH COMPARATIVE SYSTEMS GENETICS |
5R01CA138265-02 |
2008-09-25 |
2009-08-01 |
31-Jul-10 |
2009 |
KIRSCH, DAVID G |
DUKE UNIVERSITY |
DURHAM |
NC |
UNITED STATES |
NCI |
$483,906 |
Biotechnology;Breast Cancer;Cancer;Genetics;Human Genome |
OPENING THE BLOOD BRAIN BARRIER FOR MOLECULAR IMAGING |
5U41RR019703-05 |
2009-08-01 |
2009-08-01 |
31-Jul-10 |
2009 |
HYNYNEN, KULLERVO |
BRIGHAM AND WOMEN'S HOSPITAL |
BOSTON |
MA |
UNITED STATES |
NCRR |
$54,793 |
Bioengineering;Biotechnology;Brain Cancer;Brain Disorders;Breast Cancer;Cancer;Diagnostic Radiology;Nanotechnology;Neurosciences |
HER-2/IGF-IR CROSS-TALK AND HERCEPTIN RESISTANCE |
3K01CA118174-05S1 |
2009-08-01 |
2009-08-01 |
31-Jul-11 |
2009 |
NAHTA, RITA |
EMORY UNIVERSITY |
ATLANTA |
GA |
UNITED STATES |
NCI |
$109,620 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Nanotechnology |
GROWTH FACTOR RECEPTOR SIGNALING IN BREAST CANCER |
3P01CA099031-05S1 |
2009-08-01 |
2009-08-01 |
31-Jul-10 |
2009 |
HUNG, MIEN-CHIE |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$151,419 |
Breast Cancer;Cancer;Clinical Research |
RESEARCH PROGRAMS-SIGNAL TRANSDUCTION |
5P30CA016359-31 |
|
2009-08-01 |
31-Jul-10 |
2009 |
SCHLESSINGER, JOSEPH |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$27,152 |
Breast Cancer;Cancer |
BREAST CANCER VACCINE STRATEGIES FOR HER2-OVEREXPRESSING AND LUM. B TUMORS |
5P50CA058223-17 |
|
2009-08-01 |
31-Jul-10 |
2009 |
SERODY, JONATHAN STUART |
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL |
CHAPEL HILL |
NC |
UNITED STATES |
NCI |
$223,827 |
Biotechnology;Breast Cancer;Cancer;Immunization;Infectious Diseases;Prevention;Vaccine Related;Vector-Borne Diseases |
SPORE CORE 1: ADMINISTRATIVE, EVALUATION AND PLANNING |
5P50CA093683-07 |
|
2009-08-01 |
31-Jul-10 |
2009 |
MARASCO, WAYNE A. |
BRIGHAM AND WOMEN'S HOSPITAL |
BOSTON |
MA |
UNITED STATES |
NCI |
$279,688 |
Biotechnology;Cancer;Immunization;Lymphoma;Prevention;Vaccine Related |
OPTIMAL PREDICTORS OF RESPONSE TO TRASTUZUMAB |
1R01CA139431-01 |
2009-08-05 |
2009-08-05 |
31-Jul-10 |
2009 |
RIMM, DAVID L |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$587,922 |
Biotechnology;Breast Cancer;Cancer;Genetics |
RACIAL/ETHNIC AND SES DISPARITIES IN QUALITY OF BREAST CANCER SYSTEMIC THERAPY |
1R01CA139014-01 |
2009-08-11 |
2009-08-11 |
31-Jul-10 |
2009 |
GRIGGS, JENNIFER J |
UNIVERSITY OF MICHIGAN AT ANN ARBOR |
ANN ARBOR |
MI |
UNITED STATES |
NCI |
$560,091 |
Behavioral and Social Science;Breast Cancer;Cancer |
THE ROLE OF T-DARPP IN ESOPHAGEAL ADENOCARCINOMA |
1R01CA133738-01A2 |
2009-08-13 |
2009-08-13 |
31-Jul-10 |
2009 |
EL-RIFAI, WAEL |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$232,500 |
Biotechnology;Cancer;Digestive Diseases |
PROGNOSTIC AND PREDICTIVE GENE SETS IN HER2-POSITIVE BREAST CANCER:THE HERA TRIAL |
1R21CA139428-01 |
2009-08-21 |
2009-08-21 |
31-Jul-10 |
2009 |
LEYLAND-JONES, BRIAN |
EMORY UNIVERSITY |
ATLANTA |
GA |
UNITED STATES |
NCI |
$214,103 |
Breast Cancer;Cancer;Genetics |
TARGETING SIGNALING NETWORKS VIA NOVEL RNAI APPROACHES TO IMPROVE THERAPY FOR O |
2P50CA083638-11 |
2009-08-21 |
2009-08-21 |
31-May-10 |
2009 |
GODWIN, ANDREW K |
FOX CHASE CANCER CENTER |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$275,341 |
Biotechnology;Cancer;Clinical Research;Genetics;Orphan Drug;Ovarian Cancer |
PHASE I TRIAL WITH TWO HER-2 B CELL EPITOPE VACCINE IN PATIENTS WITH SOLID TUMORS |
1R21CA135608-01A2 |
2009-08-25 |
2009-08-25 |
31-Jul-10 |
2009 |
KAUMAYA, PRAVIN T.P |
OHIO STATE UNIVERSITY |
COLUMBUS |
OH |
UNITED STATES |
NCI |
$330,000 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Immunization;Lung;Lung Cancer;Prevention;Vaccine Related |
PROFILING ER, PR, EGFR AND HER2 IN BREAST CANCER USING MULTIPLEX TISSUE IMMUSTA |
5R44CA123994-03 |
2006-08-01 |
2009-08-27 |
31-Jul-10 |
2009 |
JAMES, WILLIAM M |
20/20 GENESYSTEMS, INC. |
ROCKVILLE |
MD |
UNITED STATES |
NCI |
$106,461 |
Bioengineering;Biotechnology;Breast Cancer;Cancer |
REWIRING ERBB SIGNALING IN CANCER CELLS |
5R01CA098881-07 |
2003-07-01 |
2009-08-31 |
31-Jul-10 |
2009 |
LANDGRAF, RALF |
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE |
MIAMI |
FL |
UNITED STATES |
NCI |
$273,042 |
Breast Cancer;Cancer |
TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY |
5R01CA137488-15 |
1995-08-15 |
2009-09-01 |
31-Aug-10 |
2009 |
NEUWELT, EDWARD A |
OREGON HEALTH AND SCIENCE UNIVERSITY |
PORTLAND |
OR |
UNITED STATES |
NCI |
$495,178 |
Brain Cancer;Brain Disorders;Breast Cancer;Cancer;Clinical Research;Lymphoma;Neurosciences;Orphan Drug |
TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY |
3R01CA137488-15S1 |
1995-08-15 |
2009-09-01 |
31-Aug-11 |
2009 |
NEUWELT, EDWARD A |
OREGON HEALTH AND SCIENCE UNIVERSITY |
PORTLAND |
OR |
UNITED STATES |
NCI |
$1,969,722 |
Brain Cancer;Brain Disorders;Breast Cancer;Cancer;Clinical Research;Lymphoma;Neurosciences;Orphan Drug |
DANA-FARBER/HARVARD SPORE IN BREAST CANCER |
3P50CA089393-10S1 |
2000-09-30 |
2009-09-01 |
31-Aug-11 |
2009 |
IGLEHART, JAMES DIRK |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$238,958 |
No NIH Category available. |
DANA-FARBER/HARVARD SPORE IN BREAST CANCER |
5P50CA089393-10 |
2000-09-30 |
2009-09-01 |
31-Aug-11 |
2009 |
IGLEHART, JAMES DIRK |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$2,179,546 |
No NIH Category available. |
INNATE IMMUNITY: ELUCIDATION AND MODULATION FOR CANCER THERAPY |
5P01CA095426-08 |
2002-02-01 |
2009-09-01 |
31-Aug-10 |
2009 |
CALIGIURI, MICHAEL A |
OHIO STATE UNIVERSITY |
COLUMBUS |
OH |
UNITED STATES |
NCI |
$2,044,559 |
No NIH Category available. |
PHARMACODYNAMIC ASSESSMENT OF RTK INHIBITORS IN CANCER |
7R01CA112385-06 |
2005-02-23 |
2009-09-01 |
31-Jan-11 |
2009 |
HALLAHAN, DENNIS E |
WASHINGTON UNIVERSITY |
SAINT LOUIS |
MO |
UNITED STATES |
NCI |
$186,770 |
Cancer;Diagnostic Radiology;Lung;Lung Cancer;Orphan Drug |
UTMDACC SPORE IN BREAST CANCER |
5P50CA116199-05 |
2005-09-23 |
2009-09-01 |
31-Aug-11 |
2009 |
HORTOBAGYI, GABRIEL N |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$2,180,817 |
No NIH Category available. |
REGULATION OF HER2/NEU BY ACTIVATION LOOP PHOSPHORYLATION AND ALG-2 |
5K22CA128951-03 |
2007-09-18 |
2009-09-01 |
31-Aug-10 |
2009 |
BOSE, RON |
WASHINGTON UNIVERSITY |
SAINT LOUIS |
MO |
UNITED STATES |
NCI |
$149,163 |
Biotechnology;Breast Cancer;Cancer;Genetics |
PERSONALIZED MEDICINE FOR COLORECTAL AND BREAST CANCER |
5P01CA130818-02 |
2008-09-16 |
2009-09-01 |
31-Aug-10 |
2009 |
PHILLIPS, KATHRYN A |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$1,789,311 |
No NIH Category available. |
STRUCTURE-BASED PREDICTION OF THE INTERACTOME |
3R01GM081871-02S1 |
2009-09-01 |
2009-09-01 |
31-Aug-11 |
2009 |
BERGER, BONNIE |
MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
CAMBRIDGE |
MA |
UNITED STATES |
NIGMS |
$289,931 |
Bioengineering;Biotechnology;Genetics;Human Genome;Networking and Information Technology R&D |
MEASUREMENT IN DIVERSE POPULATIONS |
5P01CA130818-02 |
|
2009-09-01 |
31-Aug-10 |
2009 |
PONCE, NINEZ ALAFRIZ |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$96,651 |
Bioengineering;Breast Cancer;Cancer |
TARGETED COMBINATIONS FOR HER2- POSITIVE BREAST CANCER BIOLOGY |
5P50CA089393-10 |
|
2009-09-01 |
31-Aug-10 |
2009 |
HARRIS, LYNDSAY N |
DANA-FARBER CANCER INSTITUTE |
BOSTON |
MA |
UNITED STATES |
NCI |
$137,947 |
Breast Cancer;Cancer |
NONINVASIVE ASSESSMENT OF CANCER RESPONSIVENESS TO THERAPY BY USE OF ..... |
5P50CA128323-02 |
|
2009-09-01 |
31-Aug-10 |
2009 |
HALLAHAN, DENNIS E |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$163,107 |
Cancer;Diagnostic Radiology |
MOUSE MODELING AND ANIMAL DEVELOPMENT |
5P01CA095426-08 |
|
2009-09-01 |
31-Aug-10 |
2009 |
MUTHUSAMY, NATARAJAN |
OHIO STATE UNIVERSITY |
COLUMBUS |
OH |
UNITED STATES |
NCI |
$247,666 |
Biotechnology;Cancer;Genetics;Lymphoma |
KINASE IMAGING |
5P50CA086355-10 |
|
2009-09-01 |
31-Aug-10 |
2009 |
JOSEPHSON, LEE |
MASSACHUSETTS GENERAL HOSPITAL |
BOSTON |
MA |
UNITED STATES |
NCI |
$252,886 |
Bioengineering;Biotechnology;Cancer;Diagnostic Radiology;Nanotechnology |
PTEN DEFICIENCY AND TRASTUZUMAB RESISTANCE |
5P50CA116199-05 |
|
2009-09-01 |
31-Aug-10 |
2009 |
YU, DIHUA |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$269,341 |
Breast Cancer;Cancer;Clinical Research |
ECONOMICS OF PERSONALIZED MEDICINE USING GENOMICS |
5P01CA130818-02 |
|
2009-09-01 |
31-Aug-10 |
2009 |
LADABAUM, URI |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$281,717 |
Bioengineering;Breast Cancer;Cancer;Clinical Research;Cost Effectiveness Research;Health Services;Prevention |
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C |
5P50CA092629-09 |
|
2009-09-01 |
31-Aug-10 |
2009 |
ROSEN, NEAL |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$362,472 |
Aging;Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Prostate Cancer;Urologic Diseases |
MULTIPLEXED NANOPARTICLE PROBES FOR THERAPEUTIC TRANSLATIONAL ONCOLOGY |
5U54CA119338-05 |
|
2009-09-01 |
31-Aug-10 |
2009 |
SIMONS, JONATHAN W |
EMORY UNIVERSITY |
ATLANTA |
GA |
UNITED STATES |
NCI |
$379,473 |
Aging;Bioengineering;Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Colo-Rectal Cancer;Digestive Diseases;Gene Therapy;Genetics;Lung;Lung Cancer;Nanotechnology |
ANTIBODY THERAPY FOR BREAST CANCER: INVESTIGATION OF IMMUNE MODULATION WITH IL-21 |
5P01CA095426-08 |
|
2009-09-01 |
31-Aug-10 |
2009 |
CARSON, WILLIAM E. |
OHIO STATE UNIVERSITY |
COLUMBUS |
OH |
UNITED STATES |
NCI |
$408,328 |
Breast Cancer;Cancer;Immunization |
COMBINATORIAL LIBRARY SCREENING CORE |
5U54CA119343-05 |
|
2009-09-01 |
31-Aug-10 |
2009 |
LIU, RIHE |
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL |
CHAPEL HILL |
NC |
UNITED STATES |
NCI |
$457,370 |
Bioengineering;Biotechnology;Cancer;Nanotechnology;Prevention |
MULTIFUNCTIONAL NANOSTRUCTURES FOR THERAPEUTIC TARGETING OF BREAST CANCER |
5U54CA119341-05 |
|
2009-09-01 |
31-Aug-10 |
2009 |
STUPP, SAMUEL I |
NORTHWESTERN UNIVERSITY |
CHICAGO |
IL |
UNITED STATES |
NCI |
$594,551 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Nanotechnology |
UTILIZATION OF PERSONALIZED MEDICINE USING GENOMICS |
5P01CA130818-02 |
|
2009-09-01 |
31-Aug-10 |
2009 |
HAAS, JENNIFER S |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$742,378 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Clinical Research;Genetics;Health Services |
THE AGING GUT: REGULATION OF CELL PROLIFERATION |
3R01AG014343-12S1 |
2009-09-15 |
2009-09-15 |
31-Aug-11 |
2009 |
MAJUMDAR, ADHIP N. |
WAYNE STATE UNIVERSITY |
DETROIT |
MI |
UNITED STATES |
NIA |
$138,482 |
Aging;Cancer;Digestive Diseases |
BIOLOGIC AND THERAPEUTIC IMPLICATIONS OF AKT ACTIVATION IN HER2+ BREAST CANCER |
1K08CA134833-01A1 |
2009-09-21 |
2009-09-21 |
31-Aug-10 |
2009 |
CHANDARLAPATY, SARAT |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$145,152 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Genetics |
BIFUNCTIONAL T CELL RECEPTOR BASED IMMUNOTHERAPEUTICS |
2R44CA097550-05A1 |
2002-07-26 |
2009-09-22 |
31-Aug-10 |
2009 |
WONG, HING C. |
ALTOR BIOSCIENCE CORPORATION |
MIRAMAR |
FL |
UNITED STATES |
NCI |
$1,000,000 |
Cancer;Clinical Research;Clinical Trials;Orphan Drug |
ONCOLOGY R&D: EXPANDING THE ROLE OF ECONOMICS TO AID PUBLIC POLICY |
1K07CA138906-01A1 |
2009-09-23 |
2009-09-23 |
31-Aug-10 |
2009 |
CONTI, RENA MARIE |
UNIVERSITY OF CHICAGO |
CHICAGO |
IL |
UNITED STATES |
NCI |
$130,837 |
Basic Behavioral and Social Science;Behavioral and Social Science;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Cost Effectiveness Research |
TARGETED THERAPIES IN BREAST CANCER |
1K23CA127469-01A2 |
2009-09-24 |
2009-09-24 |
31-Aug-10 |
2009 |
MAYER, INGRID |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$163,944 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Genetics |
MOLECULAR MAMMOGRAPHY OF HER-2 CANCERS USING GOLD NANOPARTICLES |
3R44CA124190-03S1 |
2006-07-01 |
2009-09-28 |
31-Aug-11 |
2009 |
HAINFELD, JAMES F. |
NANOPROBES, INC. |
YAPHANK |
NY |
UNITED STATES |
NCI |
$295,393 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Diagnostic Radiology;Nanotechnology |
FUNCTIONAL OPTICAL COHERENCE TOMOGRAPHY FOR MONITORING DRUG RESISTANCE IN CANCER |
1K99CA142888-01 |
2009-09-28 |
2009-09-28 |
30-Jun-10 |
2009 |
SKALA, MELISSA CAROLINE |
DUKE UNIVERSITY |
DURHAM |
NC |
UNITED STATES |
NCI |
$88,596 |
Bioengineering;Breast Cancer;Cancer;Diagnostic Radiology;Nanotechnology |
HEAT SHOCK PROTEINS IN SIGNALING AND CANCER |
2R01CA081244-11A2 |
2000-05-01 |
2009-09-29 |
31-Aug-10 |
2009 |
SHERMAN, MICHAEL Y |
BOSTON UNIVERSITY MEDICAL CAMPUS |
BOSTON |
MA |
UNITED STATES |
NCI |
$355,597 |
Biotechnology;Breast Cancer;Cancer;Prevention |
DEVELOPMENT OF NOVEL IMMUNOCONJUGATES FOR APPLICATION IN CANCER THERAPEUTICS |
1F32CA144213-01 |
2009-09-30 |
2009-09-30 |
29-Sep-10 |
2009 |
YOUNG, DOUGLAS DEAN |
SCRIPPS RESEARCH INSTITUTE |
LA JOLLA |
CA |
UNITED STATES |
NCI |
$45,218 |
Biotechnology;Cancer |
DEVELOPMENT OF TARGETED THERAPY FOR ERK PATHWAY IN BREAST CANCER |
1K99CA139006-01A1 |
2009-09-30 |
2009-09-30 |
31-Aug-10 |
2009 |
BARTHOLOMEUSZ, CHANDRA |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$114,575 |
Biotechnology;Breast Cancer;Cancer |
REGULATION OF STAT3 SIGNALING |
3R01CA122910-03S1 |
2009-09-30 |
2009-09-30 |
29-Sep-11 |
2009 |
REICH, NANCY C. |
STATE UNIVERSITY NEW YORK STONY BROOK |
STONY BROOK |
NY |
UNITED STATES |
NCI |
$171,293 |
Cancer;Genetics;Hematology |
TSG101 - A MODULATOR OF ERBB2 SIGNALING IN BREAST CANCER |
3R01CA093797-06A2S1 |
2009-09-30 |
2009-09-30 |
29-Sep-11 |
2009 |
WAGNER, KAY-UWE |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
OMAHA |
NE |
UNITED STATES |
NCI |
$197,273 |
Breast Cancer;Cancer |
GENE TARGETED THERAPY OF BRAIN TUMORS |
1R21NS067975-01 |
2009-09-30 |
2009-09-30 |
31-Aug-10 |
2009 |
SAMPSON, JOHN H |
DUKE UNIVERSITY |
DURHAM |
NC |
UNITED STATES |
NINDS |
$233,754 |
Biotechnology;Brain Cancer;Brain Disorders;Cancer;Genetics;Human Genome;Neurosciences;Orphan Drug |
ERBB RECEPTOR HOMO- AND HETERO-DIMERIZATION |
3R01CA079992-11S1 |
2009-09-30 |
2009-09-30 |
29-Sep-11 |
2009 |
LEMMON, MARK A. |
UNIVERSITY OF PENNSYLVANIA |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$427,626 |
Breast Cancer;Cancer |
A NOVEL THERAPY FOR HER2 POSITIVE HORMONE REFRACTORY BREAST CANCER |
1RC1CA145066-01 |
2009-09-30 |
2009-09-30 |
31-Aug-10 |
2009 |
HAMBURGER, ANNE W |
UNIVERSITY OF MARYLAND BALTIMORE |
BALTIMORE |
MD |
UNITED STATES |
NCI |
$467,753 |
Breast Cancer;Cancer;Genetics |
THE MOLECULAR BASIS OF PREGNANCY-ASSOCIATED PROTECTION FROM BREAST CANCER |
1RC2CA148507-01 |
2009-09-30 |
2009-09-30 |
31-Aug-10 |
2009 |
HANNON, GREGORY J |
COLD SPRING HARBOR LABORATORY |
COLD SPRING HARBOR |
NY |
UNITED STATES |
NCI |
$1,464,539 |
Breast Cancer;Cancer;Clinical Research;Estrogen;Genetics;Human Genome;Stem Cell Research;Stem Cell Research - Nonembryonic - Human |
STOCHASTIC CONTROL OF ABNORMAL MORPHOGENESIS INDUCED BY THE ERBB2 ONCOPROTEIN |
1DP2OD006464-01 |
2009-09-30 |
2009-09-30 |
31-Aug-14 |
2009 |
JANES, KEVIN A. |
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE |
CHARLOTTESVILLE |
VA |
UNITED STATES |
OD |
$2,310,000 |
No NIH Category available. |
THE MOLECULAR BASIS OF PREGNANCY-ASSOCIATED PROTECTION FROM BREAST CANCER |
1RC2CA148507-01 |
2009-09-30 |
2009-09-30 |
31-Aug-10 |
2009 |
HANNON, GREGORY J |
COLD SPRING HARBOR LABORATORY |
COLD SPRING HARBOR |
NY |
UNITED STATES |
NCI |
|
Breast Cancer;Cancer;Clinical Research;Estrogen;Genetics;Human Genome;Stem Cell Research;Stem Cell Research - Nonembryonic - Human |
ROLE OF EPHA2 RTK IN TUMOR RESISTANCE TO EGFR/HER2 INHIBITORS |
1I01BX000134-01A1 |
2009-10-01 |
2009-10-01 |
30-Sep-10 |
2009 |
CHEN, JIN |
VETERANS HEALTH ADMINISTRATION |
NASHVILLE |
TN |
UNITED STATES |
VA |
|
No NIH Category available. |
SIGNALING BY NEUREGULINS AND ERBB4 IN BREAST CANCER |
5R01CA080065-10 |
1999-07-01 |
2009-12-01 |
30-Nov-10 |
2010 |
STERN, DAVID F |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$391,179 |
Breast Cancer;Cancer;Lung;Lung Cancer |
BRK SIGNALS TO ERK5 IN BREAST CANCER |
3R01CA107547-04S1 |
2006-12-15 |
2009-12-01 |
30-Nov-10 |
2010 |
LANGE, CAROL ANN |
UNIVERSITY OF MINNESOTA TWIN CITIES |
MINNEAPOLIS |
MN |
UNITED STATES |
NCI |
$47,822 |
Breast Cancer;Cancer |
BRK SIGNALS TO ERK5 IN BREAST CANCER |
5R01CA107547-04 |
2006-12-15 |
2009-12-01 |
30-Nov-10 |
2010 |
LANGE, CAROL ANN |
UNIVERSITY OF MINNESOTA TWIN CITIES |
MINNEAPOLIS |
MN |
UNITED STATES |
NCI |
$249,257 |
Breast Cancer;Cancer |
NOVEL TREATMENT OF NF-1 ASSOCIATED MALIGNANT PERIPHERAL NERVE SHEATH TUMORS |
5R01CA122804-03 |
2007-12-07 |
2009-12-01 |
30-Nov-10 |
2010 |
CARROLL, STEVEN L |
UNIVERSITY OF ALABAMA AT BIRMINGHAM |
BIRMINGHAM |
AL |
UNITED STATES |
NCI |
$300,875 |
Cancer;Neurofibromatosis;Neurosciences |
PROSPECTIVE VALIDATION OF GENOMIC SIGNATURES OF CHEMOSENSITIVITY IN NSCLC |
5R01CA131049-02 |
2009-01-01 |
2009-12-01 |
30-Nov-10 |
2010 |
WILLARD, HUNTINGTON |
DUKE UNIVERSITY |
DURHAM |
NC |
UNITED STATES |
NCI |
$323,166 |
Biotechnology;Cancer;Clinical Research;Genetics;Lung;Lung Cancer |
NOVARTIS CAUY922A2101: A PHASE I DOSE ESCALATION, MULTI-CENTER, OPEN-LABEL STUDY |
5M01RR000865-37 |
2009-12-01 |
2009-12-01 |
30-Nov-10 |
2010 |
BRITTEN, CAROLYN D |
UNIVERSITY OF CALIFORNIA LOS ANGELES |
LOS ANGELES |
CA |
UNITED STATES |
NCRR |
$659 |
Breast Cancer;Cancer;Clinical Research |
WOMEN'S CANCERS |
5P30CA016042-35 |
|
2009-12-01 |
30-Nov-10 |
2010 |
GLASPY, JOHN A |
UNIVERSITY OF CALIFORNIA LOS ANGELES |
LOS ANGELES |
CA |
UNITED STATES |
NCI |
$69,664 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Genetics;Nutrition;Prevention |
TARGETING THE HER2 PATHWAY: MECHANISMS OF RESISTANCE & STRATEGIES TO OVERCOME |
5P50CA058183-16 |
|
2009-12-01 |
30-Nov-10 |
2010 |
OSBORNE, C KENT |
BAYLOR COLLEGE OF MEDICINE |
HOUSTON |
TX |
UNITED STATES |
NCI |
$249,997 |
Antimicrobial Resistance;Breast Cancer;Cancer;Infectious Diseases |
PROTOCOL SPECIFIC RESEARCH |
5P30CA033572-27 |
|
2009-12-01 |
30-Nov-10 |
2010 |
KRONTIRIS, THEODORE G |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$317,892 |
Brain Cancer;Brain Disorders;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Hematology;Orphan Drug |
SENIOR LEADERS |
5P30CA016042-35 |
|
2009-12-01 |
30-Nov-10 |
2010 |
GASSON, JUDITH CHERYL |
UNIVERSITY OF CALIFORNIA LOS ANGELES |
LOS ANGELES |
CA |
UNITED STATES |
NCI |
$777,779 |
Cancer;Health Disparities |
HER3 SIGNALING IN DEVELOPMENT AND CANCER OF THE BREAST |
1R01CA143126-01 |
2009-12-09 |
2009-12-09 |
30-Nov-10 |
2010 |
COOK, REBECCA SARA |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$321,625 |
Breast Cancer;Cancer |
TRANSLATIONAL RESEARCH IN BREAST CANCER |
5P50CA058183-16 |
1992-09-30 |
2009-12-11 |
30-Nov-10 |
2010 |
OSBORNE, C KENT |
BAYLOR COLLEGE OF MEDICINE |
HOUSTON |
TX |
UNITED STATES |
NCI |
$2,300,000 |
No NIH Category available. |
DETERMINANTS OF TUMOR SENSITIVITY TO EGFR-TARGETED ANTIBODIES |
5R01CA050633-20 |
1989-06-01 |
2010-01-01 |
31-Dec-10 |
2010 |
WEINER, LOUIS M |
GEORGETOWN UNIVERSITY |
WASHINGTON |
DC |
UNITED STATES |
NCI |
$330,858 |
Biotechnology;Cancer;Genetics;HIV/AIDS;Immunization |
ERBB RECEPTOR HOMO- AND HETERO-DIMERIZATION |
5R01CA079992-12 |
1999-02-01 |
2010-01-01 |
31-Dec-10 |
2010 |
LEMMON, MARK A. |
UNIVERSITY OF PENNSYLVANIA |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$255,723 |
Breast Cancer;Cancer |
TSG101 - A MODULATOR OF ERBB2 SIGNALING IN BREAST CANCER |
5R01CA093797-07 |
2002-01-01 |
2010-01-01 |
31-Dec-10 |
2010 |
WAGNER, KAY-UWE |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
OMAHA |
NE |
UNITED STATES |
NCI |
$265,863 |
Breast Cancer;Cancer |
THE BIOLOGY OF AGGRESSIVE BREAST CANCER: MINING THE TRIPLE NEGATIVE TRANSCRIPTOME |
1F32CA145054-01 |
2010-01-01 |
2010-01-01 |
31-Dec-11 |
2009 |
STRICKER, THOMAS PAUL |
UNIVERSITY OF CHICAGO |
CHICAGO |
IL |
UNITED STATES |
NCI |
$53,354 |
Biotechnology;Breast Cancer;Cancer;Genetics;Human Genome |
TARGETING JAB1 ONCOGENIC FUNCTION IN BREAST CANCER |
5R01CA090853-09 |
2001-04-01 |
2010-02-01 |
31-Jan-11 |
2010 |
CLARET, FRANCOIS X |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$255,009 |
Biotechnology;Breast Cancer;Cancer;Genetics |
THE ROLE OF SYNDECAN-1 IN MOUSE MAMMARY NEOPLASIA |
5R01CA090877-08 |
2001-04-01 |
2010-02-01 |
31-Jan-11 |
2010 |
ALEXANDER, CAROLINE MARGARET |
UNIVERSITY OF WISCONSIN MADISON |
MADISON |
WI |
UNITED STATES |
NCI |
$295,173 |
Breast Cancer;Cancer;Stem Cell Research;Stem Cell Research - Nonembryonic - Non-Human |
NSABP PARTICIPATING SITES |
5U10CA118735-05 |
2006-04-10 |
2010-02-01 |
31-Jan-11 |
2010 |
CHANG, JENNY C-N |
BAYLOR COLLEGE OF MEDICINE |
HOUSTON |
TX |
UNITED STATES |
NCI |
$53,618 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Health Disparities;Minority Health |
REGULATION OF STAT3 SIGNALING |
5R01CA122910-04 |
2007-04-01 |
2010-02-01 |
31-Jan-12 |
2010 |
REICH, NANCY C. |
STATE UNIVERSITY NEW YORK STONY BROOK |
STONY BROOK |
NY |
UNITED STATES |
NCI |
$294,500 |
Cancer;Genetics;Hematology |
CELLULARLY RESOLVED MOLECULAR PATHWAY ASSESSMENT IN BIOPSIES VIA SPECTRAL IMAGING |
5R44CA130026-03 |
2007-09-28 |
2010-02-01 |
31-Jan-11 |
2010 |
HOYT, CLIFFORD C |
CAMBRIDGE RESEARCH AND INSTRUMENTATION |
WOBURN |
MA |
UNITED STATES |
NCI |
$913,767 |
Bioengineering;Biotechnology;Cancer |
PREDICTION OF NEOADJUVANT CHEMO PATHOLOGICAL RESPONSE USING MRI MARKERS |
5R01CA127927-03 |
2008-04-01 |
2010-02-01 |
31-Jan-11 |
2010 |
SU, MIN-YING L |
UNIVERSITY OF CALIFORNIA IRVINE |
IRVINE |
CA |
UNITED STATES |
NCI |
$511,095 |
Breast Cancer;Cancer;Clinical Research;Diagnostic Radiology |
MECHANISMS OF TUMOR RESISTANCE TO ANTI-HER/ERBB THERAPEUTICS |
5R01CA129036-03 |
2008-04-02 |
2010-02-01 |
31-Jan-11 |
2010 |
FAN, ZHEN |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$319,550 |
Biotechnology;Breast Cancer;Cancer;Hematology |
MOLECULAR BASIS OF GENOMIC INSTABILITY IN AGGRESSIVE BASAL-LIKE BREAST CANCER |
1F32CA144402-01 |
2010-02-01 |
2010-02-01 |
31-Jan-11 |
2009 |
HOLCOMB, ILONA NOELANI |
STANFORD UNIVERSITY |
STANFORD |
CA |
UNITED STATES |
NCI |
$50,054 |
Biotechnology;Breast Cancer;Cancer;Genetics |
REGULATION OF BASAL-LIKE AND HER2+ BREAST CANCER PHENOTYPES BY IKK/NF-KAPPAB |
1R01CA138937-01A1 |
2010-02-01 |
2010-02-01 |
31-Dec-10 |
2010 |
BALDWIN, ALBERT SIDNEY |
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL |
CHAPEL HILL |
NC |
UNITED STATES |
NCI |
$305,763 |
Aging;Biotechnology;Breast Cancer;Cancer;Genetics |
SMALL MOLECULE INHIBITORS OF THE TRANSCRIPTIONAL ACTIVATORS ESX AND NF-KB |
5R01CA140667-02 |
2009-05-20 |
2010-03-01 |
28-Feb-11 |
2010 |
MAPP, ANNA K. |
UNIVERSITY OF MICHIGAN AT ANN ARBOR |
ANN ARBOR |
MI |
UNITED STATES |
NCI |
$305,815 |
Breast Cancer;Cancer;Genetics |
PREDICTION OF CHEMOTHERAPY INDUCED CARDIOMYOPATHY WITH MRI DETECT I |
5M01RR007122-19 |
2010-03-01 |
2010-03-01 |
28-Feb-11 |
2010 |
HUNDLEY, WILLIAM GREGORY |
WAKE FOREST UNIVERSITY HEALTH SCIENCES |
WINSTON-SALEM |
NC |
UNITED STATES |
NCRR |
$58,848 |
Cancer;Cardiovascular;Clinical Research;Diagnostic Radiology;Heart Disease;Heart Disease - Coronary Heart Disease |
TAKE HEART: EXERCISE & DIET INTERVENTION FOR HEART FAILURE IN CANCER SURVIVORS |
5R21CA135016-02 |
2009-03-13 |
2010-03-08 |
28-Feb-11 |
2010 |
BASEN-ENGQUIST, KAREN M |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$203,280 |
Behavioral and Social Science;Cancer;Cardiovascular;Clinical Research;Heart Disease;Mind and Body;Nutrition;Prevention;Rehabilitation |
PSK AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED BREAST CANCER |
1R01CA138547-01A1 |
2010-03-08 |
2010-03-08 |
31-Dec-10 |
2010 |
LU, HAILING |
UNIVERSITY OF WASHINGTON |
SEATTLE |
WA |
UNITED STATES |
NCI |
$287,877 |
Breast Cancer;Cancer;Complementary and Alternative Medicine |
QUANTITATIVE ANALYSIS OF RET RECEPTOR ACTIVATION AND SIGNALING |
1R01GM087469-01A2 |
2010-03-10 |
2010-03-10 |
31-Jan-11 |
2010 |
WHITTY, ADRIAN |
BOSTON UNIVERSITY |
BOSTON |
MA |
UNITED STATES |
NIGMS |
$289,750 |
Neurosciences |
TARGETING THE IGF SYSTEM IN BREAST CANCER |
5R01CA074285-13 |
1998-01-01 |
2010-03-11 |
28-Feb-11 |
2010 |
YEE, DOUGLAS |
UNIVERSITY OF MINNESOTA TWIN CITIES |
MINNEAPOLIS |
MN |
UNITED STATES |
NCI |
$354,113 |
Breast Cancer;Cancer |
MULTIFUNCTIONAL NANOPARTICLES FOR TARGETING ABERRANT TUMORIGENIC PATHWAYS |
1R01CA135242-01A2 |
2010-03-19 |
2010-03-19 |
31-Dec-10 |
2010 |
SENGUPTA, SHILADITYA |
BRIGHAM AND WOMEN'S HOSPITAL |
BOSTON |
MA |
UNITED STATES |
NCI |
$369,350 |
Bioengineering;Cancer;Nanotechnology |
REGULATION OF ERBB2/NEU-INDUCED MAMMARY GLAND CANCER |
5R01CA090398-09 |
2001-03-05 |
2010-03-30 |
31-Jan-11 |
2010 |
KERI, RUTH A |
CASE WESTERN RESERVE UNIVERSITY |
CLEVELAND |
OH |
UNITED STATES |
NCI |
$211,288 |
Breast Cancer;Cancer;Clinical Research;Genetics |
EARLY SCREENING OF BREAST LESION TRIAL (PHASE III PIVOTAL) |
5R44CA126441-04 |
2007-09-27 |
2010-03-30 |
28-Feb-11 |
2010 |
BENARON, DAVID A. |
SPECTROS CORPORATION |
Portola Valley |
CA |
UNITED STATES |
NCI |
$581,183 |
Bioengineering;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Diagnostic Radiology;Prevention;Prostate Cancer;Urologic Diseases |
BRAIN TUMORS - IMMUNOLOGICAL AND BIOLOGICAL STUDIES |
5R37CA011898-40 |
1976-12-01 |
2010-04-01 |
31-Mar-11 |
2010 |
BIGNER, DARELL D |
DUKE UNIVERSITY |
DURHAM |
NC |
UNITED STATES |
NCI |
$703,967 |
Brain Cancer;Brain Disorders;Cancer;Neurosciences;Orphan Drug |
ERBB2 TARGETED ANTITUMOR STRATEGIES IN BREAST CANCER |
2R01CA080195-10A2 |
1999-01-01 |
2010-04-01 |
31-Jan-11 |
2010 |
ARTEAGA, CARLOS L |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$320,163 |
Breast Cancer;Cancer |
IN VIVO ONCOGENE-INDUCED TUMORIGENESIS AND ESCAPE |
2R01CA098371-06 |
2003-04-18 |
2010-04-01 |
31-Jan-11 |
2010 |
CHODOSH, LEWIS A |
UNIVERSITY OF PENNSYLVANIA |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$347,135 |
Breast Cancer;Cancer;Genetics |
STRUCTURE-BASED PREDICTION OF THE INTERACTOME |
5R01GM081871-03 |
2008-04-01 |
2010-04-01 |
31-Mar-11 |
2010 |
BERGER, BONNIE |
MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
CAMBRIDGE |
MA |
UNITED STATES |
NIGMS |
$301,191 |
Bioengineering;Biotechnology;Genetics;Human Genome;Networking and Information Technology R&D |
RELEASABLE ANTIBODIES FOR MULTIPLEXED ANALYSIS OF CANCER BIOMARKERS |
1R21CA143275-01 |
2010-04-01 |
2010-04-01 |
31-Mar-11 |
2010 |
SOOD, ANUP |
GENERAL ELECTRIC GLOBAL RESEARCH CTR |
NISKAYUNA |
NY |
UNITED STATES |
NCI |
$338,376 |
Biotechnology;Breast Cancer;Cancer |
EXPLOITING BIOLOGICAL NETWORKS TO IMPROVE CLINICAL TREATMENT OF OVARIAN CANCER |
1R01CA140323-01A1 |
2010-04-01 |
2010-04-01 |
31-Jan-11 |
2010 |
GODWIN, ANDREW K |
FOX CHASE CANCER CENTER |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$423,060 |
Biotechnology;Cancer;Genetics;Orphan Drug;Ovarian Cancer |
DNA METHYLATION: A MECHANISM FOR AGGRESSIVE BREAST CANCER IN AFRICAN-AMERICAN WOM |
1R01CA133264-01A2 |
2010-04-01 |
2010-04-01 |
31-Jan-11 |
2010 |
AMBROSONE, CHRISTINE B. |
ROSWELL PARK CANCER INSTITUTE CORP |
BUFFALO |
NY |
UNITED STATES |
NCI |
$964,919 |
Breast Cancer;Cancer;Clinical Research;Genetics;Health Disparities;Minority Health;Prevention |
PROGRAM 3 (IMMUNOLOGY AND CANCER) |
5P30CA014599-35 |
|
2010-04-01 |
31-Mar-11 |
2010 |
GAJEWSKI, THOMAS F |
UNIVERSITY OF CHICAGO |
CHICAGO |
IL |
UNITED STATES |
NCI |
$26,979 |
Biotechnology;Cancer;Clinical Research;Immunization;Transplantation;Vaccine Related |
HUMAN IMMUNOLOGIC MONITORING |
5P30CA014599-35 |
|
2010-04-01 |
31-Mar-11 |
2010 |
GAJEWSKI, THOMAS F |
UNIVERSITY OF CHICAGO |
CHICAGO |
IL |
UNITED STATES |
NCI |
$139,619 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Immunization;Orphan Drug;Transplantation;Vaccine Related |
ROLES OF NF-KB/REL IN THE PATHOGENESIS OF BREAST CANCER |
7R01CA129129-03 |
2008-04-01 |
2010-04-08 |
31-Jan-11 |
2010 |
SONENSHEIN, GAIL E |
TUFTS UNIVERSITY BOSTON |
BOSTON |
MA |
UNITED STATES |
NCI |
$352,574 |
Breast Cancer;Cancer;Complementary and Alternative Medicine;Genetics;Nutrition |
TARGETED INTERVENTION OF BREAST ONCOGENIC PATHWAYS |
2R01CA098473-06A2 |
2003-06-13 |
2010-05-01 |
31-Mar-11 |
2010 |
SEBTI, SAID M |
H. LEE MOFFITT CANCER CTR & RES INST |
TAMPA |
FL |
UNITED STATES |
NCI |
$319,306 |
Biotechnology;Breast Cancer;Cancer;Clinical Research |
MOLECULAR BASIS OF SLITS AS TUMOR SUPPRESSORS CONTROLLING CXCR4/SDF1 IN BREAST |
3R01CA128902-03S1 |
2008-07-01 |
2010-05-01 |
30-Apr-11 |
2010 |
HINCK, LINDSAY E |
UNIVERSITY OF CALIFORNIA SANTA CRUZ |
SANTA CRUZ |
CA |
UNITED STATES |
NCI |
$33,328 |
Breast Cancer;Cancer;Genetics |
MOLECULAR BASIS OF SLITS AS TUMOR SUPPRESSORS CONTROLLING CXCR4/SDF1 IN BREAST |
5R01CA128902-03 |
2008-07-01 |
2010-05-01 |
30-Apr-11 |
2010 |
HINCK, LINDSAY E |
UNIVERSITY OF CALIFORNIA SANTA CRUZ |
SANTA CRUZ |
CA |
UNITED STATES |
NCI |
$308,832 |
Breast Cancer;Cancer;Genetics |
NR1D1 PATHWAY IN BREAST CANCER |
5R01CA136658-02 |
2009-06-01 |
2010-05-01 |
30-Apr-11 |
2010 |
CONKLIN, DOUGLAS S |
STATE UNIVERSITY OF NEW YORK AT ALBANY |
ALBANY |
NY |
UNITED STATES |
NCI |
$314,363 |
Biotechnology;Breast Cancer;Cancer;Genetics;Nutrition |
THE ROLE OF AURORA KINASE A IN UPPER GASTROINTESTINAL ADENOCARCINOMAS |
5R01CA131225-02 |
2009-06-01 |
2010-05-01 |
30-Apr-11 |
2010 |
EL-RIFAI, WAEL |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$319,343 |
Cancer;Digestive Diseases;Genetics |
THE IMPLEMENTATION OF A PHARMACOGENOMICS-BASED ALGORITHM FOR WARFARIN DOSING |
5K23HL089808-02 |
2009-07-15 |
2010-05-01 |
30-Apr-11 |
2010 |
PERERA, MINOLI |
UNIVERSITY OF CHICAGO |
CHICAGO |
IL |
UNITED STATES |
NHLBI |
$120,339 |
Clinical Research;Clinical Trials;Cost Effectiveness Research;Genetic Testing;Genetics;Health Disparities;Human Genome;Minority Health;Patient Safety |
NOVEL HER2 TARGETING IMMUNOTHERAPEUTICS FOR BREAST CANCER |
1R43AI081465-01A1 |
2010-05-01 |
2010-05-01 |
30-Apr-11 |
2010 |
JENSEN, MARK ALLEN |
ITERATIVE THERAPEUTICS, INC. |
CHICAGO |
IL |
UNITED STATES |
NIAID |
$231,045 |
Biotechnology;Breast Cancer;Cancer;Clinical Research |
SCFV PIEZOIMMUNOSENSOR DETECTION OF THERAPEUTIC ANTIBODIES IN HUMAN SERUM |
1R21EB009513-01A1 |
2010-05-01 |
2010-05-01 |
30-Apr-11 |
2010 |
ZENG, XIANGQUN |
OAKLAND UNIVERSITY |
ROCHESTER |
MI |
UNITED STATES |
NIBIB |
$231,627 |
Biotechnology;Immunization |
EVALUATION AND VALIDATION OF IMAGING BIOMARKERS OF TUMOR RESPONSE TO TREATMENT |
1R01CA138599-01A1 |
2010-05-01 |
2010-05-01 |
28-Feb-11 |
2010 |
YANKEELOV, THOMAS E |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$373,101 |
Breast Cancer;Cancer;Diagnostic Radiology |
IMPROVING INTERSTITIAL TRANSPORT IN TUMORS |
5P01CA080124-10 |
|
2010-05-01 |
30-Apr-11 |
2010 |
JAIN, RAKESH K. |
MASSACHUSETTS GENERAL HOSPITAL |
BOSTON |
MA |
UNITED STATES |
NCI |
$310,646 |
Biotechnology;Breast Cancer;Cancer;Gene Therapy;Genetics |
DEVELOPMENT OF MECHANISM-BASED STRATEGIES FOR THE TREATMENT OF ADVANCED BREAST CA |
5P01CA094060-08 |
|
2010-05-01 |
30-Apr-11 |
2010 |
ROSEN, NEAL |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$456,578 |
Breast Cancer;Cancer;Clinical Research |
NEXT GENERATION STRATEGIES TO INTERCEPT ERBB SIGNALING |
4R37CA072981-14 |
1997-04-25 |
2010-05-21 |
31-Mar-11 |
2010 |
YARDEN, YOSEF NONE |
WEIZMANN INSTITUTE OF SCIENCE |
REHOVOT |
|
ISRAEL |
NCI |
$237,319 |
Biotechnology;Breast Cancer;Cancer |
THE MOLECULAR ACTIONS OF IMATINIB MESYLATE IN GISTS |
5R01CA106588-07 |
2004-05-01 |
2010-06-01 |
31-May-11 |
2010 |
GODWIN, ANDREW K |
FOX CHASE CANCER CENTER |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$433,446 |
Biotechnology;Cancer;Clinical Research;Clinical Trials;Colo-Rectal Cancer;Digestive Diseases;Genetics;Orphan Drug;Prevention |
MECHANISMS OF INVERTEBRATE EGF RECEPTOR INHIBITION |
5R01CA125432-04 |
2007-07-01 |
2010-06-01 |
31-May-11 |
2010 |
LEMMON, MARK A. |
UNIVERSITY OF PENNSYLVANIA |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$236,655 |
Breast Cancer;Cancer |
ERBB2 DOWNREGULATION THROUGH HSP90 INHIBITION |
5R01CA116552-05 |
2007-08-01 |
2010-06-01 |
31-May-11 |
2010 |
BAND, HAMID |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
OMAHA |
NE |
UNITED STATES |
NCI |
$279,300 |
Biotechnology;Breast Cancer;Cancer |
INTEGRATED BIOCHIP SENSORS FOR DETECTION OF CANCER |
5R01CA120003-03 |
2008-07-01 |
2010-06-01 |
31-May-11 |
2010 |
BASHIR, RASHID |
UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN |
CHAMPAIGN |
IL |
UNITED STATES |
NCI |
$522,748 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Clinical Research;Nanotechnology |
SIGNAL TRANSDUCTION IN THE HEART AFTER CANCER THERAPY |
5R01HL088649-03 |
2008-08-01 |
2010-06-01 |
31-May-11 |
2010 |
GABRIELSON, KATHLEEN LOUISE |
JOHNS HOPKINS UNIVERSITY |
BALTIMORE |
MD |
UNITED STATES |
NHLBI |
$410,000 |
Biotechnology;Breast Cancer;Cancer;Cardiovascular;Heart Disease |
TARGETING SIGNALING NETWORKS VIA NOVEL RNAI APPROACHES TO IMPROVE THERAPY FOR O |
5P50CA083638-12 |
|
2010-06-01 |
31-May-11 |
2010 |
GODWIN, ANDREW K |
FOX CHASE CANCER CENTER |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$341,238 |
Biotechnology;Cancer;Clinical Research;Genetics;Orphan Drug;Ovarian Cancer |
PREDICTIVE BIOMARKERS OF ADJUVANT TRASTUZUMAB IN THE HER2+N9831 INTERGROUP TRIAL |
5R01CA129949-03 |
2008-05-20 |
2010-06-14 |
30-Apr-11 |
2010 |
PEREZ, EDITH ADALJISA |
MAYO CLINIC JACKSONVILLE |
JACKSONVILLE |
FL |
UNITED STATES |
NCI |
$198,218 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Genetics |
PROTEIN TYROSINE DEPHOSPHORYLATION & SIGNAL TRANSDUCTION |
2R01CA053840-19A2 |
1991-08-01 |
2010-07-01 |
30-Apr-11 |
2010 |
TONKS, NICHOLAS K |
COLD SPRING HARBOR LABORATORY |
COLD SPRING HARBOR |
NY |
UNITED STATES |
NCI |
$712,640 |
Breast Cancer;Cancer |
CROSSTALK TGFBETA AND HER2 (ERBB2) SIGNALING IN MAMMARY TUMORIGENESIS |
5R00CA125892-05 |
2007-07-25 |
2010-07-01 |
30-Jun-11 |
2010 |
WANG, SHIZHEN EMILY |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$249,000 |
Breast Cancer;Cancer |
MONITORING BREAST CANCER CHEMOTHERAPEUTIC RESPONSE USING DOSI, MRI AND BIOMARKERS |
5U54CA136400-02 |
2009-07-17 |
2010-07-01 |
30-Jun-11 |
2010 |
TROMBERG, BRUCE J |
UNIVERSITY OF CALIFORNIA IRVINE |
IRVINE |
CA |
UNITED STATES |
NCI |
$454,567 |
Bioengineering;Breast Cancer;Cancer;Clinical Research;Diagnostic Radiology |
THE ROLE OF NEUREGULIN IN HUMAN CARDIAC REMODELING AND HEART FAILURE |
1K23HL095661-01A1 |
2010-07-01 |
2010-07-01 |
30-Jun-11 |
2010 |
KY, BONNIE |
UNIVERSITY OF PENNSYLVANIA |
PHILADELPHIA |
PA |
UNITED STATES |
NHLBI |
$142,776 |
Cardiovascular;Clinical Research;Heart Disease;Kidney Disease |
MOLECULAR PHOTOTHERMAL THERAPY OF CANCER USING TARGETED METAL NANOPARTICLES |
1R01CA149740-01A1 |
2010-07-01 |
2010-07-01 |
31-May-11 |
2010 |
EMELIANOV, STANISLAV Y |
UNIVERSITY OF TEXAS AUSTIN |
AUSTIN |
TX |
UNITED STATES |
NCI |
$356,018 |
Bioengineering;Breast Cancer;Cancer;Diagnostic Radiology;Nanotechnology |
DEVELOPMENTAL RESEARCH PROGRAM |
5P50CA086438-10 |
|
2010-07-01 |
30-Jun-11 |
2010 |
JURCIC, JOSEPH G |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$159,080 |
Bioengineering;Biotechnology;Cancer;Clinical Research;Diagnostic Radiology;Genetics;Hematology;Lymphoma;Nanotechnology;Orphan Drug;Regenerative Medicine;Transplantation |
RESEARCH PROJECT 3: ROLE OF THE NF-KB/REL IN MAMMARY CARCINOGENESIS |
7P01ES011624-08 |
|
2010-07-01 |
30-Jun-11 |
2009 |
SONENSHEIN, GAIL E |
TUFTS UNIVERSITY BOSTON |
BOSTON |
MA |
UNITED STATES |
NIEHS |
$167,648 |
No NIH Category available. |
MOLECULAR IMAGING OF CASTRATE- RESISTANCE METASTATIC PROSTATE CANCER |
5P50CA086438-10 |
|
2010-07-01 |
30-Jun-11 |
2010 |
LARSON, STEVEN MARK |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$203,991 |
Bioengineering;Cancer;Clinical Research;Diagnostic Radiology;Nanotechnology;Prostate Cancer;Urologic Diseases |
DEVELOPMENT OF METHODOLOGIES FOR THE IN VIVO IMAGING OG THE EFFECTS OF NOVEL INHI |
5P50CA086438-10 |
|
2010-07-01 |
30-Jun-11 |
2010 |
ROSEN, NEAL |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$223,770 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Diagnostic Radiology |
RADIOIMMUNOTHERAPY: CLINICAL STUDIES |
5P01CA043904-19 |
|
2010-07-01 |
30-Jun-11 |
2010 |
WONG, JEFFREY Y |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$245,900 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Colo-Rectal Cancer;Digestive Diseases;Immunization;Vaccine Related |
CLINICAL PRODUCTION |
5P01CA043904-19 |
|
2010-07-01 |
30-Jun-11 |
2010 |
YAZAKI, PAUL |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$316,618 |
Biotechnology;Cancer;Clinical Research;Clinical Trials;Genetics |
RADIOPHARMACY AND ASSAYS |
5P01CA043904-19 |
|
2010-07-01 |
30-Jun-11 |
2010 |
COLCHER, DAVID MORRIS |
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE |
DUARTE |
CA |
UNITED STATES |
NCI |
$504,135 |
Biotechnology;Cancer;Clinical Research;Immunization;Vaccine Related |
NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT |
3U10CA012027-40S1 |
1976-12-01 |
2010-07-02 |
30-Jun-11 |
2010 |
WOLMARK, NORMAN |
NSABP FOUNDATION, INC. |
PITTSBURGH |
PA |
UNITED STATES |
NCI |
$188,932 |
Breast Cancer;Cancer;Clinical Research;Clinical Trials;Colo-Rectal Cancer;Digestive Diseases;Health Disparities;Minority Health;Patient Safety |
ENHANCING NEOADJUVANT CHEMOTHERPAY RESPONSES WITH TARGETED T CELLS |
1R01CA140314-01A1 |
2010-07-09 |
2010-07-09 |
30-Apr-11 |
2010 |
LUM, LAWRENCE G |
WAYNE STATE UNIVERSITY |
DETROIT |
MI |
UNITED STATES |
NCI |
$519,027 |
Breast Cancer;Cancer;Clinical Research;Clinical Trials;Immunization;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Vaccine Related |
ENHANCING TUMOR-TARGETED ANTIBODY THERAPY WITH A SECOND NK ACTIVATING ANTIBODY. |
1R01CA153248-01 |
2010-07-14 |
2010-07-14 |
31-May-11 |
2010 |
LEVY, RONALD |
STANFORD UNIVERSITY |
STANFORD |
CA |
UNITED STATES |
NCI |
$267,825 |
Biotechnology;Breast Cancer;Cancer;Colo-Rectal Cancer;Digestive Diseases;Hematology;Immunization;Lymphoma |
TARGETING HER-2 PROTEIN FOR BREAST CANCER USING COMPUTATIONAL APPROACH |
2P20RR016456-09 |
2010-07-15 |
2010-07-15 |
30-Apr-11 |
2010 |
SATYANARAYANAJOIS, SEETHARAMA D |
LOUISIANA STATE UNIV A&M COL BATON ROUGE |
BATON ROUGE |
LA |
UNITED STATES |
NCRR |
$55,546 |
Breast Cancer;Cancer |
NOVEL TARGETED THERAPY FOR BREAST CANCER |
2R44CA124179-02A2 |
2006-07-16 |
2010-07-16 |
30-Jun-11 |
2010 |
SERRERO, GINETTE |
A AND G PHARMACEUTICAL, INC. |
COLUMBIA |
MD |
UNITED STATES |
NCI |
$575,793 |
Biotechnology;Breast Cancer;Cancer |
STRUCTURAL STUDIES OF GROWTH FACTOR RECEPTOR FUNCTION |
5R01CA090466-09 |
2001-04-01 |
2010-08-01 |
31-Jul-11 |
2010 |
LEAHY, DANIEL J |
JOHNS HOPKINS UNIVERSITY |
BALTIMORE |
MD |
UNITED STATES |
NCI |
$222,384 |
Breast Cancer;Cancer |
BREAST CANCER TREATMENT WITH ANTIBODY TARGETED T CELLS |
5R01CA092344-08 |
2001-07-01 |
2010-08-01 |
31-Jul-11 |
2010 |
LUM, LAWRENCE G |
WAYNE STATE UNIVERSITY |
DETROIT |
MI |
UNITED STATES |
NCI |
$501,546 |
Breast Cancer;Cancer;Clinical Research;Clinical Trials;Immunization;Vaccine Related |
HER-2/IGF-IR CROSS-TALK AND HERCEPTIN RESISTANCE |
5K01CA118174-06 |
2006-08-01 |
2010-08-01 |
31-Jul-11 |
2010 |
NAHTA, RITA |
EMORY UNIVERSITY |
ATLANTA |
GA |
UNITED STATES |
NCI |
$143,856 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Nanotechnology |
MICELLE SURFACE ENGINEERING FOR ACTIVE TARGETING BY ACIDIC TUMOR EXTRACELLULAR PH |
5R01CA122356-05 |
2006-08-22 |
2010-08-01 |
31-Jul-11 |
2010 |
BAE, YOU HAN |
UNIVERSITY OF UTAH |
SALT LAKE CITY |
UT |
UNITED STATES |
NCI |
$257,668 |
Bioengineering;Cancer |
MUTANT EGF RECEPTOR-DEPENDENT LUNG CANCER IN HUMAN CELL LINES AND TRANSGENIC MICE |
2R01CA120247-05 |
2006-08-22 |
2010-08-01 |
31-May-11 |
2010 |
POLITI, KATERINA ABIGAIL |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$383,570 |
Biotechnology;Cancer;Genetics;Lung;Lung Cancer |
A NOVEL TRANSGENIC SILKWORM SYSTEM FOR RECOMBINANT GLYCOPROTEIN PRODUCTION |
5R01GM080672-04 |
2007-09-29 |
2010-08-01 |
31-Jul-11 |
2010 |
JARVIS, DONALD L. |
UNIVERSITY OF WYOMING |
LARAMIE |
WY |
UNITED STATES |
NIGMS |
$277,307 |
Bioengineering;Biotechnology |
BETA-CATENIN/TCF SIGNALING IN BREAST CANCER |
5R01CA131219-03 |
2008-09-01 |
2010-08-01 |
31-Jul-11 |
2010 |
HOWE, LOUISE R |
WEILL MEDICAL COLLEGE OF CORNELL UNIV |
NEW YORK |
NY |
UNITED STATES |
NCI |
$350,675 |
Aging;Breast Cancer;Cancer;Prevention |
IDENTIFICATION AND CHARACTERIZATION OF DRIVER GENE(S) IN RECURRENT LUNG CANCER AM |
5R01CA127547-03 |
2008-09-08 |
2010-08-01 |
31-Jul-11 |
2010 |
MU, DAVID |
PENNSYLVANIA STATE UNIV HERSHEY MED CTR |
HERSHEY |
PA |
UNITED STATES |
NCI |
$289,649 |
Biotechnology;Cancer;Genetics;Lung;Lung Cancer |
DETERMINANTS AND RISKS OF USE AND OVERUSE OF EXPENSIVE ONCOLOGY DRUGS |
5R01CA134964-03 |
2008-09-12 |
2010-08-01 |
31-Jul-11 |
2010 |
HERSHMAN, DAWN |
COLUMBIA UNIVERSITY HEALTH SCIENCES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$260,820 |
Aging;Breast Cancer;Cancer;Clinical Research;Health Disparities;Health Services;Hematology;Minority Health;Orphan Drug;Patient Safety;Prostate Cancer;Urologic Diseases |
DISSECTING MECHANISMS OF METASTASIS THROUGH COMPARATIVE SYSTEMS GENETICS |
5R01CA138265-03 |
2008-09-25 |
2010-08-01 |
31-Jul-11 |
2010 |
KIRSCH, DAVID G |
DUKE UNIVERSITY |
DURHAM |
NC |
UNITED STATES |
NCI |
$476,541 |
Biotechnology;Breast Cancer;Cancer;Genetics;Human Genome |
OPTIMAL PREDICTORS OF RESPONSE TO TRASTUZUMAB |
5R01CA139431-02 |
2009-08-05 |
2010-08-01 |
31-Jul-11 |
2010 |
RIMM, DAVID L |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$584,668 |
Biotechnology;Breast Cancer;Cancer;Genetics |
RACIAL/ETHNIC AND SES DISPARITIES IN QUALITY OF BREAST CANCER SYSTEMIC THERAPY |
5R01CA139014-02 |
2009-08-11 |
2010-08-01 |
31-Jul-11 |
2010 |
GRIGGS, JENNIFER J |
UNIVERSITY OF MICHIGAN AT ANN ARBOR |
ANN ARBOR |
MI |
UNITED STATES |
NCI |
$637,278 |
Behavioral and Social Science;Breast Cancer;Cancer |
THE ROLE OF T-DARPP IN ESOPHAGEAL ADENOCARCINOMA |
5R01CA133738-02 |
2009-08-13 |
2010-08-01 |
31-Jul-11 |
2010 |
EL-RIFAI, WAEL |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$232,625 |
Biotechnology;Cancer;Digestive Diseases |
RESEARCH PROGRAMS-SIGNAL TRANSDUCTION |
5P30CA016359-32 |
|
2010-08-01 |
31-Jul-11 |
2010 |
SCHLESSINGER, JOSEPH |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$29,995 |
Breast Cancer;Cancer |
BREAST CANCER VACCINE STRATEGIES FOR HER2-OVEREXPRESSING AND LUM. B TUMORS |
5P50CA058223-18 |
|
2010-08-01 |
31-Jul-11 |
2010 |
SERODY, JONATHAN STUART |
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL |
CHAPEL HILL |
NC |
UNITED STATES |
NCI |
$223,540 |
Biotechnology;Breast Cancer;Cancer;Immunization;Infectious Diseases;Prevention;Vaccine Related;Vector-Borne Diseases |
SPORE CORE 1: ADMINISTRATIVE, EVALUATION AND PLANNING |
5P50CA093683-08 |
|
2010-08-01 |
31-Jul-11 |
2010 |
MARASCO, WAYNE A. |
BRIGHAM AND WOMEN'S HOSPITAL |
BOSTON |
MA |
UNITED STATES |
NCI |
$280,414 |
Biotechnology;Cancer;Immunization;Lymphoma;Prevention;Vaccine Related |
REWIRING ERBB SIGNALING IN CANCER CELLS |
5R01CA098881-08 |
2003-07-01 |
2010-08-20 |
31-Jul-11 |
2010 |
LANDGRAF, RALF |
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE |
MIAMI |
FL |
UNITED STATES |
NCI |
$47,678 |
Breast Cancer;Cancer |
TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY |
5R01CA137488-16 |
1995-08-15 |
2010-09-01 |
31-Aug-11 |
2010 |
NEUWELT, EDWARD A |
OREGON HEALTH AND SCIENCE UNIVERSITY |
PORTLAND |
OR |
UNITED STATES |
NCI |
$490,363 |
Brain Cancer;Brain Disorders;Breast Cancer;Cancer;Clinical Research;Lymphoma;Neurosciences;Orphan Drug |
HEAT SHOCK PROTEINS IN SIGNALING AND CANCER |
5R01CA081244-12 |
2000-05-01 |
2010-09-01 |
31-Aug-11 |
2010 |
SHERMAN, MICHAEL Y |
BOSTON UNIVERSITY MEDICAL CAMPUS |
BOSTON |
MA |
UNITED STATES |
NCI |
$355,597 |
Biotechnology;Breast Cancer;Cancer;Prevention |
BIFUNCTIONAL T CELL RECEPTOR BASED IMMUNOTHERAPEUTICS |
5R44CA097550-06 |
2002-07-26 |
2010-09-01 |
31-Aug-11 |
2010 |
WONG, HING C. |
ALTOR BIOSCIENCE CORPORATION |
MIRAMAR |
FL |
UNITED STATES |
NCI |
$990,016 |
Cancer;Clinical Research;Orphan Drug |
PERSONALIZED MEDICINE FOR COLORECTAL AND BREAST CANCER |
5P01CA130818-03 |
2008-09-16 |
2010-09-01 |
31-Aug-11 |
2010 |
PHILLIPS, KATHRYN A |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$1,495,702 |
No NIH Category available. |
BIOLOGIC AND THERAPEUTIC IMPLICATIONS OF AKT ACTIVATION IN HER2+ BREAST CANCER |
5K08CA134833-02 |
2009-09-21 |
2010-09-01 |
31-Aug-11 |
2010 |
CHANDARLAPATY, SARAT |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$145,152 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Genetics |
ONCOLOGY R&D: EXPANDING THE ROLE OF ECONOMICS TO AID PUBLIC POLICY |
5K07CA138906-02 |
2009-09-23 |
2010-09-01 |
31-Aug-11 |
2010 |
CONTI, RENA MARIE |
UNIVERSITY OF CHICAGO |
CHICAGO |
IL |
UNITED STATES |
NCI |
$133,790 |
Basic Behavioral and Social Science;Behavioral and Social Science;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Comparative Effectiveness Research;Cost Effectiveness Research |
TARGETED THERAPIES IN BREAST CANCER |
5K23CA127469-02 |
2009-09-24 |
2010-09-01 |
31-Aug-11 |
2010 |
MAYER, INGRID |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$163,944 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Genetics |
GENE TARGETED THERAPY OF BRAIN TUMORS |
5R21NS067975-02 |
2009-09-30 |
2010-09-01 |
31-Aug-11 |
2010 |
SAMPSON, JOHN H |
DUKE UNIVERSITY |
DURHAM |
NC |
UNITED STATES |
NINDS |
$194,754 |
Biotechnology;Brain Cancer;Brain Disorders;Cancer;Genetics;Human Genome;Neurosciences;Orphan Drug |
A NOVEL THERAPY FOR HER2 POSITIVE HORMONE REFRACTORY BREAST CANCER |
5RC1CA145066-02 |
2009-09-30 |
2010-09-01 |
31-Aug-11 |
2010 |
HAMBURGER, ANNE W |
UNIVERSITY OF MARYLAND BALTIMORE |
BALTIMORE |
MD |
UNITED STATES |
NCI |
$462,585 |
Breast Cancer;Cancer;Genetics |
THE MOLECULAR BASIS OF PREGNANCY-ASSOCIATED PROTECTION FROM BREAST CANCER |
5RC2CA148507-02 |
2009-09-30 |
2010-09-01 |
31-Aug-11 |
2010 |
HANNON, GREGORY J |
COLD SPRING HARBOR LABORATORY |
COLD SPRING HARBOR |
NY |
UNITED STATES |
NCI |
$1,455,158 |
Breast Cancer;Cancer;Clinical Research;Estrogen;Genetics;Human Genome;Stem Cell Research;Stem Cell Research - Nonembryonic - Non-Human |
THE MOLECULAR BASIS OF PREGNANCY-ASSOCIATED PROTECTION FROM BREAST CANCER |
5RC2CA148507-02 |
2009-09-30 |
2010-09-01 |
31-Aug-11 |
2010 |
HANNON, GREGORY J |
COLD SPRING HARBOR LABORATORY |
COLD SPRING HARBOR |
NY |
UNITED STATES |
NCI |
|
Breast Cancer;Cancer;Clinical Research;Estrogen;Genetics;Human Genome;Stem Cell Research;Stem Cell Research - Nonembryonic - Non-Human |
NOVEL MARKERS OF ANTHRACYCLINE-INDUCED MYOCARDIAL DAMAGE |
1R21CA143787-01A1 |
2010-09-01 |
2010-09-01 |
31-Aug-11 |
2010 |
SHAPIRO, CHARLES L |
OHIO STATE UNIVERSITY |
COLUMBUS |
OH |
UNITED STATES |
NCI |
$327,090 |
Breast Cancer;Cancer;Cardiovascular;Clinical Research;Diagnostic Radiology;Heart Disease;Stem Cell Research;Stem Cell Research - Nonembryonic - Human |
A CHEMICAL BIOLOGY NETWORK FOR PERSONALIZED MEDICINE |
1RC2LM010994-01 |
2010-09-01 |
2010-09-01 |
31-Aug-11 |
2010 |
CARDOZO, TIMOTHY J |
NEW YORK UNIVERSITY SCHOOL OF MEDICINE |
NEW YORK |
NY |
UNITED STATES |
NLM |
$2,093,862 |
Networking and Information Technology R&D |
THE TRANSCRIPTION FACTOR SLUG MAY DRIVE THE PROGRESSION OF AKT AND HER2/NEU |
5U54CA143930-02 |
|
2010-09-01 |
31-Aug-11 |
2010 |
SLAMON, DENNIS J |
UNIVERSITY OF CALIFORNIA LOS ANGELES |
LOS ANGELES |
CA |
UNITED STATES |
NCI |
$38,869 |
Breast Cancer;Cancer;Genetics |
PLANNING AND EVALUATION |
5U54CA143931-02 |
|
2010-09-01 |
31-Aug-11 |
2010 |
VADGAMA, JAYDUTT V |
CHARLES R. DREW UNIVERSITY OF MED & SCI |
LOS ANGELES |
CA |
UNITED STATES |
NCI |
$42,448 |
Breast Cancer;Cancer;Genetics |
MEASUREMENT IN DIVERSE POPULATIONS |
5P01CA130818-03 |
|
2010-09-01 |
31-Aug-11 |
2010 |
PONCE, NINEZ ALAFRIZ |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$95,494 |
Bioengineering;Breast Cancer;Cancer |
NONINVASIVE ASSESSMENT OF CANCER RESPONSIVENESS TO THERAPY BY USE OF ..... |
5P50CA128323-03 |
|
2010-09-01 |
31-Aug-11 |
2010 |
HALLAHAN, DENNIS E |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$167,226 |
Cancer;Diagnostic Radiology |
KINASE IMAGING |
5P50CA086355-11 |
|
2010-09-01 |
31-Aug-11 |
2010 |
JOSEPHSON, LEE |
MASSACHUSETTS GENERAL HOSPITAL |
BOSTON |
MA |
UNITED STATES |
NCI |
$250,430 |
Bioengineering;Biotechnology;Cancer;Diagnostic Radiology;Nanotechnology |
MOUSE MODELING AND ANIMAL DEVELOPMENT |
7P01CA095426-09 |
|
2010-09-01 |
31-Aug-11 |
2010 |
MUTHUSAMY, NATARAJAN |
OHIO STATE UNIVERSITY |
COLUMBUS |
OH |
UNITED STATES |
NCI |
$252,597 |
Biotechnology;Cancer;Genetics;Lymphoma;Orphan Drug |
ECONOMICS OF PERSONALIZED MEDICINE USING GENOMICS |
5P01CA130818-03 |
|
2010-09-01 |
31-Aug-11 |
2010 |
LADABAUM, URI |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$320,985 |
Bioengineering;Breast Cancer;Cancer;Clinical Research;Cost Effectiveness Research;Health Services;Prevention |
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C |
5P50CA092629-10 |
|
2010-09-01 |
31-Aug-11 |
2010 |
ROSEN, NEAL |
SLOAN-KETTERING INSTITUTE FOR CANCER RES |
NEW YORK |
NY |
UNITED STATES |
NCI |
$361,919 |
Aging;Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Prostate Cancer;Urologic Diseases |
ANTIBODY THERAPY FOR BREAST CANCER: INVESTIGATION OF IMMUNE MODULATION WITH IL-21 |
7P01CA095426-09 |
|
2010-09-01 |
31-Aug-11 |
2010 |
CARSON, WILLIAM E. |
OHIO STATE UNIVERSITY |
COLUMBUS |
OH |
UNITED STATES |
NCI |
$414,913 |
Breast Cancer;Cancer;Immunization |
UTILIZATION OF PERSONALIZED MEDICINE USING GENOMICS |
5P01CA130818-03 |
|
2010-09-01 |
31-Aug-11 |
2010 |
HAAS, JENNIFER S |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$444,832 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Clinical Research;Genetics;Health Services |
IMMUNOBIOLOGY OF P185 RECEPTOR |
5R01CA055306-16 |
1992-05-01 |
2010-09-02 |
31-Jul-11 |
2010 |
GREENE, MARK I |
UNIVERSITY OF PENNSYLVANIA |
PHILADELPHIA |
PA |
UNITED STATES |
NCI |
$269,183 |
Biotechnology;Cancer;Immunization;Prevention |
HIGH CAPACITY NANOCARRIERS FOR CANCER CHEMOTHERAPEUTICS |
1U01CA151806-01 |
2010-09-02 |
2010-09-02 |
31-Jul-11 |
2010 |
KABANOV, ALEXANDER V |
UNIVERSITY OF NEBRASKA MEDICAL CENTER |
OMAHA |
NE |
UNITED STATES |
NCI |
$444,159 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Nanotechnology |
INNATE IMMUNITY: ELUCIDATION AND MODULATION FOR CANCER THERAPY |
7P01CA095426-09 |
2002-02-01 |
2010-09-07 |
31-Aug-11 |
2010 |
CALIGIURI, MICHAEL A |
OHIO STATE UNIVERSITY |
COLUMBUS |
OH |
UNITED STATES |
NCI |
$2,080,062 |
No NIH Category available. |
MOLECULAR MECHANISMS OF RESISTANCE TO HER2 INHIBITORS IN BREAST CANCER |
1K08CA143153-01A1 |
2010-09-07 |
2010-09-07 |
31-Aug-11 |
2010 |
REXER, BRENT N |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$163,080 |
Biotechnology;Breast Cancer;Cancer;Clinical Research |
DEVELOPMENT OF TARGETED THERAPY FOR ERK PATHWAY IN BREAST CANCER |
5K99CA139006-02 |
2009-09-30 |
2010-09-08 |
31-Aug-11 |
2010 |
BARTHOLOMEUSZ, CHANDRA |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR |
HOUSTON |
TX |
UNITED STATES |
NCI |
$115,239 |
Biotechnology;Breast Cancer;Cancer |
ANTIBODY SHARED RESOURCES |
2P30CA068485-14 |
2010-09-10 |
2010-09-10 |
31-Aug-11 |
2010 |
REYNOLDS, ALBERT B |
VANDERBILT UNIVERSITY |
NASHVILLE |
TN |
UNITED STATES |
NCI |
$109,306 |
Biotechnology;Cancer;Prevention |
RESEARCH PROJECT 3: ROLE OF THE NF-KB/REL IN MAMMARY CARCINOGENESIS |
5P01ES011624-09 |
2010-09-15 |
2010-09-15 |
30-Jun-11 |
2010 |
SONENSHEIN, GAIL E |
TUFTS UNIVERSITY BOSTON |
BOSTON |
MA |
UNITED STATES |
NIEHS |
$140,178 |
Breast Cancer;Cancer;Complementary and Alternative Medicine;Genetics;Nutrition |
CYTOPLASMIC MISLOCALIZATION OF P27KIP1 AS A CAUSATIVE FACTOR AND PROGNOSTIC MARKE |
1P50CA138293-01A1 |
2010-09-15 |
2010-09-15 |
31-Aug-11 |
2010 |
PORTER, PEGGY L |
FRED HUTCHINSON CANCER RESEARCH CENTER |
SEATTLE |
WA |
UNITED STATES |
NCI |
$1,023,777 |
Breast Cancer;Cancer;Estrogen |
PROGNOSTIC AND PREDICTIVE GENE SETS IN HER2-POSITIVE BREAST CANCER:THE HERA TRIAL |
5R21CA139428-02 |
2009-08-21 |
2010-09-16 |
31-Jul-11 |
2010 |
LEYLAND-JONES, BRIAN |
EMORY UNIVERSITY |
ATLANTA |
GA |
UNITED STATES |
NCI |
$174,733 |
Breast Cancer;Cancer;Genetics |
PHASE I TRIAL WITH TWO HER-2 B CELL EPITOPE VACCINE IN PATIENTS WITH SOLID TUMORS |
5R21CA135608-02 |
2009-08-25 |
2010-09-16 |
31-Jul-11 |
2010 |
KAUMAYA, PRAVIN T.P |
OHIO STATE UNIVERSITY |
COLUMBUS |
OH |
UNITED STATES |
NCI |
$330,000 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Immunization;Lung;Lung Cancer;Prevention;Vaccine Related |
OPTIMIZATION OF NANOPARTICLE TARGETING IN OVARIAN AND BREAST CANCER |
1U54CA151662-01 |
2010-09-01 |
2010-09-16 |
31-Aug-11 |
2010 |
GERNGROSS, TILLMAN |
DARTMOUTH COLLEGE |
HANOVER |
NH |
UNITED STATES |
NCI |
$1,111,562 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Nanotechnology |
DISCOVERY PLATFORM FOR CANCER ANTIGENS |
1R33CA143531-01A1 |
2010-09-16 |
2010-09-16 |
31-Aug-11 |
2010 |
CLAFFEY, KEVIN P. |
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT |
FARMINGTON |
CT |
UNITED STATES |
NCI |
$313,665 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Prevention |
APPLIED THERAPEUTICS & WHOLE ANIMAL IMAGING |
2P30CA014051-39 |
2010-09-20 |
2010-09-20 |
30-Apr-11 |
2010 |
HEMANN, MICHAEL |
MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
CAMBRIDGE |
MA |
UNITED STATES |
NCI |
$47,713 |
Cancer;Diagnostic Radiology |
THERANOSTIC NANOMEDICINE FOR BREAST CANCER PREVENTION AND IMAGE-GUIDED THERAPY |
1K99CA153948-01 |
2010-09-20 |
2010-09-20 |
31-Jul-11 |
2010 |
RAI, PRAKASH R |
MASSACHUSETTS GENERAL HOSPITAL |
BOSTON |
MA |
UNITED STATES |
NCI |
$121,312 |
Aging;Bioengineering;Breast Cancer;Cancer;Nanotechnology;Prevention |
EGFR PEPTIDES AS VACCINES IN ANTI-TUMOR IMMUNITY |
2R42CA128165-02A1 |
2007-04-01 |
2010-09-28 |
31-Aug-11 |
2010 |
MAMULA, MARK J. |
L2 DIAGNOSTICS, LLC |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
$628,721 |
Biotechnology;Cancer;Immunization;Prevention;Vaccine Related |
EGFR PEPTIDES AS VACCINES IN ANTI-TUMOR IMMUNITY |
2R42CA128165-02A1 |
2007-04-01 |
2010-09-28 |
31-Aug-11 |
2010 |
MAMULA, MARK J. |
L2 DIAGNOSTICS, LLC |
NEW HAVEN |
CT |
UNITED STATES |
NCI |
|
Biotechnology;Cancer;Immunization;Prevention;Vaccine Related |
BASTYR/UW ONCOMYCOLOGY TRANSLATIONAL RESEARCH CENTER |
1U19AT006028-01A1 |
2010-09-29 |
2010-09-29 |
31-Aug-11 |
2010 |
STANDISH, LEANNA J |
BASTYR UNIVERSITY |
KENMORE |
WA |
UNITED STATES |
NCCAM |
$1,147,443 |
No NIH Category available. |
FOLDAMERS: NOVEL LIGANDS FOR DIVERSE PROTEIN SURFACES |
2R01GM074756-05 |
2005-08-01 |
2010-09-30 |
31-Jul-11 |
2010 |
SCHEPARTZ, ALANNA |
YALE UNIVERSITY |
NEW HAVEN |
CT |
UNITED STATES |
NIGMS |
$330,803 |
Biotechnology |
DEVELOPMENT OF NOVEL IMMUNOCONJUGATES FOR APPLICATION IN CANCER THERAPEUTICS |
5F32CA144213-02 |
2009-09-30 |
2010-09-30 |
29-Sep-11 |
2010 |
YOUNG, DOUGLAS DEAN |
SCRIPPS RESEARCH INSTITUTE |
LA JOLLA |
CA |
UNITED STATES |
NCI |
$47,606 |
Biotechnology;Cancer |
AUGMENTING IMMUNITY VIA HER2-TARGETED IMMUNOTHERAPY AND PSK M.DISIS/L.STANDISH |
1U19AT006028-01A1 |
2010-10-01 |
2010-10-01 |
31-Aug-11 |
2010 |
STANDISH, LEANNA J |
BASTYR UNIVERSITY |
KENMORE |
WA |
UNITED STATES |
NCCAM |
$590,985 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials;Complementary and Alternative Medicine;Immunization;Prevention;Vaccine Related |
PHASE II STUDY OF DOCETAXEL & HERCEPTIN IN METASTATIC BREAST CANCER |
5M01RR000042-40 |
1977-12-01 |
|
|
2000 |
BAKER, LAURENCE H |
UNIVERSITY OF MICHIGAN AT ANN ARBOR |
ANN ARBOR |
MI |
UNITED STATES |
NCRR |
|
No NIH Category available. |
CPT11 AND TRASTUZUMAB IN ADVANCED COLORECTAL CANCER |
5M01RR000056-39 |
1978-12-01 |
|
|
2000 |
RAMANTHAN, RAMESH |
UNIVERSITY OF PITTSBURGH AT PITTSBURGH |
PITTSBURGH |
PA |
UNITED STATES |
NCRR |
|
No NIH Category available. |
BREAST CANCER |
2U10CA025224-22 |
1982-01-01 |
|
|
2001 |
PEREZ, EDITH A |
MAYO CLINIC COLL OF MEDICINE, ROCHESTER |
ROCHESTER |
MN |
UNITED STATES |
NCI |
|
No NIH Category available. |
DOCETAXEL & TRASTUZUMAB IN HER2 EXPRESSING METASTATIC BREAST CANCER |
5M01RR000054-39 |
1991-12-01 |
|
|
2000 |
FOSS, FRANCINE M |
TUFTS MEDICAL CENTER |
BOSTON |
MA |
UNITED STATES |
NCRR |
|
No NIH Category available. |
CORRELATION OF MARKER WITH RESPONSE TO CHEMOTHERAPY |
2P50CA058223-09A1 |
1992-09-30 |
|
|
2001 |
CAREY, LISA A |
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL |
CHAPEL HILL |
NC |
UNITED STATES |
NCI |
|
No NIH Category available. |
DOCETAXEL & TRASTUZUMAB IN HER2 EXPRESSING METASTATIC BREAST CANCER |
3M01RR000054-39S3 |
1999-12-01 |
|
|
2001 |
FOSS, FRANCINE M |
TUFTS MEDICAL CENTER |
BOSTON |
MA |
UNITED STATES |
NCRR |
|
No NIH Category available. |
CPT11 AND TRASTUZUMAB IN ADVANCED COLORECTAL CANCER |
5M01RR000056-40 |
2000-12-01 |
|
|
2001 |
RAMANTHAN, RAMESH |
UNIVERSITY OF PITTSBURGH AT PITTSBURGH |
PITTSBURGH |
PA |
UNITED STATES |
NCRR |
|
No NIH Category available. |
CHARACTERIZATION AND PROFILING OF MICROMETASTASES |
1U54CA090788-01 |
2001-09-26 |
|
|
2001 |
PARK, JOHN W |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
|
No NIH Category available. |
EXPRESSION ANALYSIS OF ERBB RECEPTOR TARGETED THERAPIES |
1U54CA090788-01 |
2001-09-26 |
|
|
2001 |
TRIPATHY, DEBASISH |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
|
No NIH Category available. |
CPT11 AND TRASTUZUMAB IN ADVANCED COLORECTAL CANCER |
5M01RR000056-41 |
2001-12-01 |
|
|
2002 |
RAMANTHAN, RAMESH |
UNIVERSITY OF PITTSBURGH AT PITTSBURGH |
PITTSBURGH |
PA |
UNITED STATES |
NCRR |
|
No NIH Category available. |
CPT11 AND TRASTUZUMAB IN ADVANCED COLORECTAL CANCER |
3M01RR000056-41S2 |
2001-12-01 |
|
|
2002 |
RAMANTHAN, RAMESH |
UNIVERSITY OF PITTSBURGH AT PITTSBURGH |
PITTSBURGH |
PA |
UNITED STATES |
NCRR |
|
No NIH Category available. |
DOCETAXEL & TRASTUZUMAB IN HER2 EXPRESSING METASTATIC BREAST CANCER |
5M01RR000054-41 |
2002-03-01 |
|
|
2002 |
FOSS, FRANCINE M |
TUFTS MEDICAL CENTER |
BOSTON |
MA |
UNITED STATES |
NCRR |
|
No NIH Category available. |
CHARACTERIZATION AND PROFILING OF MICROMETASTASES |
5U54CA090788-02 |
2002-05-01 |
|
|
2002 |
PARK, JOHN W |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$158,272 |
No NIH Category available. |
EXPRESSION ANALYSIS OF ERBB RECEPTOR TARGETED THERAPIES |
5U54CA090788-02 |
2002-05-01 |
|
|
2002 |
TRIPATHY, DEBASISH |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO |
SAN FRANCISCO |
CA |
UNITED STATES |
NCI |
$158,272 |
No NIH Category available. |
CORRELATION OF MARKER WITH RESPONSE TO CHEMOTHERAPY |
5P50CA058223-10 |
2002-09-13 |
|
|
2002 |
CAREY, LISA A |
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL |
CHAPEL HILL |
NC |
UNITED STATES |
NCI |
|
No NIH Category available. |
TAS::75 0849::TAS THE GOAL OF THIS PROJECT IS TO DEVELOP STC TRASTUZUMAB, A GEN |
Contract |
2010-09-30 |
|
|
2010 |
LESZCZYNIECKA, MAGDALENA |
STC BIOLOGICS, INC |
CAMBRIDGE |
MA |
UNITED STATES |
NCI |
$299,881 |
Biotechnology;Breast Cancer;Cancer |
USING GLYCOSYLTRANSFERASES FOR THE DEVELOPMENT OF TARGETED DRUG DELIVERY SYSTEM |
1Z01BC010804-02 |
|
|
|
2008 |
QASBA, PRADMAN K |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$74,913 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Immunization |
USING GLYCOSYLTRANSFERASES FOR THE DEVELOPMENT OF TARGETED DRUG DELIVERY SYSTEM |
1Z01BC010804-01 |
|
|
|
2007 |
QASBA, PRADMAN K |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$80,021 |
No NIH Category available. |
ADJUVANT THERAPY OF BREAST CANCER |
1Z01BC010560-04 |
|
|
|
2007 |
SWAIN, SANDRA M |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$122,338 |
No NIH Category available. |
IDENTIFICATION OF MOLECULAR TARGETS IN TRIPLE-NEGATIVE BREAST CANCER |
1ZIABC010980-02 |
|
|
|
2009 |
LIPKOWITZ, STANLEY |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$183,633 |
Biotechnology;Breast Cancer;Cancer;Estrogen;Genetics |
IDENTIFICATION OF MOLECULAR TARGETS IN TRIPLE-NEGATIVE BREAST CANCER |
1Z01BC010980-01 |
|
|
|
2008 |
LIPKOWITZ, STANLEY |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$185,704 |
Biotechnology;Breast Cancer;Cancer;Estrogen;Genetics |
MOLECULAR ALTERATIONS OF PRIMARY BREAST CANCER AND METASTASIS |
1ZIABC010762-05 |
|
|
|
2010 |
MERINO, MARIA |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$220,179 |
Brain Cancer;Brain Disorders;Breast Cancer;Cancer |
MOLECULAR ALTERATIONS OF PRIMARY BREAST CANCER AND METASTASIS |
1Z01BC010762-03 |
|
|
|
2008 |
MERINO NEUMANN, MARIA |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$224,353 |
Brain Cancer;Brain Disorders;Breast Cancer;Cancer;Neurosciences |
UTILIZING GLYCOSYLTRANSFERASES FOR BIOCONJUGATION |
1ZIABC010742-04 |
|
|
|
2009 |
QASBA, PRADMAN K |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$253,783 |
Bioengineering;Biotechnology;Cancer |
MOLECULAR ALTERATIONS OF PRIMARY BREAST CANCER AND METASTASIS |
1ZIABC010762-04 |
|
|
|
2009 |
MERINO NEUMANN, MARIA |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$260,049 |
Biotechnology;Brain Cancer;Brain Disorders;Breast Cancer;Cancer;Genetics |
UTILIZING GLYCOSYLTRANSFERASES FOR BIOCONJUGATION |
1Z01BC010742-03 |
|
|
|
2008 |
QASBA, PRADMAN K |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$327,744 |
Bioengineering;Biotechnology;Cancer |
UTILIZING GLYCOSYLTRANSFERASES FOR BIOCONJUGATION |
1Z01BC010742-02 |
|
|
|
2007 |
QASBA, PRADMAN K |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$350,089 |
No NIH Category available. |
DEVELOPMENTAL THERAPEUTICS |
1Z01BC010435-07 |
|
|
|
2007 |
SWAIN, SANDRA M |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$404,315 |
No NIH Category available. |
INFLAMMATORY BREAST CANCER |
1Z01SC010097-08 |
|
|
|
2007 |
SWAIN, SANDRA M |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
$416,574 |
No NIH Category available. |
TRAIL-INDUCED CELL DEATH IN BREAST CANCER CELLS |
1ZIASC007263-17 |
|
|
|
2009 |
LIPKOWITZ, STANLEY |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
$428,477 |
Breast Cancer;Cancer;Ovarian Cancer |
TRAIL-INDUCED CELL DEATH IN BREAST CANCER CELLS |
1Z01SC007263-16 |
|
|
|
2008 |
LIPKOWITZ, STANLEY |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
$433,310 |
Breast Cancer;Cancer;Ovarian Cancer |
MOLECULAR IMAGING AND TARGETED THERAPY OF HER2-POSITIVE BREAST CANCERS |
1Z01BC010727-02 |
|
|
|
2007 |
CAPALA, JACEK |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$548,064 |
No NIH Category available. |
MOLECULAR ANALYSIS OF BREAST CANCER METASTASIS TO THE BRAIN |
1Z01BC010538-06 |
|
|
|
2008 |
STEEG, PATRICIA |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$584,959 |
Biotechnology;Brain Cancer;Brain Disorders;Breast Cancer;Cancer;Genetics;Neurosciences;Orphan Drug |
MOLECULAR IMAGING AND TARGETED THERAPY OF HER2-POSITIVE BREAST CANCERS |
1Z01BC010727-03 |
|
|
|
2008 |
CAPALA, JACEK |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$654,233 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Diagnostic Radiology;Nanotechnology |
MOLECULAR ANALYSIS OF BREAST CANCER METASTASIS TO THE BRAIN |
1Z01BC010538-05 |
|
|
|
2007 |
STEEG, PATRICIA |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$716,369 |
No NIH Category available. |
MOLECULAR IMAGING AND TARGETED THERAPY OF HER2-POSITIVE BREAST CANCERS |
1ZIABC010727-04 |
|
|
|
2009 |
CAPALA, JACEK |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$755,654 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Diagnostic Radiology;Nanotechnology |
GROWTH FACTOR IMAGING |
1Z01BC010656-03 |
|
|
|
2007 |
CHOYKE, PETER L |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$768,482 |
No NIH Category available. |
METAL CHELATE CONJUGATED MONOCLONAL ANTIBODIES FOR TUMOR DIAGNOSIS AND THERAPY |
1Z01SC006353-26 |
|
|
|
2008 |
BRECHBIEL, MARTIN W |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
$814,632 |
Bioengineering;Biotechnology;Cancer;Clinical Research;Digestive Diseases;Orphan Drug;Ovarian Cancer |
INTRACELLULAR IN VIVO IMAGING |
1ZIABC010657-06 |
|
|
|
2010 |
CHOYKE, PETER L |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$837,139 |
Bioengineering;Cancer;Diagnostic Radiology;HIV/AIDS;Nanotechnology |
GROWTH FACTOR IMAGING |
1Z01BC010656-04 |
|
|
|
2008 |
CHOYKE, PETER L |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$880,575 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Clinical Research;Diagnostic Radiology;Nanotechnology;Orphan Drug |
METAL CHELATE CONJUGATED MONOCLONAL ANTIBODIES FOR TUMOR DIAGNOSIS AND THERAPY |
1ZIASC006353-28 |
|
|
|
2010 |
BRECHBIEL, MARTIN W |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
$906,883 |
Bioengineering;Biotechnology;Cancer;Diagnostic Radiology |
METAL CHELATE CONJUGATED MONOCLONAL ANTIBODIES FOR TUMOR DIAGNOSIS AND THERAPY |
1Z01SC006353-25 |
|
|
|
2007 |
BRECHBIEL, MARTIN W |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
$959,255 |
No NIH Category available. |
METAL CHELATE CONJUGATED MONOCLONAL ANTIBODIES FOR TUMOR DIAGNOSIS AND THERAPY |
1ZIASC006353-27 |
|
|
|
2009 |
BRECHBIEL, MARTIN W |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
$1,165,814 |
Biotechnology;Cancer;Clinical Research |
INTRACELLULAR IN VIVO IMAGING |
1ZIABC010657-05 |
|
|
|
2009 |
CHOYKE, PETER L |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$1,181,188 |
Cancer;Diagnostic Radiology |
SIGNAL TRANSDUCTION IN EPITHELIAL CANCER CELLS |
1Z01SC007263-15 |
|
|
|
2007 |
LIPKOWITZ, STANLEY |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
$1,314,511 |
No NIH Category available. |
GROWTH FACTOR IMAGING |
1ZIABC010656-06 |
|
|
|
2010 |
CHOYKE, PETER L |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$1,674,279 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Clinical Research;Diagnostic Radiology;Nanotechnology |
INTRACELLULAR IN VIVO IMAGING |
1Z01BC010657-04 |
|
|
|
2008 |
CHOYKE, PETER L |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$1,761,151 |
Cancer;Diagnostic Radiology |
ANTIGEN-SPECIFIC T-CELL ACTIVATION, APPLICATION TO VACCINES FOR CANCER AND AIDS |
1Z01SC004020-31 |
|
|
|
2008 |
BERZOFSKY, JAY A |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
$1,800,256 |
Biotechnology;Breast Cancer;Cancer;Clinical Research;Emerging Infectious Diseases;Immunization;Infectious Diseases;Orphan Drug;Prevention;Vaccine Related |
ANTIGEN-SPECIFIC T-CELL ACTIVATION, APPLICATION TO VACCINES FOR CANCER AND AIDS |
1Z01SC004020-30 |
|
|
|
2007 |
BERZOFSKY, JAY A |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
$2,029,401 |
No NIH Category available. |
GROWTH FACTOR IMAGING |
1ZIABC010656-05 |
|
|
|
2009 |
CHOYKE, PETER L |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
$2,362,374 |
Bioengineering;Biotechnology;Breast Cancer;Cancer;Clinical Research;Diagnostic Radiology;Nanotechnology |
KINASE ACTIVATION AND CONTROL OF APOPTOSIS IN BREAST CAN |
1Z01SC020293-04 |
|
|
|
2002 |
DENNIS, PHILLIP A. |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
|
No NIH Category available. |
KINASE ACTIVATION AND CONTROL OF APOPTOSIS IN BREAST CAN |
1Z01SC020293-03 |
|
|
|
2001 |
DENNIS, PHILLIP A. |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
|
No NIH Category available. |
MOLECULAR CONTROL OF GROWTH, DIFFERENTIATION, AND DEATH |
1Z01SC007263-12 |
|
|
|
2004 |
LIPKOWITZ, STANLEY |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
|
No NIH Category available. |
MOLECULAR CONTROL OF GROWTH, DIFFERENTIATION, AND DEATH |
1Z01SC007263-11 |
|
|
|
2003 |
LIPKOWITZ, STANLEY |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
|
No NIH Category available. |
MOLECULAR CONTROL OF GROWTH, DIFFERENTIATION, AND DEATH |
1Z01SC007263-10 |
|
|
|
2002 |
LIPKOWITZ, STANLEY |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
|
No NIH Category available. |
MOLECULAR CONTROL OF GROWTH, DIFFERENTIATION, AND DEATH |
1Z01SC007263-09 |
|
|
|
2001 |
LIPKOWITZ, STANLEY |
DIVISION OF CLINICAL SCIENCES - NCI |
|
|
|
NCI |
|
No NIH Category available. |
MOLECULAR ANALYSIS OF BREAST CANCER METASTASIS TO THE BR |
1Z01BC010538-03 |
|
|
|
2005 |
STEEG, PATRICIA |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
|
No NIH Category available. |
DEVELOPMENTAL THERAPEUTICS |
1Z01BC010435-06 |
|
|
|
2006 |
SWAIN, SANDRA M |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
|
No NIH Category available. |
ADJUVANT THERAPY OF BREAST CANCER |
1Z01BC010560-03 |
|
|
|
2006 |
SWAIN, SANDRA M |
DIVISION OF BASIC SCIENCES - NCI |
|
|
|
NCI |
|
No NIH Category available. |